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ABSTRACT 
This thesis addresses the hypothesis that multiple sclerosis (MS) patients have an 
imbalance in the frequencies of natural killer cell subsets, with fewer 
immunoregulatory and more proinflammatory NK cells compared to healthy controls. 
Ten NK cell subsets were defined according to expression of CD56, CD8, CD27 and 
CD57. Subset frequencies were compared by performing multiparameter flow 
cytometry on PBMCs from healthy controls and patients with clinically isolated 
syndrome (CIS) or relapsing-remitting MS. CD56
dim
 CD8
+
 CD57
+
 CD27
-
 NK cells 
had a higher frequency in untreated relapsing-remitting MS patients compared to 
healthy controls and their frequency was decreased in patients on interferon-β 
treatment. CD56
bright 
NK cells, particularly the CD8
-
 CD27
-
 subset, had a significantly 
lower frequency in untreated MS and CIS patients. CD8
- 
CD57
-
 CD27
-
 subsets of both 
CD56
dim
 and CD56
bright
 NK cells were expanded in interferon-β-treated patients in 
remission but not relapse. Characteristics of two CD56
dim
 subsets displaying an 
apparent reciprocal relationship (CD8
+
 CD57
+
 CD27
-
 and CD8
-
 CD57
-
 CD27
-
) were 
compared by qRT-PCR, flow cytometry and killing assays. CD56
dim
 CD8
+
 CD57
+
 
CD27
-
 NK cells were more cytotoxic and expressed higher levels of transcripts 
encoding IFNγ, T-bet and other factors associated with IFNγ signalling. This is 
consistent with the hypothesis that there is a shift towards a more pro-inflammatory 
NK cell phenotype in MS patients, which is reversed by interferon-β treatment. In 
order to determine whether these NK cells exert their effects mainly in the blood or in 
the central nervous system (CNS), mononuclear cells were extracted from the CNS of 
Line 7 mice, which develop spontaneous autoimmune demyelination due to 
expression of a human MS-associated HLA/TCR combination. NK cells were 
detected in spleen, but not CNS, of these mice, suggesting that their role in this 
particular disease model is restricted to regulation of other leukocytes outside the 
CNS. 
  
4 
 
Acknowledgements 
 
I would like to thank my supervisors Prof. Danny Altmann and Dr. Rosemary Boyton 
for their feedback on this thesis. I am grateful to Danny for giving me the opportunity 
to work on this project and giving me the freedom to pursue my own ideas and to 
Rosemary for helping me to focus them in the latter stages of my project. 
 
A big thank you to everyone on the 8
th
 floor who has helped me over the years, to all 
those who have taught me techniques, collected blood, kept the place running 
smoothly, discussed ideas and made the department a more fun place to be. In 
particular, I would like to thank Dr. Fatemah Kamel for her tireless work in collecting 
patient blood samples. Thank you also to Dr. Richard Nicholas, Dr. Omar Malik and 
Dr. Paolo Giannetti for providing access to MS and CIS pateints, the nurses at 
Charing Cross who helped to take the samples and to all the people that donated 
blood, both patients and controls, without whom this study would not have been 
possible.  
 
I would also like to extend my gratitude to Anna Ettorre for looking after the FACS 
Aria II, which was essential for virtually all the experiments I performed, and for 
helping to set up the machine for cell sorting. 
 
I am grateful to Dr. Dan Lowther who optimised and taught me the Line 7 CNS 
extraction procedure and to Marie-Laure Aknin, Dr. Debs Chong, Dr. Karen Chu and 
Kathryn Quigley who assisted in the scoring and processing of these mice.  
 
Finally I would like to thank my friends, especially Nishkala Thiru and Richard 
Browning, for distracting me when experiments weren’t working and the Medical 
Research Council for funding me throughout my Masters and PhD. 
 
 
 
 
  
5 
 
Table of Contents 
 
1. INTRODUCTION ................................................................................................ 18 
1.1 Natural Killer Cells ....................................................................................... 18 
1.1.1 NK Cell Development ............................................................................ 18 
1.1.2 NK Cell Function is Determined by the Balance of Signals from 
Activating and Inhibitory Receptors .................................................................... 21 
1.1.3 NK Cell Education Determines Responsiveness to Activating Signals 27 
1.1.4 NK Cells Form Synapses with Target Cells and Kill Susceptible Targets 
via Granzyme Release and Other Mechanisms ................................................... 31 
1.1.5 NK Cells Produce a Range of Cytokines and Chemokines ................... 38 
1.1.6 NK Cells Interact with Other Leukocytes and Regulate their Function 48 
1.1.7 NK Cells can be Divided into Subsets with Distinct Functions ............ 55 
1.2 The Role of T cells and NK Cells in Multiple Sclerosis ............................... 66 
1.2.1 Genetic and Environmental Risk Factors are Associated with 
Development of MS ............................................................................................. 67 
1.2.2 CD4+ T cells Infiltrate the CNS and Promote Recruitment and 
Activation of Other Leukocytes, leading to Myelin and Axonal Damage .......... 70 
1.2.3 Disease Initiation Requires Activation of Peripheral T Cells – Potential 
Role of Viruses and Impaired Immunoregulatory Mechanisms .......................... 78 
1.2.4 Current Therapies for MS have Benefits and Limitations ..................... 80 
1.2.5 Evidence of a Role for NK Cells in Multiple Sclerosis ......................... 86 
1.3 Aims .............................................................................................................. 96 
2. METHODS ........................................................................................................... 97 
2.1 Human PBMC Isolation ................................................................................ 97 
2.2 Flow Cytometry Evaluation of Human PBMC (Surface Staining) ............... 98 
2.3 PBMC Stimulation and Intracellular Cytokine Staining ............................... 98 
2.4 Cell Sorting for RNA .................................................................................... 99 
6 
 
2.5 RNA Extraction ........................................................................................... 100 
2.6 Reverse Transcription ................................................................................. 101 
2.7 Quantitative RT-PCR Arrays ...................................................................... 101 
2.8 Individual qRT-PCR Assays ....................................................................... 103 
2.9 K562 Killing Assays ................................................................................... 103 
2.10 Preparation and Staining of Cells from Line 7 mice ............................... 104 
2.11 Buffers and Medium: ............................................................................... 107 
3. RRMS PATIENTS EXHIBIT DIFFERENCES IN FREQUENCIES OF 
SPECIFIC NK CELL SUBSETS ............................................................................... 125 
3.1 Expression and Co-expression of CD8, CD27 and CD57 on CD56
dim 
and 
CD56
bright
 NK Cells ................................................................................................ 127 
3.2 Confirmation of Differences in Frequency of NK Cell Subsets in RRMS 
Patients and the Effects of IFNβ Treatment ........................................................... 129 
3.3 Multiparameter Analysis Reveals Differences in NK Cell Subset Frequencies 
that are not Restricted to the CD56
bright
 Population ............................................... 133 
3.4 Subset Frequencies in Healthy Adults do not Differ Significantly in Relation 
to Age or Gender .................................................................................................... 138 
3.5 Discussion ................................................................................................... 140 
4. TRANSCRIPTIONAL AND FUNCTIONAL DIFFERENCES BETWEEN 
CD56
DIM
 CD8
-
 CD27
-
 CD57
-
 AND CD56
DIM
 CD8
+
 CD27
-
 CD57
+
 NK CELLS ..... 146 
4.1 Identification of Transcriptional Differences between CD8- CD27- CD57- 
and CD8
+
 CD57
+
 CD56
dim
 NK Cell Subsets ......................................................... 147 
4.2 Cell Surface Expression of Cytokine Receptors ......................................... 157 
4.3 Differences in Expression of Activating and Inhibitory Receptors ............ 159 
4.4 CD56dim CD8- CD27- CD57- NK Cells Produce Similar Levels of IFNγ to 
CD8
+
 CD57
+
 NK Cells and do not make IL-17 or IL-22 ...................................... 162 
4.5 CD56dim CD8+ CD57+ NK cells are more cytotoxic than CD56dim CD8- 
CD27
-
 CD57
-
 NK Cells .......................................................................................... 165 
4.6 Discussion ................................................................................................... 167 
7 
 
5. NK CELLS DO NOT INFILTRATE THE CNS IN THE LINE7 MURINE 
MODEL OF MULTIPLE SCLEROSIS .................................................................... 173 
5.1.1 NKp46
+
 NK Cells were Not Detected in the CNS of Line 7 Mice ...... 175 
5.1.2 Lack of NKp46 Detection was not due to Antibody Sequestration ..... 178 
5.1.3 NKG2D was also Not Detected on CNS-derived Lymphocytes ......... 179 
5.1.4 Discussion ............................................................................................ 181 
6. DISCUSSION ..................................................................................................... 185 
6.1 Summary ..................................................................................................... 195 
 
  
8 
 
List of Figures 
Figure 1-i: NK cells develop from bone marrow HSCs. ............................................. 19 
Figure 1-ii: Missing self and stressed self recognition. ............................................... 23 
Figure 1-iii: NK cell education maintains tolerance of NK cells lacking self-specific 
inhibitory receptors. ..................................................................................................... 30 
Figure 1-iv: NK cells stimulate T cell activation and Th1 polarisation both directly 
and indirectly.. ............................................................................................................. 51 
Figure 1-v: CD56
bright
 CD16
-
 NKG2A
+
 NK cells differentiate into CD56
dim
 CD16
+
 
NKG2A
-
 NK cells. ....................................................................................................... 65 
Figure 1-vi: CD4
+
 T cells initiate CNS inflammation and demyelination.  ................. 73 
Figure 2-i: Gating strategy for enumeration of NK cell subsets.  .............................. 108 
Figure 2-ii: Classification of NK cells into ten subsets. ............................................ 109 
Figure 2-iii: Sorted NK cell subsets have high purity. ............................................... 110 
Figure 3-i: Co-expression pattern of NK cell surface markers. ................................. 128 
Figure 3-ii: Total NK cell frequency does not differ between MS patients and controls 
and is not significantly influenced by interferon-β or Tysabri therapy. .................... 129 
Figure 3-iii: Untreated RRMS and CIS patients have a higher proportion of CD8
+
 
compared to CD8
-
 NK cells. ...................................................................................... 130 
Figure 3-iv: Untreated RRMS patients have a reduced frequency of CD56
bright
 NK 
cells which is reversed by IFNβ treatment. ................................................................ 132 
Figure 3-v: CD56
bright
 subset frequencies are altered in MS patients. ....................... 134 
Figure 3-vi: MS patients have a higher frequency of CD56
dim
 CD8
+
 CD27
-
 CD57
+
 NK 
cells. ........................................................................................................................... 135 
Figure 3-vii: Interferon-β alters frequencies of several CD56dim NK cell subsets..... 136 
Figure 3-viii: Frequencies of CD56
dim
 subsets are not significantly different in relapse 
compared to remission. .............................................................................................. 137 
 Figure 3-ix: No significant gender- or age-related differences in the frequency of NK 
cells or NK cell subsets were detected. ...................................................................... 139 
Figure 4-i: Clusters of co-regulated genes are associated with CD56
dim
 CD8
-
 CD27
-
 
CD57
-
 and CD8
+
 CD27
-
 CD57
+
 NK cell subsets. ...................................................... 152 
Figure 4-ii: Confirmation of transcriptional differences by individual qRT-PCR 
assays. ........................................................................................................................ 156 
Figure 4-v: Expression of cytokine receptors.  .......................................................... 158 
9 
 
Figure 4-iii: The CD8
+
 CD57
+
 subset contains significantly fewer NKG2A
+
 NK cells.
 .................................................................................................................................... 160 
Figure 4-iv: Differences in expression of activating receptors. ................................. 161 
Figure 4-vi: IFNγ production in the CD56dim CD8- CD27- CD57- subset in response to 
PMA/ionomycin stimulation is lower than that of CD56
bright
 NK cells and not 
significantly different to that of the CD56
dim
 CD8
+
 CD57
+
 subset. ........................... 163 
Figure 4-vii: CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells do not produce IL-22 or IL-17A.
 .................................................................................................................................... 164 
Figure 4-viii: CD8
+
 CD57
+
 NK cells express higher levels of cytotoxic molecules. 165 
Figure 4-ix: CD8
+
 CD57
+
 NK cells exhibit higher cytotoxicity towards K562 target 
cells. ........................................................................................................................... 166 
Figure 5-i: NK cells expressing NKp46 are present in the spleen of Line 7 mice….175 
Figure 5-ii: NKp46
+
 leukocytes are not found in the CNS of Line 7 mice………...176 
Figure 5-iii: NKp46
+
 leukocytes are not found in the CNS of Line 7 mice………. 177 
Figure 5-iv: Enrichment of lymphocyte population by FACS…………………….. 178 
Figure 5-v: NKp46 was not detected in FACS-sorted lymphocytes isolated from CNS 
of a Line 7 mouse…………………………………………………………………...179 
Figure 5-vi: NKG2D
+
 lymphocytes were not detected in the CNS of Line 7 mice. 180 
Figure 6-i: Predicted signalling pathways and functions of CD8
+
 CD57
+
 and CD8
-
 
CD57
-
 subsets of CD56
dim
 CD27
-
 NK cells. . ............................................................ 196 
 
  
10 
 
List of Tables 
Table 2-i: Reagents for reverse transcription……………………………………….101 
Table 2-ii: Scoring of clinical disease in Line 7 mice……………………………....105 
Table 2-iii: Antibodies for detection of human antigens……………………………111 
Table 2-iv: Antibodies for detection of murine antigens……………………………113 
Table 2-v: Excitation and detection wavelengths of fluorochromes and dead cell dyes 
measured on FACS Aria II………………………………………………………...  113 
Table 2-vi: Primer list for Th17 for Autoimmunity & Inflammation RT
2
 Profiler PCR 
Array………………………………………………………………………………..114 
Table 2-vii: Age and gender of healthy controls used for comparison of subset 
frequencies…………………………………………………………………………..119 
Table 2-viii: Age and gender of CIS patients……………………………………….120 
Table 2-ix: Age, gender and disease status of untreated MS patients………………121 
Table 2-x: Age, gender and disease status of patients on interferon-β therapy.....…122 
Table 2-xi: Age, gender and disease status of Tysabri-treated patients…………….123 
Table 2-xiii: Summary of age and gender of patient and control groups…………..124 
 
Table 4-i: Cytokine and chemokine expression determined by qRT-PCR array…...148 
Table 4-ii: Expression of cell surface receptors and adaptor molecules determined by 
qRT-PCR…………………………………………………………………………. ..149 
Table 4-iii: Expression of intracellular signalling molecules and transcription factors 
determined by qRT-PCR array……………………………………………………...150 
Table 4-iv: Expression of other genes determined by qRT-PCR array……………..151 
Table 4-v: Genes with significantly higher expression in the CD56
dim
 CD8
+
 CD57
+
 
NK cell subset………………………………………………………………………153 
Table 4-vi: Genes with significantly higher expression in the CD56
dim
 CD8
-
 CD27
-
 
CD57
-
 NK cell subset……………………………………………………………….153 
 
  
11 
 
ABBREVIATIONS 
ADCC:  antibody-dependent cellular cytotoxicity 
AID:  activation-induced cytidine deaminase 
ANOVA: analysis of variance 
AP-1:  activator protein 1 
Apaf-1:  apoptotic peptidase activating factor 1 
Ape-1:  apurinic endonuclease-1 
APC:  antigen-presenting cell  
ATF:  activating transcription factor 
ATP:  adenosine triphosphate 
Bak:  bcl-2 homologous antagonist/killer 
Bid:  BH3 interacting-domain death agonist 
Bim:  Bcl-like protein 11  
BBB:  blood-brain barrier 
BD:  Becton Dickinson 
BDNF:  brain-derived neurotrophic factor 
bZIP:  basic leucine zipper domain 
CAD:  caspase-activated DNase 
CamKII: calmodulin-dependent protein kinase II 
CapG:  tropomysin, capping protein (actin filament), gelsolin-like 
CBP:  cAMP-responsive-element-binding protein 
CD:  cluster of differentiation 
cDNA:  complementary deoxyribonucleic acid 
CEBP:  Ccaat-enhancer-binding protein 
CI:  confidence interval 
CIITA:  class II, major histocompatibility complex, transactivator 
CIS:  clinically isolated syndrome 
CNS:  central nervous system 
12 
 
CSF:  cerebrospinal fluid 
cSMAC: central supramolecular activation cluster 
Ct:  cross threshold 
DAP:  DNAX-activating protein 
DC:  dendritic cell 
DMEM: Dulbecco’s modified Eagle medium 
DNA:  deoxyribonucleic acid 
DNAM-1: DNAX accessory molecule 1 
E4BP4:  E4-binding protein 4 
EAE:  experimental autoimmune encephalomyelitis 
EBV:  Epstein-Barr virus 
ERK:  extracellular signal-related kinase 
ERM:  Ezrin, radixin and moesin 
F-actin:  Filamentous actin 
FACS:  fluorescence-activated cell sorting 
FADD:  Fas-associated death domain 
FITC:  fluorescein isothyocyanate 
FL:  Flt3 ligand 
FMO:  fluorescence minus one control 
FoxP3:  Forkhead box P3 
FSC:  forward scatter 
GA:  Glatiramer acetate 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
GAS:  Gamma-activated site 
GATA3: GATA binding protein 3 
G-CSF:  granulocyte colony stimulating factor 
GFP:  green fluorescent protein 
GM-CSF: granulocyte-macrophage colony stimulating factor 
13 
 
Grb2:  growth factor receptor-bound protein 2 
GWAS: genome-wide association study 
HA:  haemagglutinin 
HCV:  hepatitis C virus 
HLA:  human leukocyte antigen 
HMG2:  high mobility group protein 2 
HMGB1: high mobility group box 1 
HPRT1: hypoxanthine phosphoribosyltransferase 1 
HSC:  haematopoetic stem cell 
ICAD:  inhibitor of caspase-activated deoxyribonuclease 
ICAM:  intercellular adhesion molecule 
iDC:  immature dendritic cell 
IFN:  interferon 
Ig:  immunoglobulin 
IGF:  insulin-like growth factor 
IGSF4:  immunoglobulin superfamily member 4 
IL:  interleukin 
iNKT cell: invariant natural killer T cell 
iNOS:  inducible nitric oxide synthase 
IP3:  inositol 1,4,5-triphosphate 
IP-10:  IFNγ-inducible protein 10 
IRF:   interferon regulatory factor 
ITAM:  immunoreceptor tyrosine-based activation motif 
ITIM:  immunoreceptor tyrosine-based inhibitory motif 
JAK:  Janus kinase 
JNK:  cJun N-terminal kinase 
KIR:  killer immunoglobulin-like receptor 
KLRG1: killer cell lectin-like receptor subfamily G member 1 
14 
 
LAT:  linker of activated T cells 
Lck:  lymphocyte-specific protein tyrosine kinase 
LFA-1:  lymphocyte function-associated antigen 1 
LIF:  leukaemia inhibitory factor 
LILR:  leukocyte immunoglobulin-like receptor 
LMP2:  latent membrane protein 2 
LPS:  lipopolysaccharide 
MAPK:  mitogen-activated protein kinase 
MAP3K: mitogen-activated protein kinase kinase kinase 
MBP:  myelin basic protein 
MCP:  monocyte chemotactic protein 
MEK:  mitogen-activated protein kinase kinase 
MEKK1: MAP/ERK kinase kinase 1 
MFI:  median fluorescence intensity 
MHC:  major histocompatibility complex 
MIC:  MHC class I polypeptide-related sequence 
Mig:  monokine induced by IFN-gamma 
MIP:  macrophage inflammatory protein 
MMP:  matrix metalloproteinase 
MOG:   myelin oligodendrocyte protein  
mRNA:  messenger ribonucleic acid 
Mts1:  metastasis-associated protein 1 
MS:  multiple sclerosis 
Munc:  mammalian uncoordinated 
NADPH: nicotinamide adenine dinucleotide phosphate-oxidase 
NCR:  Natural cytotoxicity receptor 
NFATC2: Nuclear factor of activated T cells, cytoplasmic 2 
NF-κB:  nuclear factor κB 
15 
 
NK cell:  natural killer cell 
NKG:  natural killer group 
OVA:  ovalbumin 
PAK:  p21-activated kinase 
PARP:  poly (ADP-ribose) polymerase 
PBMC:  peripheral blood mononuclear cells 
PBS:  phosphate buffered saline 
PCR:  polymerase chain reaction 
pDC:  plasmacytoid dendritic cell 
PDGF:  platelet-derived growth factor 
PHA:  phytohaemagglutinin 
PI3K:  phosphatidylinositol-3-OH kinase 
PIP2:  phosphatidylinositol 4,5-bisphosphate 
PKB:  protein kinase B 
PKC:  protein kinase C 
PKR:  protein kinase R 
PLC-γ:  phospholipase C-γ 
PLP:  proteolipid protein 
PMA:  phorbol myristate acetate 
PML:  progressive multifocal leukoencephalopathy 
PPMS:  primary progressive multiple sclerosis 
pSMAC: peripheral supramolecular activation cluster 
qPCR:  quantitative polymerase chain reaction 
qRT-PCR: quantitative reverse transcription polymerase chain reaction 
R:  receptor 
Rac1:  ras-related C3 botulinum toxin substrate 1 
RANTES: regulated on activation, normal T expressed and secreted 
RIP:  receptor interacting protein 
16 
 
RNA:  ribonucleic acid 
RNS:  reactive nitrogen species 
ROR:  receptor tyrosine kinase-like orphan receptor 
ROS:  reactive oxygen species 
RPMI:  Roswell Park Memorial Institute medium 
RRMS:  relapsing-remitting multiple sclerosis 
RT-PCR: reverse transcription polymerase chain reaction 
S1P:  sphingosine-1-phosphate 
S1PR1:  sphingosine-1-phosphate receptor 1 
SCF:  stem cell factor 
SEM:  standard error of the mean 
SHP:  Src homology domain-containing protein tyrosine phosphatase 
SLAM:  signalling lymphocyte activation molecule 
SLP-76: SH2 domain-containing leukocyte protein of 76 kDa 
SMAC:  supramolecular activation cluster 
SNARE: soluble NSF protein attachment receptor 
SOCS3: suppressor of cytokine signalling 3 
SPMS:  secondary progressive multiple sclerosis 
STAT:  signal transducer and activator of transcription 
SDF-1:  stromal-derived factor 1 
Syk:  spleen tyrosine kinase 
TAK1:  TGFβ-activated kinase 1 
TAP:  transporter associated with antigen processing 
T-bet (Tbx21): T-box expressed in T cells 
t-Bid:  truncated BH3 interacting-domain death agonist 
TCR:  T cell receptor 
TGF-β:  transforming growth factor β 
Th:  Thelper 
17 
 
TIMP:  tissue inhibitor of matrix metalloproteinases 
TNF:  tumour necrosis factor 
TRADD: TNF receptor-asociated death domain 
TRAF2: TNF-R associated factor 2 
TRAIL: TNF-related apoptosis-inducing ligand 
Treg:  regulatory T cell 
TRIF:  TIR-domain-containing adapter-inducing interferon-β 
UK:  United Kingdom 
ULBP:  UL16 binding protein 
VCAM: vascular cell adhesion molecule 
VDR:  vitamin D receptor 
VDRE:  vitamin D response element 
VEGF:  vascular endothelial growth factor 
VLA-4:  very late antigen 4 
WASp:  Wiscott-Aldrich Syndrome protein 
WIP:  WASp-interacting protein 
ZAP-70: zeta-chain-associated protein kinase 70 
  
18 
 
1. INTRODUCTION 
1.1 Natural Killer Cells 
Natural killer (NK) cells are granular lymphocytes of the innate immune system, first 
noted for their ability to rapidly recognise and kill tumour cells (Kiessling et al. 1975, 
Glimcher et al. 1977). Early studies defined them by their ability to respond to cells 
lacking major histocompatibility complex class I (MHC class I), a molecule found on 
the surface of all healthy mammalian cells but often downregulated as a result of 
severe cellular stress, tumorigenic transformation or infection (Kärre et al. 1986, 
Ljunggren et al. 1985, Ljunggren et al. 1988). However, it is now understood that NK 
cell activation can occur in a number of ways, and is typically determined by the 
balance of many different activating and inhibitory signals. Furthermore, their 
function goes beyond direct killing of target cells: it is now known that NK cells 
interact with many other cell types via cytokines and cell-cell contact, to influence 
both innate and adaptive immune responses. 
1.1.1 NK Cell Development 
NK cells, like all leukocytes, are derived from haematopoetic stem cells (HSCs) found 
in cord blood and fetal and adult bone marrow and liver (Mrózek et al. 1996, 
Williams et al. 1997, Weissman and Shizuru 2008, Eissens et al. 2012). Development 
of both mouse and human HSCs into mature NK cells has been recapitulated in vitro 
and is summarised in figure 1-i. The earliest stages of development require the 
presence of stromal cells or stromal-derived cytokines such as Flt3-ligand (FL), 
interleukin (IL)-3 and stem cell factor (SCF) (Shibuya et al. 1995, Williams et al. 
1997, Yu et al. 1998, Rosmaraki et al. 2001). This stimulates transition of CD34
+
 
pluripotent HSCs into committed NK progenitors expressing CD122, a receptor chain 
shared by the IL-2 and IL-15 receptors (Rosmaraki et al. 2001, Yu et al. 1998, Ikawa 
et al. 1999, LeClerq et al. 1996). Upon reaching this stage, progenitors require either 
IL-2 or IL-15 to continue their development into mature CD56
bright
 NK cells (Shibuya 
et al. 1995, Mrózek et al. 1996, Williams et al. 1997, Suzuki et al. 1997, Yu et al. 
1998). CD56
bright
 NK cells are then thought to give rise to the CD56
dim
 population 
(discussed in chapter 1.1.7.1). 
19 
 
 
 
 
 
 
Figure 1-i: NK cells develop from bone marrow HSCs. Stem cells pass through 
multipotent and/or bi-potent stages before upregulating CD122 and committing to the NK 
cell lineage, after which they mature further into CD56
bright
 NK cells. Receptors which have 
been acquired at each developmental stage are shown in green, while loss of a receptor is 
indicated in red. 
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During the transition from pluripotent HSCs to committed NK progenitors, stem cells 
are thought to pass through multipotent and/or bipotent stages, however these stages 
have not been fully elucidated. Common lymphoid progenitors have been described in 
adult mouse bone marrow, giving rise to T, B and NK cells, but not myeloid cells 
(Kondo et al. 1997). However, other studies have indicated that there are a number of 
different intermediates that can give rise to NK cells, including progenitors of the 
myeloid lineage (Perez et al. 2003, Vitale et al. 2008, Grzywacz et al. 2011). NK cells 
seem to have the closest developmental association with T cells. CD25
-
 CD122
-
 
bipotent T/NK cell progenitors expressing GATA binding protein 3 (GATA3) and 
cytoplasmic CD3ε have been identified in mouse and human fetal thymus (Sanchez et 
al. 1994, Michie et al. 2000, Ikawa et al. 1999). These bipotent progenitors first 
become biased towards one lineage before fully committing; those which acquire 
CD25 mostly become T cells, but have not completely lost NK potential, whilst 
CD122
+
 progenitors are strongly biased towards the NK cell lineage (Ikawa et al. 
1999). A recent study by Lewis Lanier’s team indicates that the transcriptional profile 
of mature NK cells shows a high level of similarity to T cells in comparison to other 
leukocytes, which further supports the notion that they are developmentally related 
(Bezman et al. 2012).  
In vivo, development of HSCs into mature NK cells most likely takes place both in the 
bone marrow and at other sites. CD122
+
 NK progenitors are readily found in both 
lymph node and thymus (Ikawa et al. 1999, Freud et al. 2006, Eissens et al. 2012). 
However their CD34
+
 CD122
-
 uncommitted precursors are reported only in very small 
numbers in lymph node (Freud et al. 2006, Eissens et al. 2012). In thymus, bipotent 
T/NK progenitors are present, but not pluripotent HSCs (Sanchez et al. 1994, 
Leclercq et al. 1996, Michie et al. 2000, Ikawa et al. 1999, Kawamoto et al. 1998). 
Though NK progenitors are found in the thymus, this does not appear to be a crucial 
site for NK cell development, since peripheral NK cells, unlike T cells, are present 
and functional in athymic mice and thymectomised mice and humans, but not in mice 
with depleted bone marrow (Colucci et al. 2003). This has led to a model in which 
NK cells begin the developmental process in the bone marrow, then migrate to other 
sites such as secondary lymphoid tissue, where they mature further into CD56
bright
 NK 
cells (Freud et al. 2005, Eissens et al. 2012). The requirement for cytokines produced 
by bone marrow stromal cells is certainly consistent with the earliest developmental 
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stages occurring in the bone marrow. Progenitors of all stages, however, are found in 
bone marrow, from HSCs through committed NK progenitors to mature NK cells, so 
it is likely that many NK cells complete the entire developmental process in the bone 
marrow, while others migrate (Rosmaraki et al. 2001, Eissens et al. 2012). The 
relative importance of the different sites in the latter stages of NK cell development is 
unclear, although one can speculate on the roles that each might play. NK cell 
development in the bone marrow is likely to be driven by IL-15 constitutively 
produced by stromal cells (Mrózek et al. 1996). In lymph nodes however, 
development might be driven by IL-2 and IL-15 from activated T cells and dendritic 
cells (DCs) (Mrózek et al. 1996, Freud et al. 2005, Freud et al. 2006). Therefore one 
can hypothesise that the bone marrow might be a site for a more consistent, 
continuous generation of mature NK cells, whereas lymph node might provide bursts 
of NK cell maturation during the latter stages of infection, thus replenishing the 
mature NK cell pool. In addition, since these NK cells are initially of the 
immunoregulatory CD56
bright
 subset and in close proximity to activated T cells and 
DCs they might have a role in dampening the immune response once an infection is 
cleared (Fehniger et al. 2003, Ferlazzo et al. 2004). 
1.1.2 NK Cell Function is Determined by the Balance of Signals from 
Activating and Inhibitory Receptors 
A characteristic of NK cells is the ability to recognise “missing self” (see figure 1-ii). 
This refers specifically to their ability to respond to a lack of MHC class I molecules 
on a target cell, often a characteristic of tumour and virus-infected cells (Kärre et al. 
1986, Ljunggren et al. 1985, Ljunggren et al. 1988, Lanier et al. 2008). In this way, 
NK cells are able to kill pathogenic cells which have evaded recognition by CD8
+
 T 
cells. When an NK cell encounters a potential target cell, the outcome is determined 
by the recognition of ligands for a range of activating and/or inhibitory receptors (see 
figure 1-ii). Some activating ligands are constitutively expressed at low levels, which 
would not be enough to activate NK cells in the presence of inhibitory signals. 
However, when the inhibitory signal is absent, the weak activating signals may be 
sufficient to induce cytotoxicity (“missing self” recognition). Target cells expressing 
high levels of stress-induced activating ligands, such as MHC class I polypeptide-
related sequence (MIC) A and MICB, however, may be killed even in the presence of 
an inhibitory ligand (“stressed self/ induced self”) (Bauer et al. 1999, Cosman et al. 
22 
 
2001). The balance of signals from activating and inhibitory receptors can also 
influence production of cytokines such as interferon (IFN)γ (Cassatella et al. 1989, 
Draghi et al. 2007, Fauriat et al. 2010a, De Maria et al. 2011). Meanwhile, cytokines 
produced by other cells can induce a more activated, cytotoxic phenotype amongst 
NK cells, which enhances their ability to kill susceptible targets and produce further 
proinflammatory cytokines (Nagler et al. 1990, Gerosa et al. 2005, Mailliard et al. 
2005, Draghi et al. 2007). 
Important receptors involved in regulation of NK cell activity include the natural 
cytotoxicity receptors (NCRs), CD16, the natural killer group (NKG)2 family and the 
killer immunoglobulin-like receptor (KIR) family in humans or Ly49 family in 
rodents (Lanier 2008). Many other receptors and co-receptors, such as DNAX 
accessory molecule-1 (DNAM-1), leukocyte immunoglobulin-like receptors (LILRs), 
killer cell lectin-like receptor subfamily G member 1 (KLRG1) and the signalling 
lymphocyte activation molecule (SLAM) family can also influence the decision 
whether or not to kill a target (Tahara-Hanaoka et al. 2004, Ito et al. 2006, Vaidya and 
Matthew 2006, Cruz-Munoz et al. 2009, Kaur et al. 2012, Stegmann et al. 2012).  
Many of the activating receptors (including NCRs, CD16 and KIR) signal via 
immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor proteins 
such as DNAX-activating protein (DAP)12, CD3ζ and FcεRI-γ (Lanier 2008). ITAM 
phosphorylation upon receptor cross-linking induces binding of zeta-chain-associated 
protein kinase 70 (ZAP-70) and spleen tyrosine kinase (Syk) and activates a signalling 
cascade resulting in transcription of cytokine and chemokine genes as well as 
cytoskeletal reorganisation leading to polarisation and release of lytic granules 
(Brumbaugh et al. 1997, Lanier et al. 1998). Meanwhile, ligation of the inhibitory 
receptors NKG2A and KIR causes phosphorylation of the two immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) in the intracytoplasmic tail (Bruhns et al. 
1999, Kabat et al. 2002). Phosphorylated ITIMs act as docking sites for the Src 
homology domain-containing protein tyrosine phosphatases (SHP)-1 and -2, which 
dephosphorylate components of the activation pathway, thereby neutralising the 
activating signal (Le Dréan et al. 1998, Bruhns et al. 1999, Yusa and Campbell 2003, 
Vyas et al. 2004). Signalling pathways associated with both activating and inhibitory 
receptors are transient and localised around the NK-target cell synapse, so as not to 
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affect the ability of an NK cell encountering inhibitory ligands to subsequently kill a 
different target cell which lacks such ligands (Lanier 2008, Kaplan et al. 2011). 
 
Figure 1-ii: Missing self and stressed self recognition. (A) Missing self: When target cells do not 
express ligands specific for an NK cell’s inhibitory receptors, the threshold for activation is lowered, 
allowing the NK cell to kill target cells expressing normal levels of activating ligands. (B) Inhibitory 
signals antagonise components of the activation pathway, thereby sparing target cells expressing 
moderate levels of both activating and inhibitory ligands. (C) Stressed self: Cells expressing 
abnormally high levels of activating ligands (such as stressed or infected cells) induce cytotoxicity even 
in the presence of inhibitory ligands. Activating receptors and ligands are shown in green and yellow 
and inhibitory receptors and ligands in red and orange respectively. 
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One of the most potent activating receptors is NKG2D, which recognises the MHC 
class I chain-related molecules MICA, MICB and UL16-binding proteins (ULBPs) 1-
6 (Bauer et al. 1999, Cosman et al. 2001, Steinle et al. 2001). NKG2D is expressed on 
all NK cells, as well as γδ and CD8+ αβ T cells (Bauer et al. 1999). NKG2D 
homodimers associate with DAP10 (Wu et al. 1999). Phosphorylation of DAP10’s 
signalling motif allows it to bind phosphatidylinositol-3-OH kinase (PI3K) and 
growth factor receptor-bound protein 2 (Grb2), inducing a signalling pathway distinct 
from that of other activating receptors (Wu et al. 1999, Upshaw et al. 2006). NKG2D 
is particularly efficient at inducing cytotoxicity, but to a lesser extent also stimulates 
proliferation and production of cytokines including IFNγ (Bauer et al. 1999, Cosman 
et al. 2001, Kubin et al. 2001, Draghi et al. 2007, Lanier 2008). The NKG2D ligands 
ULBPs 1-3 are constitutively expressed at low levels on a variety of cell types, though 
they are further upregulated by viral infection (Cosman et al. 2001, Draghi et al. 
2007). Conversely, MICA and MICB are virtually absent from most normal cells but 
are highly expressed on some tumours (Groh et al. 1999, Pende et al. 2002, Carbone 
et al. 2005). NKG2D ligands are induced/ upregulated by the DNA damage response 
pathway (Gasser et al. 2005, Tang et al. 2008). NKG2D therefore has a key role in 
recognition of “stressed self”. MICA is also expressed by activated effector T cells, 
regulatory T cells (Tregs) and macrophages, which may provide a mechanism for NK 
cell-mediated elimination of potentially pathogenic overstimulated leukocytes once an 
infection has been cleared (Molinero et al. 2002, Hamerman et al. 2004, Roy et al. 
2008).  
Other members of the NKG2 family found on NK cells include the activating receptor 
NKG2C and the inhibitory receptor NKG2A (Houchins et al. 1997). Both of these 
function as heterodimers with CD94 and recognise human leukocyte antigen (HLA)-
E, a non-classical HLA molecule which presents signal peptides derived from other 
class I HLA molecules (Borrego et al. 1998, Braud et al. 1998, Lee et al. 1998, 
Brooks et al. 1999, Valés-Gómez et al. 1999). NKG2A is found on all CD56
bright
 NK 
cells and around 50% of CD56
dim
 NK cells (Vitale et al. 2004). It is more frequently 
expressed and has a higher binding affinity and more important role in regulating NK 
function than NKG2C (Valés-Gómez et al. 1999, Béziat et al. 2010). Binding affinity 
is, however, dependent on the sequence of the peptide bound to HLA-E, and this in 
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turn can affect the efficacy of NKG2A’s inhibitory function (Brooks et al. 1999, 
Valés-Gómez et al. 1999).  
The more recently described NCRs (including NKp30, NKp44 and NKp46), another 
family of activating receptors common to humans and mice, recognise a wide range of 
ligands, some of which are likely still to be discovered. NKp44 and NKp46 recognise 
influenza virus haemagglutinin (HA) on the surface of infected cells (Arnon et al. 
2001, Mandelboim et al. 2001). NKp44 is also able to bind directly to envelope 
proteins of Dengue and West Nile viruses and to the surface of mycobacteria, whilst 
NKp46 recognises the normally intracellular intermediate filament protein vimentin, 
which is upregulated on the surface of monocytes infected with Mycobacterium 
tuberculosis (Garg et al. 2006, Esin et al. 2008, Hershkovitz et al. 2009). NKp30 
mediates activation by DCs and also recognises the tumour antigens B7-H6 and 
nuclear factor HLA-B-associated transcript 3 (Ferlazzo et al. 2002, Vitale et al. 2005, 
Pogge van Strandmann et al. 2007, Brandt et al. 2009). NKp46 and NKp30 are found 
on all NK cells, whereas NKp44 is predominantly restricted to CD56
bright
 NK cells in 
secondary lymphoid tissue and gut, but may be induced on activated peripheral blood 
NK cells (Moretta et al. 2001). NCRs are considered to be specific to NK cells and 
are absent from other peripheral blood leukocytes, though data from our lab suggests 
that NKp46 may be found on astrocytes (Durrenberger et al. 2012).  
Another important activating receptor is the Fc receptor CD16 (FcγRIII). This 
receptor mediates antibody-dependent cellular cytotoxicity (ADCC), a process which 
links NK cells to the adaptive immune response (Heijnen and van der Winkel 1997). 
Target cells coated with immunoglobulin (Ig)G cross-link CD16 on NK cells, 
resulting in tyrosine phosphorylation of the CD3ζ adaptor molecule, which triggers a 
cytotoxic response against the target as well as cytokine production (Ullberg and 
Jondal 1983, Cassatella et al. 1989, O’Shea et al. 1991, Vivier et al. 1991, Trinchieri 
and Valiente 1993). The efficacy of ADCC is dependent on both the density of 
antibody on the coated cell and the affinity of the antibody for its target antigen 
(Velders et al. 1998, Bowles and Weiner 2005). Unlike other NK cell activating 
receptors, triggering of CD16 alone is sufficient to elicit a cytolytic response amongst 
resting NK cells (Bryceson et al. 2005). 
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Missing self recognition in humans is largely mediated by a highly polymorphic 
family of receptors for classical human leukocyte antigen class I (HLA class I) 
molecules, the killer immunoglobulin-like receptors (KIRs), which are absent from 
lower mammals including mice (Parham 2005). The KIR family comprises both 
activating and inhibitory receptors. Inhibitory KIRs have long cytoplasmic tails 
containing two ITIMs (denoted  “L”) (Biassoni et al. 1996, Bruhns et al. 1999). 
Activating KIRs usually have short cytoplasmic tails (“S”) containing a basic amino 
acid in the transmembrane region, allowing them to interact with a region containing 
an acidic residue in the ITAM-containing adaptor protein DAP-12 (Biassoni et al. 
1996, Lanier et al. 1998, Lanier 2008). The exception to this is the long-tailed 
receptor KIR2DL4, which contains a single ITIM as well as a basic residue (Faure 
and Long 2002). It primarily activates NK cells via the FC receptor γ protein 1, but 
also possesses ITIM-dependent inhibitory function (Faure and Long 2002, Kikuchi-
Maki et al. 2003, Kikuchi-Maki et al. 2005).  
Each KIR has specificity for HLA molecules containing a particular motif. KIRs with 
two extracellular domains (KIR2D) mainly recognise HLA-C molecules and display a 
preference towards either “C1” alleles, with serine at position 77 and asparagine at 
position 80, or “C2” alleles, containing asparagine at position 77 and lysine at position 
80 (Colonna et al. 1993). KIR3DL1 and KIR3DL2 recognise specific alleles of HLA-
A and –B, whilst KIR2DL4 interacts with HLA-G (Cella et al. 1994, Gumperz et al. 
1995, Rajagopalan and Long 1999, Hansasuta et al. 2004, Stern et al. 2008, Vivian et 
al. 2011). The affinity of the interaction and therefore the strength of the activating/ 
inhibitory signal, is influenced by KIR/HLA polymorphism and possibly by the 
peptide bound to the HLA molecule at the time (Hansasuta et al. 2004, Ianello et al. 
2008, Sanjanwala et al. 2008, Sharma et al. 2009, Colantonio et al. 2011, Fadda et al. 
2011, Vivian et al. 2011). 
Not only are the individual genes encoding KIR and HLA highly polymorphic, there 
is also copy number and haplotype variation (Uhrberg et al. 1997, Hsu et al. 2002, 
Parham 2005, Jiang et al. 2012). Most KIR genes are not common to all individuals: 
some people have more activating KIRs whereas others have a more inhibitory 
repertoire (Uhrberg et al. 1997, Parham 2005). In addition to this, individuals vary in 
the proportion of NK cells expressing KIRs, and each KIR
+
 NK cell within an 
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individual expresses a different combination of KIRs on the cell surface (Yawata et 
al. 2008). KIR genotype is a major source of variation between individuals with 
regard to NK cell activation and influences susceptibility to infection, autoimmunity, 
cancer and reproductive disorders (Yen et al. 2001, Martin et al. 2002, van der Silk et 
al. 2003, Hiby et al. 2004, Khakoo et al. 2004, Suzuki et al. 2004, Verheyden et al. 
2004, Jones et al. 2006, Martin et al. 2007, Hiby et al. 2008, Lorentzen et al. 2009, 
Hiby et al. 2010). Haplotypes associated with activation, especially those containing 
the activating KIR 2DS1 or 2DS2, have been associated with autoimmune diseases 
including multiple sclerosis, diabetes, psoriasis, rheumatoid arthritis and ulcerative 
colitis (Yen et al. 2001, van der Silk et al. 2003, Suzuki et al. 2004, Jones et al. 2006, 
Lorentzen et al. 2009). Inhibitory haplotypes may lead to increased susceptibility to 
infection, allowing haplotypes which predispose to autoimmunity to persist in the 
population (Martin et al. 2002). However, during some infections, certain inhibitory 
receptors may be protective, perhaps as a result of licensing conferring enhanced 
ability to recognise missing self (Khakoo et al. 2004, Martin et al. 2007) (see chapter 
1.1.3).  
Close to the KIR locus are genes encoding another family of both activating and 
inhibitory receptors, the LILRs, which are expressed on some NK cells, as well as T 
cells, B cells, monocytes and DCs (Kaur et al. 2012). In a similar manner to KIRs, 
activating LILRs (LIRA) associate with ITAM-containing adaptor proteins, while 
inhibitory LILRs (LIRB) transmit signals via their own ITIMs. Several of the LILRs 
bind classical and non-classical MHC class I ligands and LILRA4 binds tetherin (a 
membrane protein that inhibits release of viral particles), while the ligands for many 
of the LILR family are not yet known (Cosman et al. 1997, Colonna et al. 1998, 
Chapman et al. 1999, Allen et al. 2001, Cao et al. 2009, Ryu et al. 2011, Kaur et al. 
2012). 
1.1.3 NK Cell Education Determines Responsiveness to Activating Signals 
NK cell education refers to a process thought to take place during development that 
prevents activation of NK cells lacking inhibitory receptors specific for self-ligands 
(see figure 1-iii). This is likely an important mechanism preventing autoreactivity. 
Olsson et al. first presented evidence to support this concept in C57BL/6 mice in 
1995. Ly49
+
 (equivalent to human KIR
+
) NK cells were only able to kill tumour cells 
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lacking Ly49 ligands when they were derived from mice which expressed its ligand 
H-2D(d) on normal cells. Meanwhile, Ly49A
+
 NK cells are more effectively inhibited 
by their ligand, H-2b, when derived from mice which express this ligand (Dorfman 
and Raulet 1996). Therefore the immunological environment in which NK cells 
develop appears to tune their responsiveness to both presence and absence of 
inhibitory signals. The selective nature of education was demonstrated by Kim et al. 
(2005), who showed that adding a transgene encoding the ligand for Ly49C into MHC 
class I- deficient strains resulted in Ly49C
+
, but not Ly49A
+
, NK cells regaining the 
ability to mount an IFNγ response.  
The exact mechanism by which education occurs is not yet understood. Some models 
suggest that NK cells expressing self-inhibitory receptors are “licensed” to become 
responsive to activating signals (Kim et al. 2005). Alternatively, education has been 
described as a process of “disarming”, whereby NK cells lacking such receptors are 
eliminated from the repertoire, inactivated, or perhaps become anergic due to 
persistent activating signals (Valiante et al. 1997, Fernandez et al. 2005, Raulet and 
Valance 2006, Yawata et al. 2008). 
A study of human NK cell clones found that over 98% were inhibited by autologous 
HLA class I, leading to the “at least one” hypothesis, that NK cells not expressing an 
inhibitory receptor for self-HLA are eliminated from the repertoire (Valiante et al. 
1997). However, this study examined NK cell clones from just two donors, who were 
most likely not representative of the population, since subsequent studies have 
described the presence of substantial numbers of NKG2A
- 
KIR
-
 NK cells in peripheral 
blood (Anfossi et al. 2006, Cooley et al. 2007, Yawata et al. 2008). Though present, 
such cells are hyporesponsive to stimulation by cytokines, tumour cells or antibody-
mediated crosslinking of activating receptors (Anfossi et al. 2006, Cooley et al. 
2007). In humans, NK cells which do not express NKG2A must not only express at 
least one inhibitory KIR in order to respond effectively, this KIR must also be specific 
for self-HLA (Anfossi et al. 2006, Yawata et al. 2008). However, NK cell education 
is not as simple as just an “on/off” switch; more recently it has been described as a 
“rheostat” (Joncker et al. 2009).  The more self-specific inhibitory receptors an NK 
cell expresses, the greater the cytotoxic and IFNγ response to a variety of stimuli (Yu 
et al. 2007, Yawata et al. 2008, Brodin et al. 2009, Joncker et al. 2009). Just one HLA 
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ligand can abolish the response of NK cells expressing multiple self-specific 
inhibitory receptors, meaning that those cells with the highest potential response have 
the most stringent criteria for activation (they will only be activated when several self 
HLA molecules are missing) (Yu et al. 2007).   
Since the NKG2A
-
 KIR
-
 NK cells described in peripheral blood resemble mature 
CD56
dim
 NK cells in expression of CD16, CD162R and other surface receptors, and 
lack markers such as CD117 associated with progenitor cells, it seems most likely that 
these cells have differentiated from mature NKG2A
+
 KIR
- 
NK cells (Anfossi et al. 
2006). If this is indeed the case, it would argue against a model in which cells become 
permanently licensed at an early stage of maturity, since these cells were presumably 
functional and “licensed” prior to loss of NKG2A. Perhaps NK cells in fact require 
continual licensing throughout their lifetime in order to remain fully functional. Or 
perhaps both arming and disarming occur upon gain and loss of an inhibitory receptor 
respectively. 
It appears that the hyporesponsiveness of unlicensed NK cells can be overcome under 
certain conditions. In vitro, pre-stimulation with IL-2 or polyinosinic-polycytidylic 
acid (poly I:C) partially abrogates hyporesponsiveness (Kim et al. 2005). In addition, 
strong activation of unlicensed NK cells has been reported during infection with 
Listeria monocytogenes or mouse cytomegalovirus and in leukaemia patients 
following HLA-matched HSC transplantation (Fernandez et al. 2005, Yu et al. 2009, 
Orr et al. 2010).  
Although discussion of education has so far focussed largely on the role of inhibitory 
receptors, it seems that activating receptors may also be involved in the process. Noé 
mice, which have a defect in NKp46 expression, have hyperresponsive NK cells, 
which are more able to stimulate the T cell response, and are therefore able to clear 
infection more rapidly (Narni-Mancinelli et al. 2012). In humans, the responsiveness 
of KIR2DS2
+
 NK cells to target cells is tuned down in individuals homozygous for 
the KIR2DS2 ligand HLA-C2, though cytokine responsiveness is not affected (Fauriat 
et al. 2010b). Thus, it seems that education tunes an NK cell’s responsiveness 
according to its ability to recognise both activating and inhibitory signals. 
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Figure 1-iii: NK cell education maintains tolerance of NK cells lacking self-specific inhibitory 
receptors. NK cell responsiveness is determined by engagement of  inhibitory and activating 
molecules during a process known as NK cell education. NK cells that lack inhibitory receptors (A) or 
that only express inhibitory receptors specific for non-self HLA molecules (B) are present in the 
repertoire, but are hyporesponsive to stimulation via their activating receptors. Conversely, inability to 
recognise common activation signals during education may result in hyperresponsiveness (D). 
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1.1.4 NK Cells Form Synapses with Target Cells and Kill Susceptible 
Targets via Granzyme Release and Other Mechanisms 
NK cells induce death of targets primarily through directed secretion of cytotoxic 
granules, as well by engaging receptors of the tumour necrosis factor (TNF) 
superfamily such as Fas and TNF-related apoptosis-inducing ligand (TRAIL) 
receptors (Scott et al. 2008). Compared to resting CD8
+
 T cells, resting NK cells 
express higher levels of granzymes and molecules associated with vesicular transport 
and cytoskeletal rearrangement, allowing them to respond more rapidly (Bezman et 
al. 2012). NK cells must first contact the target cell, then form an immunological 
synapse through which cytolytic molecules and cytokines can be directly targeted 
towards the susceptible target cell (Davis et al. 1999, Vyas et al. 2001, McCann et al. 
2003, Orange et al. 2003, Culley et al. 2009).  
Initial interactions, possibly mediated by CD2/sialyl Lewis X and/or selectins, are 
followed by firm adhesion mediated by higher affinity receptor-ligand interactions 
involving integrins such as lymphocyte function-associated antigen 1 (LFA-1) and 
macrophage receptor 1, which rapidly cluster at the synapse during initiation and also 
participate in activation of cytolytic pathways (Davis et al. 1999, Riteau et al. 2003, 
Orange 2008, Mace et al. 2010). Signals from activating and inhibitory receptors will 
then determine progression to either an activating or inhibitory synapse (Vyas et al. 
2001, Vyas et al. 2002, Culley et al. 2009). Once tight contacts have been formed 
between NK and susceptible target cells, around half of these interactions result in 
killing, which can be either rapid (within 2-5 minutes of conjugate formation) or 
delayed, with a prolonged period of contact during which calcium levels and actin 
accumulation fluctuate prior to polarisation and release of cytotoxic granules 
(Wulfing et al. 2003). 
If activating signals are sufficient to override inhibitory ones, an activating (lytic) 
synapse can be formed. Filamentous (F)-actin accumulation at the synapse leads to 
symmetrical spreading which broadens the interface between NK cell and target cell 
and increases stability of the NK cell:target cell conjugate (McCann et al. 2003, 
Wulfing et al. 2003, Culley et al. 2009) . Ezrin, radixin and moesin (ERM) family 
proteins, which connect actin filaments to membrane structures, are present at the 
synapse and may be involved in recruitment of further receptors and associated 
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signalling molecules to synaptic lipid rafts, forming a supramolecular activation 
cluster (SMAC) (McCann et al. 2003, Watzl et al. 2003, Masilamani et al. 2006). A 
dense ring of F-actin forms at the peripheral (p) SMAC and integrins and talin also 
localise to this region in an actin-dependent manner (McCann et al. 2003, Orange et 
al. 2003, Vyas et al. 2001). Meanwhile, adaptor and signalling molecules such as Syk, 
ZAP-70, SH2 domain-containing leukocyte protein of 76 kDa (SLP-76) and SHP-1 
accumulate in the centre of the synapse, forming the cSMAC (Vyas et al. 2001). 
Dynein drives migration of lytic granules along microtubules to the microtubule 
organising centre (MTOC), which then polarizes towards the centre of the synapse 
(Küpfer et al. 1983, Küpfer et al. 1985, Stinchcombe et al. 2011, Mentlik et al. 2010). 
A number of hypodense regions of actin form within the central part of the synapse, 
where the gaps between filaments are large enough to allow granules to pass through 
(Brown et al. 2011, Rak et al. 2011). Granules migrate along filaments towards the 
cell membrane in a myosin IIA-dependent manner before fusing with the cell 
membrane and being released in the direction of the target cell (Andzelm et al. 2007, 
Sanborn et al. 2009).  
Following activating receptor ligation, the protein tyrosine kinase Syk is recruited to 
phosphorylated ITAMs and becomes activated (Brumbaugh et al. 1997). Activation of 
Syk has an important role in NK cell cytotoxicity, mediated in part by its 
phosphorylation of the nucleotide guanine exchange factors Vav 1-3 (Brumbaugh et 
al. 1997, Deckert et al. 1996, Galandrini et al. 1999). Vav 2 and 3 appear to be more 
important in signalling induced via DAP12 or FcRγ, whereas Vav1 is crucial for 
NKG2D/DAP10-induced cytotoxicity and may also be activated by integrin 
engagement (Riteau et al. 2003, Cella et al. 2004, Graham et al. 2006). Tyrosine 
phosphorylation of Vav and consequent activation of its target ras-related C3 
botulinum toxin substrate 1 (Rac1), are important for triggering actin reorganisation, 
broadening of the immunological synapse and polarisation of lytic granules (Billadeau 
et al. 1998, Cella et al. 2004, Graham et al. 2006). Blocking of the p21-activated 
kinase (PAK1)/mitogen-activated protein kinase kinase (MEK)/extracellular signal-
related kinase (ERK) pathway, which is activated by Rac1, severely impairs cytotoxic 
function (Cella et al. 2004). Syk also induces lipid raft polarisation and activates 
PI3K, another inducer of the Rac1/PAK/MEK/ERK pathway and phospholipase C-γ 
(PLC-γ), which initiates the inositol 1,4,5-triphosphate (IP3)/ Ca2+ signaling pathway 
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through its cleavage of membrane-associated phosphatidylinositol 4,5-bisphosphate 
(PIP2) (Ting et al. 1992, Cassatella et al. 1989, Azzoni et al. 1992, Windebank et al. 
1988, Lou et al. 2000, Jiang et al. 2002). Protein kinase C is activated via this 
pathway and phosphorylates WASp-interacting protein (WIP), leading to formation of 
a complex containing WIP, actin, myosin IIA and the cytoskeletal regulator Wiscott-
Aldrich Syndrome protein (WASp), which is crucial for F-actin accumulation and 
subsequent cytotoxic activity (Graves et al. 1986, Orange et al. 2002, Krzewski et al. 
2006). Activation of talin in response to LFA-1 ligation by intercellular adhesion 
molecule 1 (ICAM-1) also induces the PIP2 pathway and recruits the actin nucleating 
protein complex Arp2/3, which mediates actin polymerisation promoted by WASp 
(Mace et al. 2010). Meanwhile, the increased calcium levels promote interaction of 
mammalian uncoordinated (Munc)- 13-4 with soluble NSF protein attachment 
receptor (SNARE) proteins and Rab27a, which is important for fusion of cytotoxic 
granules with the cell surface membrane (Feldmann et al. 2003, Johnson et al. 2011, 
Boswell et al. 2012). 
If there is sufficient inhibitory input however, an inhibitory synapse will form 
between the NK cell and the target cell. Rings of inhibitory receptors such as long- 
tailed KIR and associated signalling molecules form at the synapse around a central 
cluster of adhesion molecules (Davis et al. 1999, Vyas et al. 2001, McCann et al. 
2003, Treanor et al. 2006, Orange 2008). This so-called supramolecular inhibitory 
cluster (SMIC) blocks further recruitment of activating receptors and signalling 
molecules and antagonises their signalling function (Watzl et al. 2003,Vyas et al. 
2004, Endt et al. 2007). Ligation of inhibitory receptors causes them to translocate to 
the centre of the synapse, where the phosphorylated ITIMs provide a docking site for 
the tyrosine phosphatases SHP-1 and -2, releasing them from autoinhibition (Yusa et 
al. 2003, Vyas et al. 2004). SHP-1 dephosphorylates components of the activation 
pathway such as Vav1, SLP-76, the ERM family, pp36 (an adaptor protein required 
for recruitment of PLC-γ) and possibly Syk, thereby preventing actin reorganisation, 
blocking recruitment of activating receptors and lipid raft polarisation, preventing 
symmetrical cell spreading and promoting detatchment from the target cell (Valiante 
et al. 1996, Brumbaugh et al. 1997, Binstadt et al. 1998, Burshtyn et al. 2000, 
Stebbins et al. 2003, Watzl et al. 2003, Masilamani et al. 2006, Endt et al. 2007, , 
Culley et al. 2009).  
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NK cell lytic granules consist of an inner electron-dense region containing cytotoxic 
mediators surrounded by a multivesicular lysosomal-like cortical layer (Burkhardt et 
al. 1990). Their contents include the membrane perturbing enzyme perforin, pro-
apoptotic serine proteases known as granzymes and enzymes such as cathepsin B 
which protect the NK cell from apoptotic induction by components of its own 
granules (Lieberman 2003, Balaji et al. 2002).  
Perforin is essential for induction of apoptosis by granzymes (Kägi et al. 1994, Walsh 
et al. 1994). Originally, it was proposed that perforin-mediated formation of pores in 
the cell surface membrane provided passages for granzymes to diffuse into the target 
cell. However there is limited evidence to support this hypothesis and in order to form 
large enough pores to facilitate diffusion of granzymes into the target cell, very high 
concentrations of perforin are required, much higher than the concentration needed to 
facilitate granzyme-induced apoptosis (Browne et al. 1999, Trapani and Smyth 2002). 
At lower concentrations of perforin, small pores are formed in the target cell 
membrane, triggering a Ca
2+
 flux– induced repair process, which prevents necrotic 
cell death and leads to endocytosis of perforin and granzymes in enlarged endosomes 
(Thiery et al. 2010). Several studies have shown that granzymes can enter the target 
cell independently of perforin, for instance by binding to the mannose 6-phosphate 
receptor, but that perforin is required for cytosolic and nuclear localisation of 
granzymes and apoptotic induction once inside the cell (Froelich et al. 1996, Shi et al. 
1997, Pinkosi et al. 1998, Motyka et al. 2000). One important function of perforin is 
likely to be disruption of endosomal trafficking (Browne et al. 1999, Thiery et al. 
2011). Perforin forms pores in the endocytic membrane, triggering endosome rupture 
and release of granzymes into the cytosol of the target cell (Thierry et al. 2011).  
Human cytolytic granules contain granzymes A, B, H, K and M, with A and B being 
the most abundant (Lieberman 2003). Granzyme B can induce apoptosis via both 
caspase-dependent and –independent mechanisms. It is able to activate both apical 
caspases (8 and 10) and executioner caspases (3, 6 and 7) by cleaving after aspartic 
acid residues between the large and small subunits of the procaspase (Medema et al. 
1997a, Talanian et al. 1997, Yang et al. 1998a). Caspases themselves also cleave at 
sites following aspartic acid residues, but vary in specificity. Apical caspases cleave 
downstream executioner caspases, which then cleave a variety of substrates, resulting 
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in activation of pro-apoptotic and degradation of anti-apoptotic molecules (Lieberman 
2003). In cell-free assays, caspase 7 and 10 are the most efficiently processed by 
granzyme B, however in cell culture, full maturation of caspase 7 is dependent on the 
activation of caspase 3 and/or 10  (Talanian et al. 1997, Yang et al. 1998a). Cleavage 
of caspase 10 is likely to occur first (Talanian et al. 1997). Caspase 10 can in turn 
activate caspase 3, which can also be directly but inefficiently cleaved by granzyme B 
(Talanian et al. 1997). Activated caspase 3 removes the propeptide from the caspase 7 
precursor, making it accessible to granzyme B which then cleaves it at a different site, 
resulting in production of active caspase 7 (Yang et al. 1998a).  
Caspases 3 and 7 proteolytically inactivate inhibitor of caspase-activated 
deoxyribonuclease (ICAD) which releases caspase-activated DNase (CAD) from 
inhibition (Enari et al. 1998, Liu et al. 1999, Wolf et al. 1999). CAD oligomerizes 
into a functional complex and creates blunt ended double-stranded breaks in DNA, 
producing oligonucleosomal fragments of approximately 200 base pairs (Liu et al. 
1999, Wolf et al. 1999, Enari et al. 1998 Lieberman 2003). Caspases also cleave poly 
(ADP-ribose) polymerase (PARP), preventing it from synthesising ADP-ribose 
polymers for DNA repair (Labeznik et al. 1994, Gu et al. 1995, Tewari et al. 1995, 
Germain et al. 1999). Chromatin condensation is induced by the cleaved form of 
Acinus, another target of caspase 3 (Sahara et al. 1999). Caspase 8 cleaves the pro-
apoptotic protein BH3 interacting-domain death agonist (Bid), the truncated form of 
which (tBid) translocates to the mitochondrial outer membrane, where it induces 
oligomerization of  bcl-2 homologous antagonist/killer (Bak), allowing it to form 
pores in the outer mitochondrial membrane, facilitating release of cytochrome C (Li et 
al. 1998). Another important mitochondrial target is NDUFS1, the 75 kDa subunit of 
respiratory complex I (Ricci et al. 2004). Caspase 3- mediated cleavage disrupts its 
function in the electron transport chain, causing loss of membrane potential, increased 
reactive oxygen species (ROS) production and reduced adenosine triphosphate (ATP) 
levels (Ricci et al. 2003, Ricci et al. 2004). Morphological changes, membrane 
blebbing and packaging of fragmented DNA into apoptotic bodies have also been 
attributed to enzymes activated by caspases, including Rho-associated protein kinase 
1 (ROCK-1), which mediates myosin light phosphorylation and coupling of actin-
myosin filaments to the plasma membrane, gelsolin which severs actin filaments, and 
PAK-2, a serine/threonine kinase which phosphorylates myosin light chain, MEK1 
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(inducer of p38 and cJun N-terminal kinase (JNK) pathways) and the p47
phox
 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) subunit (Kothakota 
et al. 1997, Bokoch 1998, Rudel et al. 1998, Coleman et al. 2001).  
Granzyme B is also able to directly cleave many caspase targets (Lieberman 2003). 
These include ICAD, as well as proteins involved in recognising and repairing DNA 
damage such as PARP and DNA-dependent protein kinases (Sharif-Askari et al. 2001, 
Thomas et al. 2000, Andrade et al. 1998). Granzyme B also induces microtubule 
polymerisation and cytoskeletal rearrangement by removing an autoinhibitory domain 
from alpha tubulin (Goping et al. 2006). In addition, it can directly cleave Bid, 
causing release of cytochrome C from the mitochondrianda (Barry et al. 2000, Sutton 
et al. 2000, Wang et al. 2001a). Granzyme B also cleaves myeloid cell leukaemia 
sequence 1L (Mcl-1L), preventing its sequestration of Bcl-like protein 11 (Bim), 
another inducer of cytochrome C release (Han et al. 2004). Cytochrome C and dATP 
promote binding of caspase 9 to apoptotic peptidase activating factor 1(Apaf-1), 
resulting in activation of caspase 9, which in turn cleaves the executioner caspases 3 
and 7 (Li et al. 1997). Direct cleavage of Bid by granzyme B appears to have a more 
important role in granzyme B-induced apoptosis than caspase-mediated Bid cleavage 
(Trapani et al. 1998, Heibein et al. 1999, MacDonald et al. 1999, Sutton et al. 2000, 
Waterhouse et al. 2006). However this positive feedback loop may be important for 
preventing repolarisation of the mitochondrial membrane (MacDonald et al. 1999, 
Waterhouse et al. 2006).  
Granzyme A does not activate caspase 3 or downstream effectors such as PARP, but 
induces DNA damage, nuclear condensation and membrane blebbing in a caspase-
independent manner (Beresford et al. 1999). The mitochondrial membrane becomes 
depolarised and production of ROS is increased, however, in contrast to granzyme B, 
these effects are not dependent on the Bid/Bcl2 or caspase pathways and cytochrome 
C is not released (Lieberman 2003, Martinvalet et al. 2005). Granzyme A directly and 
efficiently cleaves lamins A, B and C (which are also cleaved by granzyme B- 
activated caspases), resulting in disruption of the nuclear envelope (Zhang et al. 
2001a). It also inactivates several components of the endoplasmic reticulum-
associated SET complex. These include the DNA bending protein high mobility group 
protein 2 (HMG2) and apurinic endonuclease-1 (Ape1), an enzyme which inhibits 
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generation of reactive oxygen species, repairs oxidised DNA and reduces oxidised 
transcription factors (Fan et al. 2002, Fan et al. 2003a, Guo et al. 2008). SET itself is 
also cleaved by granzyme A, releasing the tumour metastasis suppressor NM23H1 
from inhibition, prompting its translocation to the nucleus, where it creates single-
strand nicks in chromosomal DNA (Fan et al. 2003b). Therefore granzyme A both 
induces DNA damage and prevents its repair. Granzyme A also has functions beyond 
apoptosis, such as inducing monocyte proinflammtory cytokine secretion and 
retraction of neurites by mouse neuronal cells (Suidan et al. 1994, Metkar et al. 2008). 
Both granzyme A and B can independently induce apoptosis in the presence of 
perforin, however they also act synergistically (Lieberman 2003). One explanation for 
this is that granzyme A cleaves several histone proteins, including histone H1, which 
facilitates chromatin hypercondensation (Zhang et al. 2001b). This results in 
unfolding, thereby increasing access to DNases including CAD, which mediates 
oligonucleosomal DNA degradation in response to granzyme B.  
Granzyme K induces apoptosis in a similar manner to granzyme A. It induces loss of 
mitochondrial membrane potential and rapid generation of ROS via cleavage of Ape1 
and possibly other mechanisms (Guo et al. 1998, MacDonald et al. 1999). Like 
granzyme A, it cleaves SET, activating NM23H1 to create single-stranded DNA nicks 
(Zhao et al. 2007a). It can also directly cleave Bid, leading to release of cytochrome C 
and endonuclease G (Zhao et al. 2007b). 
The functions of granzymes H and M are only now being elucidated. Cell death-
related substrates of granzyme H include Bid and ICAD (Hou et al. 2008). Granzyme 
M indirectly triggers caspase cascades by cleavage of survivin and directly cleaves 
PARP, ICAD, PAK2 and the nuclear phosphoprotein nucleophosmin which is 
essential for cell survival (Lu et al. 2006, Cullen et al. 2009, Hu et al. 2010). It 
inactivates the ROS antagonist heat shock protein 75 and cleaves the cytoskeletal 
components ezrin and alpha-tubulin, disrupting microtubule organisation 
(Bovenschen et al. 1999, Hua et al. 2007). Granzyme M also enhances granzyme B- 
mediated killing by inactivating the granzyme B inhibitor proteinase inhibitor 9 
(Mahrus et al. 2004). In addition to their apoptotic function, granzymes H and M both 
cleave proteins essential for viral replication (Andrade et al. 2007, van Domselaar et 
al. 2010).  
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NK cells can also trigger cell death independently of granzymes, by ligation of the 
TNF superfamily receptors, Fas (CD95) and the TRAIL receptors DR4 and DR5. 
Binding of trimeric or hexameric Fas or TRAIL to receptor trimers causes 
dimerization of the trimers and organisation of receptor complexes into large clusters 
(Chan et al. 2000, Siegel et al. 2000, Holler et al. 2003, Valley et al. 2012). Fas-
associated death domain (FADD) proteins are recruited to the cytoplasmic death 
domains of the activated Fas/TRAIL receptors (Boldin et al. 1995, Chinnaiyan et al. 
1995, Kischkel et al. 2000, Sprick et al. 2000). FADD then recruits pro-caspase 8 to 
the receptor complex, triggering proximity-induced dimerisation (Muzio et al. 1996, 
Medema et al. 1997b, Muzio et al. 1998, Kischkel et al. 2000, Sprick et al. 2000, 
Boatright et al. 2003). Dimerisation is essential for inducing autoproteolytic activity 
of pro-caspase 8 and renders it susceptible to cleavage by other nearby pro-caspase 8 
dimers (Muzio et al. 1998, Yang et al. 1998b, Chang et al. 2003, Donepudi et al. 
2003). Pro-caspases are cleaved first between the large and small subunits, and then at 
a second site separating the large subunit from the pro-domain (Chang et al. 2003). 
Substrate specificity is altered upon processing: whereas pro-caspase 8 specifically 
cleaves other pro-caspase 8 molecules, mature caspase 8 instead cleaves pro-caspase 
3, triggering the same apoptotic pathways as described for granzyme B (Stennicke et 
al. 1998, Chang et al. 2003). Caspase 8 also cleaves receptor interacting protein 
(RIP), which activates activator protein 1 (AP-1) and nuclear factor (NF)-κB 
signalling and initiates necrotic cell death when the apoptotic pathway is blocked (Lin 
et al. 1999, Holler et al. 2000). There is evidence that caspase 10, another apical 
caspase activated upon dimerization, can also be recruited to FADD following Fas or 
TRAIL stimulation, however whether or not this plays a significant role in 
Fas/TRAIL-mediated apoptosis is contraversial (Kischkel et al. 2001, Wang et al. 
2001b, Sprick et al. 2002, LaFont et al. 2010). Caspase 10 also cleaves caspase 3 and 
therefore may provide and alternative apoptotic pathway in caspase 8-deficient cells 
(Stennicke et al. 1998, Wang et al. 2001b). 
1.1.5 NK Cells Produce a Range of Cytokines and Chemokines 
In addition to their direct role in killing infected or abnormal cells, NK cells are also 
able to exert influence on many other aspects of the immune response, via cytokine 
production, contact-dependent stimulation or inhibition and killing of other leukocytes 
such as T cells, B cells and DCs.  
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Activated NK cells release large quantities of IFNγ, a pleiotropic cytokine which is 
also produced by Thelper (Th)1, CD8
+
 T cells and invariant natural killer T (iNKT) 
cells (Schroder et al. 2004). IFNγ production can be induced by cytokines 
(particularly IL-12 with IL-18), ligation of activating receptors upon encounter with 
target cells, interactions with other leukocytes, or a combination of these (Cassatella 
et al. 1989, Cuturi et al. 1989, Fehniger et al. 1999, Fauriat et al. 2010a). It has effects 
on antigen presentation, antibody production, T cell polarisation, macrophage 
function, leukocyte trafficking, cell cycle and apoptosis (Schroder et al. 2004).  
IFNγ upregulates expression of MHC class II and CIITA (class II, major 
histocompatibility complex, transactivator), a master regulator of the MHC class II 
antigen presentation pathway (Figueiredo et al. 1989, Chang et al. 1995, Barrerra et 
al. 1997, O’Keefe et al. 2001, Valledor et al. 2008). It also enhances expression of 
cathepsins and lysosomal proteases involved in peptide production for the MHC class 
II pathway and induces expression of new proteasome subunits that increase the 
quantity and diversity of peptides available for MHC class I (Schroder et al. 2004). In 
addition, IFNγ upregulates co-stimulatory molecules on antigen-presenting cells 
(APCs), leading to more efficient activation of antigen-specific CD4
+
 T cells 
(Menèndez Iglesias et al. 1997, Lee et al. 2006). 
If present during T cell receptor (TCR) stimulation, IFNγ has both direct and indirect 
effects on T cell polarisation, promoting Th1 and Treg and inhibiting Th2 and Th17 
differentiation (Harrington et al. 2005, Park et al. 2005, Murugaiyan et al. 2010). 
Effects on dendritic cells are important in this: IFNγ promotes production of the Th1-
promoting cytokine IL-12 and the Treg-promoting cytokine IL-27, but inhibits 
expression of the Th17-polarising protein osteopontin by DCs (Murugaiyan et al. 
2010). It also has effects on B cells, promoting isotype switching to IgG2a and 
antagonising IL-4-induced expression of the FcεR2 receptor for IgE (Rousset et al. 
1988, Gao et al. 2001).  
IFNγ enhances macrophage function by upregulating Fc receptors, promoting 
phagocytosis and inducing transcription of NADPH oxidase subunits and inducible 
nitric oxide synthase (iNOS), causing generation of ROS and reactive nitrogen species 
(RNS) (Nathan et al. 1983, Newburger et al. 1988, Cassatella et al. 1990a, Cassatella 
et al. 1990b, Gupta et al. 1992, Zhang et al. 2012). It also promotes leukocyte 
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trafficking by inducing dilation of blood vessels and expression of chemokines and 
adhesion molecules involved in adhesion of leukocytes to vascular endothelial cells 
(Schroder et al. 2004, Kebir et al. 2009). In contrast to its activating effects, IFNγ can 
also act to inhibit cell proliferation and increases sensitivity of activated T cells and 
myeloid cells to pro-apoptotic signals by promoting expression of death receptors, 
caspases 8 and 9, protein kinase R (PKR) and various components of the 
mitochondrial apoptotic pathway (Refaeli et al. 2002, Li et al. 2007).  
IFNγ binds to the type II IFN receptor, composed of IFNGR1 and IFNGR2 subunits, 
which associate with Janus kinase (JAK)1 and JAK2 respectively (Platanias 2005). 
Binding of IFNγ causes the receptor subunits to dimerise, leading to 
autophosphorylation of JAKs, which then phosphorylate the signal transducer and 
activator of transcription 1 (STAT1) transcription factor at tyrosine
701
. Phosphorylated 
STAT1 dimerises and translocates to the nucleus, where it binds to Gamma-activated 
sites (GAS) in the DNA and modulates transcription. For optimal transcriptional 
induction, co-activators are required, such as the histone acetyltransferases, p300 and 
cAMP-responsive-element-binding protein (CBP), which are involved in chromatin 
remodelling (Zhang et al. 1998, Da Fonseca et al. 2001, Varinou et al. 2003, Li et al. 
2010a). Interaction of STAT1 with these co-activators requires serine
727
 
phosphorylation, mediated by protein kinase B (PKB), protein kinase C (PKC)δ, 
casein kinase 2, calmodulin-dependent protein kinase II (CamKII), ERK or JNK, 
several of which are activated by other IFNγ-induced signalling pathways such as the 
PI3K pathway (Nair et al. 2002, Uddin et al. 2002, Deb et al. 2003, Varinou et al. 
2003, Harvey et al. 2007, Valledor 2008, Li et al. 2010a). In addition to its role in 
phosphorylation of STAT1, JNK1 also induces upregulation of MHC class II 
molecules and stabilises CITTA mRNA (Valledor et al. 2008). 
One of STAT1’s direct target genes is the transporter associated with antigen 
processing (TAP) 1 (Min et al. 1996, Cramer et al. 2000, Rouyez et al. 2005). TAP 
transports peptides from the cytoplasm to the endoplasmic reticulum, where they bind 
to MHC class I, and is essential for presentation of intracellular antigen by MHC class 
I (Spies et al. 1991, Neefjes et al. 1993, de la Salle et al. 1994, Owen et al. 1999, 
Johnson et al. 2000). However, many of STAT1’s effects are mediated via expression 
of other transcriptional master regulators containg GAS sites in their promoter, 
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including interferon regulatory factor 1 (IRF1) and Ccaat-enhancer-binding protein 
(C/EBP)β (Poli et al. 1998, Taniguchi et al. 2001).  
C/EBP binding motifs are found in promoters of pro-inflammatory genes including 
IL-6, IL-1β, TNFα, IL-8, IL-12, granulocye-colony stimulating factor (G-CSF), 
iNOS, lysozyme, myeloperoxidase and neutrophil elastase (Poli 1998). IRF1 is serine 
phosphorylated by PKC and CamKII and binds strongly to IRF-E sequences, found in 
many promoters, mostly those of pro-inflammatory genes (Taniguchi et al. 2001). 
IRF1 promotes antigen presentation by MHC class I and II by modulating expression 
of β2-microglobulin, B7-H1, CIITA, TAP1, the proteosomal subunit latent membrane 
protein 2 (LMP2) and proteosomal activators PA28α and -β, (Min et al. 1996, White 
et al. 1996, Hobart et al. 1997, O’Keefe et al. 2001, Taniguchi et al. 2001, Lee et al. 
2006). It promotes anti-viral responses via induction of IFN-α and –β, and 
antibacterial responses via induction of iNOS in macrophages and microglia and the 
NADPH oxidase component gp91
phox
 in myelomonocytic cells (Matsuyama et al. 
1993, Kamijo et al. 1994, Eklund et al. 1998). By upregulating IL-12 expression in 
macrophages, it indirectly promotes Th1 differentiation and in the absence of IRF1 
only a Th2 response can be mounted to infection (Lohoff et al. 1997, Taki et al. 
1997). IRF-1 also induces IL-15 in bone marrow stromal cells, promoting 
differentiation and activation of NK cells (Ogasawara et al. 1998). The 
proinflammatory role of IRF1 is highlighted by its role in autoimmunity: mice 
deficient in IRF1 are protected against experimental autoimmune encephalomyelitis 
(EAE) and collagen-induced arthritis (Tada et al. 1997). 
Strong p38 activation has also been observed following IFNγ stimulation of 
macrophages (Valledor et al. 2008, Matsuzawa et al. 2012). p38 stabilises transcripts 
for CCR5, CXCL10, CCL5 and TNFα, increases expression of CXCL9, IL-1β and 
iNOS2 and promotes autophagy (Valledor et al. 2008, Matsuzawa et al. 2012). 
TNFα  is also commonly produced by NK cells and regulates many of the same genes 
as IFNγ, since NF-κB, a key target of TNFα signalling, not only binds to the IRF-1 
promoter, enhancing its expression, but also interacts with phosphorylated IRF-1 to 
synergistically induce expression of multiple target genes (Taniguchi et al. 2001). 
Most target genes can be induced by either IFNγ or TNFα alone, but are more 
effectively induced when both are present (Schroder et al. 2004). 
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Binding of TNFα to TNF-R1 induces receptor trimerisation and release of the Silencer 
of Death Domain inhibitory protein (Li and Lin 2008). This allows binding of TNF 
Receptor-Associated Death Domain (TRADD), which recruits FADD, TNF-R 
Associated Factor 2 (TRAF2) and RIP. TRAF2 oligomerisation induces binding and 
activation of mitogen-activated protein kinase kinase kinases (MAP3Ks) such as 
MAP/ERK kinase kinase 1 (MEKK1) and TGFβ-activated kinase 1 (TAK1), 
triggering a mitogen-activated protein kinase (MAPK) cascade leading to activation 
of JNK, p38 and IκB kinase (Baud et al. 1999, Li and Lin 2008, Fan et al. 2010).  
JNK and p38 activate the AP-1 family of transcription factors, which consists of 
homodimers or heterodimers of basic leucine zipper domain (bZIP) proteins such as 
Jun, Fos and activating transcription factor (ATF) (Karin et al. 1997). C-Jun and Fos 
dimers promote cell proliferation by inducing expression of cyclins and both 
downregulating and inhibiting function of the tumour suppressor p53 (Shaulian and 
Karin 2001, Hommura et al. 2004). AP-1 transcription factors also target various 
genes involved in motility and invasion, thereby upregulating expression of cathepsin 
L and matrix metalloproteinases (MMPs) 1, 3 and 9 (involved in cellular matrix 
degradation), CapG (tropomysin, capping protein (actin filament), gelsolin-like) and 
metastasis-associated protein 1 (Mts1) (cytoskeletal regulation) and CD44 (adhesion) 
and downregulating the adhesion molecules immunoglobulin superfamily member 4 
(IGSF4) and protocadherin gamma-C3 (Ozanne et al. 2007). 
IκB kinase phosphorylates the NFκB inhibitor IκB, thereby targeting it for 
ubiquitination and degradation (Chen 2005). NF-κB therefore becomes activated and 
translocates to the nucleus, where it activates transcription of multiple target genes, 
including IRF1, TAP1 and LMP2 (Min et al. 1996, Taniguchi et al. 2001, Marqués et 
al. 2004, Li and Lin 2008). NF-κB has been described as ‘a central mediator of the 
human immune response’, directly regulating over 150 target genes (Pahl 1999). 
These include at least 27 cytokines and chemokines (mostly pro-inflammatory), 
cytokine receptors, adhesion molecules such as ICAM1 and vascular cell adhesion 
molecule 1 (VCAM1), immunoglobuins, matrix metalloproteinases, lysozyme, iNOS, 
and genes involved in antigen presentation, complement pathways and regulation of 
ROS production (Pahl 1999).  
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TNFα signalling can also lead to activation of caspases (Deng et al. 2003, Li and Lin 
2008). Caspase 8 does not appear to be recruited to TNF receptors as it is to Fas or 
TRAIL, rather it is activated indirectly by mitochondrial Smac (second mitochondria-
derived activator of caspases) and DIABLO (direct IAP binding protein with low pI) 
release following Jnk-mediated Bid cleavage (Deng et al. 2003, Harper et al. 2003). 
However, TNF-α does not usually induce apoptosis or necrosis due to the protective 
effects of NF-κB activation (Sakon et al. 2003, Morgan et al. 2008). NF-κB induces 
expression of cellular inhibitor of apoptosis proteins (cIAPs), the capase 8 inhibitor 
cFLIP (cellular FLICE-like inhibitory protein), antioxidant enzymes and the Bcl-2 
family protein A1, which inhibits cytochrome C release and caspase activation 
(Mattson et al. 1997, Djavaheri-Mergny et al. 2004, Morgan et al. 2008). Sustained 
JNK activation is required for both apoptosis and necrosis and this is dependent on 
ROS, which inhibit JNK phosphatases by converting a catalytic cysteine residue to 
sulfenic acid and induce dissociation of the JNK inhibitor glutathione S-transferase π 
(Adler et al. 1999, Deng et al. 2003, Kamata et al. 2005). NF-κB promotes expression 
of antioxidant enzymes thioredoxin and manganese superoxide dismutase, thus 
preventing sustained JNK activation and protecting against both TNFα-induced and 
exogenous ROS-induced apoptosis (Mattson et al. 1997, Javelaud et al. 2001, 
Djavaheri-Mergny et al. 2004).  
Another cytokine produced by NK cells is granulocyte-macrophage colony 
stimulating factor (GM-CSF), which is effectively induced by α-CD16 and IL-2 or by 
combinations of cytokines such as IL-15 and IL-18 or IL-1 and TNFα (Cuturi et al. 
1989, Fehniger et al. 1999, Hamilton 2002). GM-CSF promotes differentiation of 
bone marrow progenitors into granulocytes, macrophages and eosinophils, stimulates 
differentiation of monocytes into macrophages and promotes survival of monocytes, 
macrophages and neutrophils (Metcalf et al. 1986, Young et al. 1990, Coxon et al. 
1999, Hashimoto et al. 2001). It has also been used together with IL-4 to derive 
dendritic cells from monocytes in vitro (Agakawa et al. 1996). GM-CSF and TNF-α 
both enhance phagocytosis, ADCC and N-formyl-methionyl-leucyl-phenylalanine- 
induced oxidative burst in neutrophils (Klebanoff et al. 1986, Metcalf et al. 1986, 
Perussia et al. 1987, Weisbart et al. 1987, Lopez et al. 1988). Eosinophil ADCC, 
phagocytosis and ROS production is also promoted by GM-CSF, as is eosinophil and 
neutrophil adhesion to endothelial cells (Lopez et al. 1988, Walsh et al. 1990). 
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Stimulation of monocytes with GM-CSF again enhances adherence to vascular 
endothelial cells, as well as enhancing ADCC and lipopolysaccharide (LPS)-induced 
cytokine production and increasing activity of urokinase plasminogen activators, 
which convert plasminogen to plasmin, a serine protease which degrades fibrin and 
activates collagenases to promote degradation of the extracellular matrix (Gamble et 
al. 1989, Wing et al. 1989, Hart et al. 1991).  
NK cells incubated with malignant melanoma cells and IL-2 also produce large 
quantities of IL-5, which are augmented by addition of IL-4 (Warren et al. 1995). 
Long-term culture with IL-4 in the presence of an IL-12- neutralising antibody 
polarises NK cells to an “NK2” phenotype, characterised by high production of IL-5 
and IL-13, with impaired IFNγ secretion  (Peritt et al. 1998). IL-5 was first identified 
as an eosinophil proliferation and differentiation factor (Lopez et al. 1986). It also 
activates mature eosinophils, promoting ADCC, phagocytosis, granule polarisation 
and ROS production, while inhibiting apoptosis (Lopez et al. 1986, Lopez et al. 1988, 
Walsh et al. 1990, Yamaguchi et al. 1991). In addition, IL-5 upregulates the 
complement receptor C3bi and increases eosinophil adhesion by stimulating CDllb 
expression (Lopez et al. 1986, Lopez et al. 1988, Walsh et al. 1990). IL-5-induced 
eosinophil infiltration during infection is important for induction of a protective 
antibody response and IL-5 production by NK cells specifically has been shown to 
have an important role in recruitment of eosinophils in vivo (Walker et al. 1998, 
Herbert et al. 2000). Activation of eosinophils is important for control of parasitic 
infections (Herbert et al. 2000, Vallance et al. 2000). Unlike GM-CSF, IL-5 does not 
mediate these effects in neutrophils (Lopez et al. 1988, Walsh et al. 1990). However, 
effects on B and T lymphocytes have been identified, including enhanced tumour-
specific cytotoxic T cell responses and increased production of IgG or IgM in B cells 
stimulated with 2,4-dinitrophenyl or Staphylococcus aureus Cowan I (SAC) 
respectively (Harada et al. 1987, Nagasawa et al. 1991, Bertolini et al. 1993, 
Morikawa et al. 1993). 
IL-13 induces isotype switching and IgE production and upregulates expression of the 
IgE receptor FcεRII and MHC class II on monocytes, macrophages and B cells 
(Cocks et al. 1993, de Waal Malefyt et al. 1993a, McKenzie et al. 1993, Punnonen et 
al. 1993, Defrance et al. 1994, Sinha et al. 2008). B cell proliferation and production 
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of IgM and IgG4 in response to CD40 stimulation are also enhanced by IL-13 (Cocks 
et al. 1993, Defrance et al. 1994, McKenzie et al. 1993). EAE induction in IL-13-
deficient mice suggests that IL-13 enhances inflammation in this model, promoting T 
cell proliferation, macrophage central nervous system (CNS) infiltration and 
production of IL-12 and IFNγ (Sinha et al. 2008). However, IL-13 also has anti-
inflammatory functions, protecting against endotoxic shock by antagonising effects of 
TNFα and LPS stimulation (Muchamuel et al. 1997). Activation of MEK and JNK in 
myeloid cells is inhibited by IL-13, thereby preventing activation of AP-1 and NF-κB 
in response to TNF-α or LPS and inhibiting expression of multiple cytokine and 
chemokine genes and production of ROS and RNS (de Waal Malefyt et al. 1993a, 
Minty et al. 1993, Sozzani et al. 1995, Bogdan et al. 1997, Manna and Agarwal 
1998). IL-13 also protects against apoptosis by inhibiting caspase 3 activation (Manna 
and Agarwal 1998). 
NK cells can also produce the regulatory cytokine IL-10. In the absence of polarising 
cytokines, only around 7% of freshly isolated human peripheral blood NK cells from 
healthy individuals make IL-10 protein in response to phytohaemagglutinin (PHA) 
stimulation, most of which are found within the CD56
dim
 KIR
+
 subset (Deniz et al. 
2008). However, NK cells from hepatitis C virus (HCV) -infected patients secrete 
substantial amounts of IL-10 in response to melanoma target cells (De Maria et al. 
2007). Upregulation of NKp30 on these NK cells suggests interaction with DCs, 
perhaps forming a negative feedback loop whereby prolonged DC IL-12 production 
stimulates NK cell IL-10 production and suppressive function (De Maria et al. 2007). 
In vitro, strong IL-10 production can be induced in nearly all NK cells (including both 
CD56
dim
 and CD56
bright
) by culture with IL-12 in combination with IL-2, IL-15 or IL-
4-neutralising antibody (Mehrotra et al. 1998, Peritt et al. 1998, Fehniger et al. 1999). 
IL-10 mRNA is also induced by stimulating antibodies directed against CD2 and 
CD16 and by vitamin D3 plus dexamethasone (Deniz et al. 2008). IL-10 transcription 
reaches its peak after 24 hours, but protein secretion is delayed (Mehrotra et al.1998, 
Maroof et al. 2008). For instance, during Leishmania donovani infection, NK cells 
begin secreting IL-10 and acquire regulatory function after around 21 days (Maroof et 
al. 2008). Its slow induction in comparison to other cytokines is consistent with a role 
in preventing chronic inflammation by suppressing activated leukocytes in the late 
stages of an immune response.  
46 
 
Incubation of APCs with IL-10 suppresses their ability to drive antigen-induced T cell 
proliferation, CD8
+
 T cell cytotoxic function and production of both Thelper (Th)-1 and 
Th2 cytokines by CD4
+
 T cells (Del Prete et al. 1993, Groux et al. 1998). This is due 
to downregulation of MHC class I and II and adhesion/ co-stimulatory molecules such 
as CD80, CD86 and ICAM1 (de Waal Malefyt et al. 1991, Groux et al. 1998). IL-10 
also directly inhibits IL-2 production and proliferation of T cells stimulated via their 
TCR and blocks activation of the PI3K pathway by CD28 co-stimulation (de Waal 
Malefyt et al. 1993b, Taga et al. 1993, Akdis et al. 2000). In monocytes, IL-10 
antagonises lipopolysaccharide (LPS)- or IFNγ-mediated induction of IL-1α and –β, 
IL-6, IL-8, TNF-α, G-CSF and GM-CSF transcription (Hashimoto et al. 2001, de 
Waal Malefyt et al. 1991). IL-12 production is also inhibited, which in turn leads to a 
reduction in IFNγ (D’Andrea et al. 1993). However, IL-10 appears to have positive 
effects on the humoral response. Though it promotes apoptosis of newly activated B 
cells, when added during the maturation stage it increases cell viability, promotes 
differentiation into plasma cells and enhances the proliferative and immunoglobulin 
responses to antigen or CD40 stimulation (Rousset et al. 1991, Itoh et al. 1994, Itoh 
and Hirohata 1995).  It also upregulates expression of FcγRI, II and III on monocytes 
and promotes FcγR-mediated phagocytosis (te Welde et al. 1992, Hashimoto et al. 
1997).  
NK cells also produce chemokines, including IL-8, RANTES (regulated on activation, 
normal T expressed and secreted /CCL5) and macrophage inflammatory proteins 
(MIP) 1α and 1β. IL-8 production can be induced by a variety of stimuli, including 
poly(I:C), IL-15 or activation of Fc receptors in the presence of IL-2, IL-12 or platelet 
factor 4 (Marti et al. 2002, Chuang et al. 2006, Roda et al. 2006, El-Shazly et al. 
2011). IL-8 is a chemotactic factor for neutrophils and T cells (Larsen et al.1989, 
Leonard et al. 1991, Douglass et al. 1996). It induces shape change in neutrophils, 
promoting development of the long lamellipodia required for cell migration, 
upregulates β2-integrins and induces lectin shedding, facilitating their transmigration 
through blood vessel walls (Thelen et al. 1988, Huber et al. 1991). It also activates 
neutrophils to produce ROS and release granules containing antimicrobial proteins 
such as elastase and chemotactic factors for T cells and monocytes (Peveri et al. 1988, 
Thelen et al. 1988, Taub et al. 1996). In addition, IL-8 regulates angiogenesis by 
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enhancing endothelial cell proliferation, inhibiting apoptosis, upregulating MMP2 and 
MMP9 and promoting capillary tube reorganisation (Li et al. 2003). 
RANTES, MIP1α and MIP1β are related chemokines with overlapping functions and 
receptor specificities. CCR3 binds only RANTES (Daugherty et al. 1996, Ponath et 
al. 1996a, Ponath et al. 1996b), CCR1 and CCR4 bind RANTES and MIP1α but not 
MIP1β (Gao et al. 1993, Neote et al. 1993, Ben-Baruch et al. 1995, Power et al. 
1995), and CCR5 binds all three (Raport et al. 1996). Secretion of these chemokines 
can be induced in NK cells by multiple mechanisms, including culture with IL-2, IL-
12 and/or IL-15, incubation with K562 or antibody-coated tumour cells, CD16 
crosslinking, or stimulation of the activating receptors NKG2D or 2B4 (Oliva et al. 
1998, Fehniger et al. 1999, Roda et al. 2006, Fauriat et al. 2010a). All three are 
chemotactic factors for monocytes, macrophages, DCs and CD4
+
 T cells, particularly 
of the Th1 type (Schall et al. 1990, Taub et al. 1993, Wang et al. 1993, Uguccioni et 
al. 1995, Raport et al. 1996, Sozzani et al. 1997, Roth et al. 1998, Siveke and 
Hamann 1998, Kawai et al. 1999, Lee et al. 2000). Monocytes and Th1 cells 
upregulate integrins in response to these chemokines, increasing their ability to adhere 
to endothelial cells and migrate across the vascular endothelium (Taub et al. 1993, 
Vaddi and Newton 1994, Roth et al. 1998, Kawai et al. 1999). RANTES, MIP1α and 
MIP1β also enhance macrophage NO2
-
 production and phagocytosis (Villalta et al. 
1998). B cell antigen-specifc antibody production is also increased, with MIP1α and 
MIP1β preferentially promoting IgG1 and IgG2b, while RANTES stimulates IgG2a 
and IgG3 (Lillard et al. 2001, Lillard et al. 2003). RANTES, and to a lesser extent 
MIP1α, induce basophil and eosinophil chemotaxis and leukotriene release (Rot et al. 
1992, Bischoff et al. 1993, Daugherty et al. 1996, Beck et al. 1997, Lee et al. 2000). 
MIP1α is also a chemotactic factor for neutrophils, B cells and CD8+ memory T cells, 
which do not appear to migrate in response to either RANTES or MIP1β (Schall et 
al.1990, Schall et al. 1993, Taub et al. 1993, Beck et al. 1997, Lee et al. 2000, Ramos 
et al. 2005). It also has effects on NK cells themselves, as a potent NK cell 
chemoattractant and enhancer of cytotoxicity (Taub et al. 1995, Bluman et al. 1996). 
Finally, MIP1α also has specific effects on stem cells: it is the only one of these 
chemokines to suppress proliferation of HSC and GM-CSF-stimulated early myeloid 
progenitors (Broxmeyer et al. 1993, Van Ranst et al. 1996).  
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1.1.6 NK Cells Interact with Other Leukocytes and Regulate their Function 
NK cells engage in contact-dependent interactions with other leukocytes, in some 
cases promoting their activation and in other cases inducing cell death.  
Interaction of NK cells with B cells results in contact-dependent reciprocal activation. 
Activated B cells interact with NK cells via LFA1-ICAM1 and CD40-CD40L, 
inducing IFNγ and TNFα production in both the NK cell and the B cell (Becker et al. 
1990, Blanca et al. 2001, Gao et al. 2005). IFNγ then induces B cell proliferation and 
TNF-α promotes both proliferation and antigen-specific immunoglobulin production 
(Becker et al. 1990, Blanca et al. 2001). NK cells also induce transcripts for Iγ2a and 
activation-induced cytidine deaminase (AID), which are necessary, though not 
sufficient, for isotype switching to IgG2a (Gao et al. 2001, Gao et al. 2005). Recently 
it has been shown that NK cells can also enhance antigen processing and presentation 
in B cells, resulting in increased proliferation of antigen-specific CD4
+
 T cells 
(Jennings and Yuan 2009). 
CD56
bright
 NK cells activated with IL-12, IL-15 and IL-18 promote TNF-α production 
by monocytes in a contact-dependent manner (Dalbeth et al. 2004). In turn, contact 
with monocytes synergises with cytokines to induce NK cell IFNγ production. IL-15-
activated NK cells can also induce contact-dependent differentiation of monocytes 
into DCs with a preference for Th1 priming, partly due to secretion of GM-CSF 
(Zhang et al. 2007).  
Both resting and activated NK cells can induce maturation of immature (i) DCs 
(Carbone et al. 1999, Gerosa et al. 2002, Tosi et al. 2004). Maturation is induced most 
efficiently by NKG2A
low
 KIR
-
 NK cells (Vitale et al. 2005). Formation of NK-DC 
conjugates is important in promoting upregulation of HLA-DR and co-stimulatory 
molecules CD83 and CD86 during DC maturation and activation (Gerosa et al. 2002, 
Piccioli et al. 2002, Tosi et al. 2004, Gerosa et al. 2005). NK cells in contact with 
iDCs are activated via NKp30 and appear to upregulate TNFα production in the iDC, 
which promotes DC maturation in an autocrine manner (Gerosa et al. 2002, Piccioli et 
al. 2002, Vitale et al. 2005). Neutralisation of IFNγ has relatively little effect on 
maturation, implying that other mechanisms are required (Gerosa et al. 2002, Piccioli 
et al. 2002, Vitale et al. 2005). These may include secretion of the leaderless cytokine 
high-mobility group box 1 (HMGB1), a powerful inducer of DC maturation, which is 
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produced spontaneously by activated NK cells and induced in resting NK cells upon 
co-culture with iDC (Semino et al. 2005). HMGB1 release is induced by IL-18, which 
iDCs secrete directly into the synapse via lysosomal exocytosis (Semino et al. 2005). 
Activated NK cells can also selectively lyse iDCs, which express lower levels of 
HLA-E and HLA class I than mature DCs (Carbone et al. 1999, Wilson et al. 1999, 
Spaggiari et al. 2001, Della Chiesa et al. 2003). Only NKG2A
+
 NK cells lacking self-
specific KIR are able to kill autologous iDCs, with NKG2A
low
 NK cells killing more 
effectively than NKG2A
high
 (Della Chiesa et al. 2003). Killing of iDCs is dependent 
on NKp30 (and to a lesser extent NKp46) and is most likely mediated by perforin and 
granzymes (Wilson et al. 1999, Spaggiari et al. 2001, Ferlazzo et al. 2002, Vitale et 
al. 2005).  
The outcome of the interaction between NK cell and iDC is dependent on the ratio of 
the cell types present. If NK cells outnumber DCs, they are likely to kill them, with 
most efficient killing at ratios of 5:1 (NK:iDC) and above (Piccioli et al. 2002, 
Semino et al. 2005). However, at a 1:5 ratio, with iDCs outnumbering NK cells, iDCs 
are not efficiently lysed (in fact their survival is enhanced) and instead mature 
(Piccioli et al. 2002, Semino et al. 2005, Vitale et al. 2005). This stimulatory effect on 
DC maturation was observed at raios as low as 1:40 (NK:iDC) (Piccioli et al. 2002). 
Induction of iDC maturation or apoptosis during an immune response is likely to 
increase the chances of T cells interacting with mature, rather than immature DCs, 
thus promoting activation rather than anergy. 
In addition to being responsible for most of the early IFNγ production during 
infection, NK cells are also important in stimulation of mature dendritic cell function 
and IL-12 production, which in turn induces IFNγ production in T cells, the major 
IFNγ producers at later stages of infection (Mocikat et al. 2003) (see figure 1-iv). 
CD56
bright
 NK cells colocalise with DCs in human lymph nodes (Ferlazzo et al. 2004). 
LPS-activated DC in the lymph node can also release factors which recruit further NK 
cells from the blood (Martín-Fontecha et al. 2004). Meanwhile, IL-18 produced by 
macrophages and DCs in the periphery induces CCR7 expression on CD56
dim
 NK 
cells (which do not usually express this receptor), allowing them to migrate towards 
CCL19 and CCL21 in the lymph node (Mailliard et al. 2005). Activated DCs express 
IL-15 on their cell surface, which is presented to NK cells by IL-15Rα and induces 
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their proliferation (Ferlazzo et al. 2004). Cytoskeletal rearrangement in the DC 
permits synaptic delivery of IL-12 directly to the NK cell (Borg et al. 2004). Together 
with NCR ligation, this induces secretion of IFNγ, which reciprocally upregulates IL-
12 expression in the DC (Ferlazzo et al. 2002, Borg et al. 2004, Ferlazzo et al. 2004, 
Gerosa et al. 2005).  IFNγ production by NK cells is reported to be crucial for Th1 
polarisation, due to its effects on DCs and its ability to induce the central Th1 
transcriptional mediator, T-bet, in activated T cells (Afkarian et al. 2002, Martín-
Fontecha et al. 2004). NK cells primed with IL-18 produce more IFNγ upon 
interaction with DCs and are particularly effective at inducing DC IL-12 production 
and promoting Th1 as opposed to Th2 differentiation (Mailliard et al. 2005).  
Activated NK cells can also induce a stable type-1 polarised “effector/ memory” DC, 
termed “DC1” (Mailliard et al. 2003). DC1 continue to efficiently prime T cells and 
produce IL-12 when NK cells are removed from culture. Compared to DCs matured 
in the absence of NK cells, DC1 produce more IL-12 upon CD40L stimulation and 
strongly induce production of IFNγ but not IL-4 by antigen-specific CD8+ T cells and 
naïve CD4
+
 T cells. In order to polarise DCs, NK cells must be activated by at least 
two signals e.g. IL-2 and IL-18 or K562 cells and IFNα (Mailliard et al. 2003).  
IFNα and –β produced by activated myeloid and plasmacytoid (p) DCs enhance NK 
cytolytic activity (Gerosa et al. 2005). This promotes subsequent lysis of susceptible 
targets including iDCs, however mature DCs, particularly pDCs, are themselves 
relatively resistant to NK-mediated cell death (Gerosa et al. 2005). 
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Figure 1-iv: NK cells stimulate T cell activation and Th1 polarisation both directly and indirectly. 
Stimulation via NKp30 causes the NK cell to release unidentified soluble factors that induce DC 
production of TNFα, which acts in an autocrine manner to drive DC maturation. Meanwhile, IL-18 
from DCs drives NK cell production of HMGB1, which also induces DC maturation and upregulation 
of costimulation molecules. IL-12, IL-15 and IL-18 produced by mature DCs activate NK cells to 
upregulate costimulation molecules and produce IFNγ. IFNγ promotes expression of the Th1 
transcription factor T-bet in CD4
+
 T cells and enhances production of IL-12 by DCs, which also 
promotes Th1 polarisation. Contact with co-stimulatory molecules such as OX40L and CD80 on NK 
cells enhances priming of antigen-specific T cells by mature DCs.  
 
In addition to promoting DC priming, NK cells also have direct effects on T cells. 
Firstly, they can enhance T cell responses by engaging the co-stimulatory receptors 
CD28 and OX40 (Zingoni et al. 2004). Co-stimulation is required for optimal 
proliferation, cytokine production and long-term survival in response to TCR-
mediated antigen recognition (Gramaglia et al. 2000, Zingoni et al. 2005). OX40L is 
induced on NK cells stimulated with cytokines (IL-2, -12 or -15) followed by ligation 
of activating receptors (NKG2D, CD16 or 2DS2) and binds to OX40, which is 
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expressed primarily on activated T cells (Ohshima et al. 1998, Gramaglia et al. 2000, 
Zingoni et al. 2004). Cytokine-activated NK cells also express CD80 and CD86, 
ligands for the CD28 co-stimulatory receptor (Hanna et al. 2004a, Zingoni et al. 
2004).  NK cells activated by both cytokine and receptor stimulation strongly promote 
CD4
+
 T cell proliferation and production of IL-2 and IFNγ, but not IL-4 (Hanna et al. 
2004a, Zingoni et al. 2004). Blocking experiments indicate that both OX40 and CD28 
are involved, though OX40 appears to be more important (Zingoni et al. 2004). These 
results are in contrast to a previous study where OX40 ligation enhanced Th2 
polarisation of human umbilical cord-derived CD4
+
 T cells (Ohshima et al. 1998). 
This suggests that OX40L itself might be a more general co-activator of T cells, and 
that the Th1 bias observed in the former study was due to other mechanisms, such as 
NK cell IFNγ production. Interestingly, in vivo OX40 stimulation in mice induces a 
Th1 bias during the initial response to antigen, but enhances both Th1 and Th2 recall 
responses (De Smedt et al. 2002). The latter is likely due to enhanced expansion and 
survival of antigen-specific T cells during the latter phase of the primary response, 
which means that more memory cells remain to deal with a secondary challenge 
(Gramaglia et al. 2000).  
NK cells themselves can also have an antigen presenting function. HLA-DR-
expressing NK cells represent less than 10% of NK cells in healthy peripheral blood 
and around 50% of lymph node NK cells (Burt et al. 2008, Evans et al. 2011). HLA-
DR
+
 NK cells proliferate preferentially in response to IL-2 or IL-15 stimulation and 
upregulate CXCR3, a receptor promoting migration to lymph nodes and sites of 
inflammation (Evans et al. 2011). Both CD56
dim
 and CD56
bright
 NK cells can process 
and present soluble protein antigens to CD4
+
 T cells via MHC class II (Roncarolo et 
al. 1991). This stimulates T cell proliferation and production of IFNγ and IL-2, which 
in turn enhances IFNγ production by NK cells (Hanna et al. 2004a, Evans et al. 2011). 
NK cells are able both to expand antigen-specifc memory T cells and to prime naïve T 
cells, albeit not as effectively as DCs (Hanna et al. 2004a). They also induce IFNγ 
production in CD8
+
 T cells, again less effectively than DCs (Burt et al. 2008). In the 
presence of plentiful antigen, NK cells induce a similar level of T cell proliferation to 
that induced by B cell lines, however at suboptimal antigen concentrations NK cells 
are less effective (Roncarolo et al. 1991).  
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NK cell antigen presenting function appears to be coupled to cytotoxicity. Activated 
NK cells that have killed influenza-infected target cells can specifically activate T 
cells recognising influenza HA peptides (Hanna et al. 2004a). This suggests that NK 
cells that have killed infected cells are presenting peptides derived from the cell that 
they have killed, thus bypassing the need for DCs. HA binds to NKp46, triggering 
internalisation of the receptor-HA complex to MHC class II-loading compartments, 
allowing the protein to be processed and presented to CD4
+
 T cells (Hanna et al. 
2004a). B cell antibody production may be important for internalisation of proteins 
not directly recognised by NK cell receptors: incubation of HA protein with HA-
specific antibodies leads to formation of immune complexes that bind to CD16 and 
these can also be internalised and processed for peptide presentation (Hanna et al. 
2004a). 
NK cells also appear to be important in inducing T cell memory. NK cells which have 
been activated by MHC class I-deficient RMA-S tumour cells promote subsequent T-
cell mediated rejection of MHC class I-sufficient RMA cells, by a mechanism 
involving CD70-CD27 interaction (Kelly et al. 2001). Vaccination with ovalbumin 
(OVA)-expressing targets was found to be more effective at inducing a CD8
+
 recall 
response and protecting against subsequent infection with OVA-expressing Listeria 
monocytogenes when the original target cells lacked the MHC class I molecule K
b
 
(Krebs et al. 2009). K
b
-sufficient targets, which would be lysed by T cells rather than 
NK cells, were poor inducers of memory responses, suggesting that direct stimulation 
of CD8
+
 T cells in the absence of NK cell help is not effective at generating memory 
cells. NK cell enhancement of CD8 memory appears to be cell intrinsic and is 
dependent on MyD88/ TIR-domain-containing adapter-inducing interferon-β (Trif) 
signalling in the T cell (Krebs et al. 2009). NK cells also promoted OVA-specific IgG 
production and enhanced the CD4
+
 IFNγ response by a cell extrinsic mechanism, 
probably due to enhanced DC priming. Interaction of the murine HLA-E homolog, 
Qa1-Qdm, with NKG2A has also been reported to play an important role in expansion 
and memory function of CD4
+
 T cells (Lu et al. 2007). 
NK cells also have an important role during the memory response itself. Though they 
do not themselves have antigen-specific memory, they are rapidly activated during a 
recall response. NK cells represent over 70% of IFNγ-secreting and degranulating 
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cells 12-18 hours after restimulation of peripheral blood mononuclear cells (PBMC) 
from individuals vaccinated against rabies (Horowitz et al. 2010). Activation of NK 
cells is dependent on IL-2 produced by CD4
+
 memory T cells, as well as IL-12 and 
IL-18 production by myeloid cells. Large amounts of IL-2 are produced within 6 
hours of restimulation with inactivated rabies virus, whereas IFNγ production by T 
cells is initially low. Both pre- and post-vaccination NK cells respond to rabies virus 
when cultured with post-vaccination T cells, but neither degranulate when stimulated 
in the presence of pre-vaccination T cells, indicating that the memory function is 
mediated by T cells, not NK cells.  Similar enhancement of NK cell responses in 
vaccinated individuals has been observed in PBMC stimulated with influenza virus or 
malarial antigens (Long et al. 2008, Horowitz et al. 2012). 
Activated NK cells have also been shown to lyse Tregs expanded by Mycobacterium 
tuberculosis, which upregulates the NKG2D ligand ULBP1 on Tregs but not T 
effector cells (Roy et al. 2008). This might help NK cells to selectively target Tregs 
that would otherwise impair the immune response against the bacterium.  
However, NK cells can also act to dampen the immune response. Following α-CD3 
stimulation, T cells phosphorylate ataxia-telangiectasia mutated, a kinase involved in 
upregulation of NKG2D ligands following DNA damage (Cerboni et al. 2007). Both 
CD4
+
 and CD8
+
 T cells upregulate ligands for NKG2D in response to antigen 
stimulation or other stimuli and are lysed by IL-2-activated NK cells in an 
NKG2D/LFA-1-dependent, granzyme-dependent manner (Rabinovich et al. 2003, 
Cerboni et al. 2007, Nielsen et al. 2012). NK cells preferentially kill activated, rather 
than resting T cells, despite slight upregulation of MHC class I on activated T cells 
(Rabinovich et al. 2003, Molinero et al. 2006, Nielsen et al. 2012). Neutralisation of 
NKG2A further enhances killing of CD4
+
 T cells, indicating that expression of HLA-
E on activated T cells does confer some degree of protection (Nielsen et al.2012). 
Killing of activated CD8
+
 T cells by NK cells occurs during lymphocytic 
choriomeningitis virus infection and has a profound effect on the anti-viral immune 
response, promoting viral persistence (Lang et al. 2012). 
IL-2- activated NK cells can lyse monocytes (Spaggiari et al. 2001). Furthermore, 
macrophages stimulated with high doses of LPS are killed by both resting and 
activated NK cells (Nedvetzki et al. 2007). They upregulate the NKG2D ligands 
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ULBP1-3 and MICA, which induce NK cell proliferation, IFNγ production and 
formation of a supramolecular activating cluster, leading to release of cytotoxic 
molecules and death of the macrophage with which it is interacting (Nedvetzki et al. 
2007). NK cells are also activated by NKp46 ligands on neutrophils and induce their 
apoptosis via the Fas/FasL pathway (Thorén et al. 2012). 
1.1.7 NK Cells can be Divided into Subsets with Distinct Functions 
Natural killer cells can be divided into subsets with different functional 
characteristics, which are typically defined by the presence/absence or expression 
level of one particular surface marker. The most well characterised human NK cell 
subsets are the CD56
dim
 and CD56
bright
 described by Lanier et al. in 1986. In 
peripheral blood, the majority of NK cells (around 90%) are CD56
dim
, whereas 
CD56
bright
 NK cells predominate in lymph nodes and tonsil and are enriched at sites of 
inflammation (Cooper et al. 2001a, Fehniger et al. 2003, Dalbeth et al. 2004, Ferlazzo 
et al. 2004). CD56
dim
 NK cells are considered to account for cytotoxicity, while 
CD56
bright
 NK cells are thought to be the main producers of cytokines (Cooper et al. 
2001b). The latter assumption is based mainly on the higher levels of both pro- and 
anti-inflammatory cytokine secretion following stimulation with phorbol myristate 
acetate (PMA) and ionomycin, LPS or cytokines (Cooper et al. 2001b, Jacobs et al. 
2001). However, recent studies indicate that under certain circumstances CD56
dim
 NK 
cells can also secrete large quantities of cytokines such as IFNγ and CD56bright NK 
cells can efficiently lyse certain kinds of target cell.  
The nature of the activating signal is likely to be key in determining the relative 
response of each subset. Though CD56
bright
 NK cells produce more IFNγ and other 
cytokines in response to stimulation with soluble mediators such as PMA/ionomycin, 
IL-12, IL-15 or IL-18, CD56
dim
 NK cells are reported to produce more cytokines than 
CD56
bright
 when stimulated with target cells or via activating receptors (Jacobs et al. 
2001, Fauriat et al. 2010a, Juelke et al. 2010). An important study by Fauriat et al. 
showed that a much higher proportion of CD56
dim
 compared to CD56
bright
 NK cells 
produce IFNγ, TNFα, MIP1α and MIP1β following stimulation with K562 or 
Drosophila S2 cells transfected with ICAM-1, ULBP1 and CD48 (Fauriat et al. 
2010a). Following stimulation with various combinations of IL-12, IL-15 and IL-18, 
CD56
bright
 NK cells were more likely to produce IFNγ and TNFα. However the 
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frequency of MIP1α+ cells was similar between the two subsets, while MIP1β-
producing cells were in fact more frequent within the CD56
dim
 subset. When NK cells 
were stimulated simultaneously with both target cells and cytokines, the frequency of 
IFNγ-producing cells was similar, but a significantly higher proportion of CD56dim 
NK cells produced TNFα, MIP1α and MIP1β, demonstrating that CD56dim NK cells 
are also an important source of cytokines (Fauriat et al. 2010a). The level of cytokine 
and chemokine production by each subset, either per cell or overall secretion, was 
however not reported.  
Differences in the kinetics of cytokine release between the two subsets have also been 
analysed. CD56
dim
 NK cells produce IFNγ 2-4 hours after triggering of NKp46 or 
NKp30 (De Maria et al. 2011). Conversely CD56
bright
 NK cells only begin to produce 
substantial amounts of IFNγ after 16 hours, by which time CD56dim IFNγ production 
has ceased. Resting CD56
dim
 NK cells had 2.14-times more IFNγ transcript than 
CD56
bright
, which may explain their ability to respond so rapidly.  
Though it is now clear that both subsets are capable of producing a range of cytokines 
and chemokines, there are differences in the secretory profiles of the two subsets. For 
example, CD56
dim
 NK cells preferentially produce osteopontin, angiogenin and 
insulin-like growth factor (IGF)-1, whereas transforming growth factor (TGF)β-1/2/3, 
IL-15, IL-16, IL-18, GM-CSF and vascular endothelial growth factor (VEGF) are 
produced predominatly by CD56
bright
 NK cells (Hanna et al. 2004b, Wendt et al. 
2006). Amongst chemokines, higher expression of CCL1, CCL17, XCL1 and CXCL6 
was observed in the CD56
bright
 subset, while the CD56
dim
 subset expressed higher 
levels of monocyte chemotactic protein (MCP)-1,2 and 3, MIP-1α and β, RANTES, 
IL-8, CXCL2 and eotaxins (Hanna et al. 2004b, Wendt et al. 2006). Upon activation, 
CD56
bright
 NK cells also exhibited higher expression of TNF-superfamily members 
such as lymphotoxin-β, OX-40L, TRAIL and receptor activator of nuclear factor κB 
ligand (RANKL) (Wendt et al. 2006).  
CD56
dim 
NK cells are characterised by high expression of CD16, which is usually 
absent, or otherwise low in the CD56
bright
 subset (Cooper et al. 2001b, Jacobs et al. 
2001). This restricts ADCC function to the CD56
dim
 subset (Nagler et al. 1989). 
CD56
bright
 NK cells typically lack KIR, with the exception of KIR2DL4 (Jacobs et al. 
2001, Wendt et al. 2006). Transcripts for CD58 (LFA-3), CD160, CD161, 2B4 and 
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lectin-like transcript 1 (LLT-1) costimulatory receptors and the CD3ζ adaptor 
(associated with CD16  and NCR signalling) are present in both subsets, but 
expressed at higher levels by CD56
dim
 NK cells (Baume et al. 1992, Hanna et al. 
2004b, Wendt et al. 2006). CD2, on the other hand, is upregulated in the CD56
bright
 
subset (Hanna et al. 2004b). Both subsets express similar levels of NKG2D and 
NKp30 on the cell surface, but NKp46 expression is slightly higher on CD56
bright
 NK 
cells (Vitale et al. 2004). The inhibitory receptor NKG2A is expressed on all 
CD56
bright
 NK cells and some CD56
dim
 (Vitale et al. 2004). 
CD56
bright
 NK cells display poor cytotoxicity towards many of the targets that are 
lysed efficiently by CD56
dim
 NK cells (Cooper et al. 2001b, Jacobs et al. 2001). This 
is likely to be due to lower expression of certain adhesion molecules, which may 
account for their reduced ability to form conjugates with K562 cells, and lower 
expression of cytotoxic molecules including perforin and granzymes A and B (Jacobs 
et al. 2001, Wendt et al. 2006, Chattopadhyay et al. 2009). Despite this, they are still 
capable of effectively lysing certain targets such as activated T cells (Bielekova et al. 
2006, Jiang et al. 2011, Nielsen et al. 2012). Granzyme K is expressed almost 
exclusively in the CD56
bright
 subset and is important for induction of T cell apoptosis 
by this population (Hanna et al. 2004b, Wendt et al. 2006, Jiang et al. 2011). IL-2 
activated CD56
bright
 NK cells also express higher levels of TRAIL than CD56
dim
 NK 
cells and this pathway also contributes to killing of activated CD4
+
 T cells, which 
express DR4 and DR5 TRAIL receptors (Nielsen et al. 2012). The frequency of 
degranulating cells amongst the CD56
bright
 subset is around double that of the CD56
dim
 
when incubated with autologous activated CD4
+
 T cells from healthy controls, 
however they lyse the T cells to a similar extent (Jiang et al. 2011, Nielsen et al. 
2012). This may be due to higher levels of the more potent granzymes such as 
granzyme B in granules of CD56
dim
 NK cells. However, during an inflammatory 
response, the greater IL-2 responsiveness of CD56
bright
 NK cells is likely to mean a 
greater augmentation of their cytotoxic function compared to the CD56
dim
 subset. 
Accordingly, CD56
bright
 NK cells from daclizumab-treated MS patients, which are 
activated by the higher levels of available IL-2, had considerably higher cytotoxicity 
towards activated T cells than did CD56
dim
 NK cells (Bielekova et al. 2006).  
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CD56
bright
 NK cells are able to proliferate and have enhanced cytotoxic function in 
response to stimulation with very low doses of IL-2 that are insufficient to stimulate 
CD56
dim
 NK cells (Nagler et al. 1989, Nagler et al. 1990, Baume et al. 1992). 
CD56
bright
 NK cells constitutively express CD25, a component of the high affinity IL-
2 receptor which is only found on CD56
dim
 NK cells following activation with target 
cells and IL-2 (Caligiuri et al. 1990, Nagler et al. 1990, Baume et al. 1992, Wendt et 
al. 2006). However, even when expression of CD25 is induced on CD56
dim
 NK cells, 
their proliferation is still lower than that of CD56
bright
 NK cells, suggesting that 
differences in signalling mechanisms may also be involved (Baume et al. 1992). 
CD56
bright
 NK cells also exclusively express c-kit receptor, stimulation of which 
enhances IL-2-induced IFNγ production and proliferation (Matos et al. 1993, Carson 
et al. 1997). IL-7 receptor (IL7R) is also exclusively expressed on the CD56
bright 
population, therefore only CD56
bright
 NK cells proliferate and upregulate cytotoxic 
function in response to IL-7 (Hanna et al. 2004b, Wendt et al. 2006, Nielsen et al. 
2012). In addition, CD56
bright
 NK cells express considerably higher levels of IL12Rβ2 
transcript, though this difference is abrogated following activation (Wendt et al. 
2006). This may explain the enhanced IFNγ response and strong upregulation of 
cytotoxic function when this subset is stimulated with IL-12/IL-18. Although both 
subsets express similar levels of IL-21R, CD56
bright
 NK cells also seem to be more 
responsive to this cytokine, which again is likely due to the differential expression of 
various signalling molecules (Hanna et al. 2004b, Wilk et al. 2008, Nielsen et al. 
2012).  
These subsets also have differing capacity for interaction with other leukocytes. 
Interaction with monocytes induces CD56
bright
 NK cells to produce large amounts of 
IFNγ and in turn, NK cells promote TNFα production in the monocytes (Dalbeth et al. 
2004). CD56
dim
 NK cells do not promote TNFα production as strongly (Dalbeth et al. 
2004). CD56
bright
 NK cells are also more effective at inducing monocyte-derived DCs 
due to their higher level of GM-CSF secretion (Zhang et al. 2007). LPS-activated 
dendritic cells also preferentially induce proliferation and IFNγ production in the 
CD56
bright
 subset (Vitale et al. 2004). In addition, CD56
bright
 NK cells have higher 
levels of antioxidants such as cell surface thiols and are resistant to H2O2 produced by 
phagocytes, which induces apoptosis in CD56
dim
 NK cells (Harlin et al. 2007, Thorén 
et al. 2007). 
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Differences in chemokine receptors and adhesion molecules are likely to influence the 
localisation of these two subsets. CD56
bright
 NK cells constitutively express CD62L, 
CD44 and CCR7, which are associated with migration to lymph nodes (Frey et al. 
1998, Campbell et al. 2001, Hanna et al. 2004b, Vitale et al. 2004, Wendt et al. 
2006). CCR7 expression can be induced on activated CD56
dim
 NK cells, but CD62L is 
only expressed on a small minority of CD56
dim
 NK cells, both resting and activated 
(Wendt et al. 2006). CCR5, CCR6 and CXCR3 are also found predominantly on the 
CD56
bright
 subset (Campbell et al. 2001, Vitale et al. 2004, Berahovich et al. 2006, 
Wendt et al. 2006). Conversely, CXCR1, CXCR2 and CX3CR1 are largely restricted 
to the CD56
dim
 subset (Campbell et al. 2001). A number of other adhesion molecules 
appear to be differentially expressed, which may have implications for both migration 
and interaction with target cells: ICAM-1, ICAM-2, LFA-3, activated leukocyte cell 
adhesion molecule and integrin αE have all been associated with CD56dim NK cells, 
whereas ICAM3 and integrins α5, αM and αX are preferentially expressed by the 
CD56
bright
 subset (Frey et al. 1998, Hanna et al. 2004b, Wendt et al. 2006). 
A number of other markers have also been used to define distinct subsets of NK cells, 
including CD8, CD27, CD57, CD62L and CX3CR1 (Srour et al. 1990, Lowdell et al. 
2002, Addison et al. 2005, Silva et al. 2008, Vossen et al.  2008, Chattopadhyay et al. 
2009, Björkström et al. 2010, Juelke et al. 2010, Lopez-Vergès et al. 2010, Hamann et 
al. 2011).  
CD8 is expressed on around 40% of NK cells, most of which express only α/α 
homodimers, as opposed to the α/β heterodimers found on most CD8+ T cells (Baume 
et al. 1990). The CD8
+
 NK cell subset is reported to be more cytotoxic towards K562 
cells and primary leukaemic blasts than the CD8
-
 subset (Srour et al. 1990, Lowdell et 
al. 2002, Addison et al. 2005). However, CD8
+
 and CD8
-
 NK cells express similar 
levels of KIR, activating receptors (NKP30, NKp44, NKp46 and NKG2D) and 
intracellular perforin and granzyme A, the factors typically associated with differing 
cytotoxic function in other subsets (Addison et al. 2005). This led to speculation that 
the CD8 molecule itself might contribute directly to NK cell function. CD8α/α dimers 
bind to both classical and non-classical HLA class I and are predicted to modulate 
avidity of HLA class I/TCR interactions (Sanders et al. 1991, Gao et al. 1997, Gao et 
al. 2000). Conceivably, CD8 might also influence the interaction between HLA class I 
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and KIR or LILR, thereby modulating induction of positive or negative signalling by 
these receptors. However, target cells transfected with HLA-Cw*0304 were still 
protected from lysis when the NK cell effector population expressed CD8, indicating 
that CD8 does not modulate signals from inhibitory KIR (Addison et al. 2005). CD8 
might also trigger signalling in its own right. In T cells, CD8 associates with 
lymphocyte-specific protein tyrosine kinase (Lck) and dephosphorylates it, causing 
Lck in turn to phosphorylate CD3ζ, triggering a signalling cascade resulting in 
activation of linker of activated T cells (LAT) and PLCγ, which modulate cytoskeletal 
reorganisation, calcium flux, proliferation and gene transcription (Gibbings and Dean 
Befus 2009). Meanwhile, CD8 ligation in myeloid cells enhances FcRγ-mediated 
responses (Gibbings and Dean Befus 2009). In support of a signalling role for CD8 on 
NK cells, its ligation causes a rapid and sustained influx of extracellular-derived 
calcium (Lowdell et al. 2002, Spaggiari et al. 2002, Addison et al. 2005). However, 
ligation of CD8 does not appear to induce lytic activity per se (Lowdell et al. 2002, 
Addison et al. 2005). According to Addison et al., CD8
+
 NK cells undergo a 
considerably lower rate of activation-induced apoptosis than CD8
-
 NK cells, an effect 
that is abrogated by blocking MHC class I (Addison et al. 2005). CD8
+
 NK cells are 
protected from apoptosis even when killing MHC-deficient targets, due to 
simultaneous formation of both NK cell:target cell and NK cell:NK cell conjugates, 
whereby NK cells themselves provide the MHC class I ligand for CD8 (Addison et al. 
2005). This study appears to contradict the previous findings of Spaggiari et al. 
(2002), who found that soluble HLA class I caused apoptosis of CD8
+
 NK cell clones 
by inducing expression of FasL, which then binds to the NK cell’s own Fas (CD95) 
receptors. However, this may reflect differential effects of soluble versus membrane-
bound ligands, as has been observed for other receptor-ligand combinations, including 
NKG2D and its ligands (Groh et al. 2002, Song et al. 2006, Cao et al. 2007, Cerboni 
et al. 2009). 
CD27 is a member of the TNF receptor family which distinguishes NK cell subsets in 
both humans and mice. Interaction of CD27 with its ligand CD70 promotes NK cell 
activation and cytokine production (Takeda et al. 2000, Kelley et al. 2001). CD27 is 
more frequently expressed on CD56
bright
 NK cells and, like the CD56
bright
 subset, 
CD27
+
 NK cells are enriched in tonsil and spleen (Silva et al. 2008, Vossen et al.  
2008). CD27 is also found on a smaller percentage of CD56
dim
 NK cells (Silva et al. 
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2008, Vossen et al. 2008). CD27
+
 NK cells express high levels of NKp46 and nearly 
all are CD94
+
 CD62L
+
, whereas the frequency of KIR-expressing cells is considerably 
lower than amongst CD27
- 
NK cells (Silva et al. 2008, Vossen et al. 2008).Within 
CD56
bright
 and CD56
dim
 subsets, expression of CD27 is associated with a lower level 
of perforin and granzyme B expression and lower cytotoxicity towards K562 cells. 
However, NKG2D-mediated killing of P815-MICA targets is similar or even higher 
using CD27
+
 NK cells (Silva et al. 2008). In this case the slightly higher expression of 
NKG2D observed on CD27
+
 NK cells might compensate for the lower expression of 
perforin and granzyme B (Silva et al. 2008). CD27
+
 NK cells also make more IFNγ in 
response to stimulation with PMA/ionomycin or cytokines (IL-12 combined with IL-
15 or IL-18) (Silva et al. 2008, Vossen et al. 2008). CD56
dim
 NK cells always 
produced less IFNγ than CD56bright, but within each of those subsets, there was a 
significant reduction in cytokine production when cells lacked CD27 (Vossen et al. 
2008). In mice, CD27 expression is also reported to enhance activation by DCs 
(Hayakawa and Smyth 2006). 
CD57 is a carbohydrate antigen expressed on some CD56
dim
, but not CD56
bright
 NK 
cells (Mitsumoto et al. 2000, Chattopadhyay et al. 2009, Lopez-Vergès et al. 2010). 
The CD57
+
 NK cell population expands during viral infection and CD57 expresion 
can be induced on CD57
-
 CD56
dim
 NK cells in vitro by incubation with IL-2 (Lopez-
Vergès et al. 2010, Lopez -Vergès et al. 2011). CD56
dim
 CD57
+
 NK cells express 
lower levels of NKp30, NKp46, NKG2D, KLRG1, CCR5, CXCR3 and CXCR4 and 
higher levels of most KIRs than CD56
dim
 CD57
- 
 NK cells and are typically LIR-1
+
, 
CD27
-
 and CD62L
-
 (Björkström et al. 2010, Lopez-Vergès et al. 2010). They express 
slightly higher levels of CD16 and accordingly produce more IFNγ in response to 
CD16 stimulation (Lopez-Vergès et al. 2010). However, CD56
dim
 CD57
-
 NK cells 
produce more IFNγ in response to IL-12+IL-18 stimulation, which may be related to 
their higher surface expression of IL-18Rα and higher levels of IL-12Rβ2 transcripts 
(Björkström et al. 2010, Lopez-Vergès et al. 2010). When stimulated with target cells 
or a combination of IL-2 and antibodies directed against NKG2D, NKp46 and 2B4, 
both subsets produce similar quantities of IFNγ (Lopez-Vergès et al. 2010). CD57+ 
NK cells have a reduced proliferative response to stimulation with target cells plus IL-
2 and to various combinations of cytokines, however, unlike CD57
+
 T cells, they are 
not more susceptible to activation-induced cell death than their CD57
-
 counterparts 
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(Björkström et al. 2010, Lopez-Vergès et al. 2010). CD56
dim
 CD57
+
 NK cells also 
express higher levels of granzyme B and perforin, however cytotoxicity towards K562 
is not significantly different (Chattopadhyay et al. 2009, Lopez-Vergès et al. 2010). 
Antibody-coated target cells are killed more efficiently by CD57
+
 NK cells, but this is 
probably related to their higher expression of CD16 (Lopez-Vergès et al. 2010).  
A number of functional differences between CX3CR1
+
 and CX3CR1
-
 NK cells have 
recently been identified. CX3CR1 expression is upregulated by stimulation with IL-2, 
IL-12, IL-15 or TGFβ (Hamann et al. 2011). CX3CR1+ NK cells are more cytotoxic 
towards K562 target cells, whereas CX3CR1
-
 NK cells produce 100-fold more IL-13, 
30-fold more IL-5 and significantly more IL-10, GM-CSF and TNF-α in response to 
PMA/ionomycin stimulation (Infante-Duarte et al. 2005, Hamann et al. 2011). 
However these differences may in part be due to the fact that CX3CR1
+
 NK cells are 
all CD56
dim
, whereas the CX3CR1 popualtion contains both CD56
bright
 and CD56
dim
 
NK cells (Hamann et al. 2011). CD56
dim
 CX3CR1
low/- 
 NK cells appear to represent an 
intermediate population between CD56
bright
 and CD56
dim
 CX3CR1
+
, as they have 
intermediate expression of KIR (expressed highly on CX3CR1
+
 NK cells) and 
NKG2A, NKp30, NKp46, CD27 and CD62L, all of which are expressed 
preferentially on CD56
bright
 NK cells (Hamann et al. 2011). CX3CR1
high
 NK cells 
show virtually no proliferative response to IL-2, whereas CD56
dim
 CX3CR1
low/- 
cells 
exhibit proliferation only slightly lower than that of CD56
bright
 NK cells. The 
percentage of CD56
dim
 NK cells expressing CD57 however is the same in both 
CX3CR1
+
 and CX3CR1
-
 subsets (Hamann et al. 2011).  
All the above subsets are found within peripheral blood. However, other subsets have 
been described that are associated with specific tissues. For instance an NKp44
+
 
subset, termed “NK-22,” has been identified in tonsils that expresses CCR6, receptor 
tyrosine kinase-like orphan receptor (ROR) α, RORC, IRF4 and aryl hydrocarbon 
receptor and produces IL-22, IL-26 and leaukaemia inhibitory factor (LIF) in response 
to IL-23 stimulation or interaction with activated monocytes (Cella et al. 2008). These 
cytokines stimulate epithelial cells to proliferate and release IL-10 (Cella et al. 2008). 
IL-17 production was not observed in NK-22 cells, however another RORγ+ subset 
has also been reported in tonsils which produces both IL-17 and IL-22 as well as TNF 
and lymphotoxin-α and -β when activated (Cella et al. 2008, Cupedo et al. 2009). 
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These cells appear to be derived from lymphoid tissue inducer cells and express IL7R, 
NKp44, NKp46 and NKp30, but lack NKG2D (Cupedo et al. 2009). It is possible that 
these two subsets are in fact the same population and that IL-17 was not detected in 
the former study due to the shorter stimulation time. Both subsets lack perforin, have 
low granzyme expression and produce little IFNγ in response to PMA/ionomycin 
stimulation (Cella et al. 2008, Cupedo et al. 2009). 
During pregnancy, another distinctive subset of NK cells appears in the decidua, 
constituting around 70% of all decidual lymphocytes (Moffett-King 2002). Decidual 
NK cells are CD56
superbright
 CD16
-
 NKG2A
high
 CD9
+
, have low cytotoxicity and 
express many genes that are not transcribed in peripheral NK cells (King et al. 2000, 
Koopman et al. 2003, Kopcow et al. 2005, Keskin et al. 2007). Peripheral blood NK 
cells take on a similar phenotype when cultured with TGFβ, a cytokine produced by 
decidual stromal cells (Keskin et al. 2007). 
1.1.7.1 Developmental Relationship of CD56dim and CD56bright NK Cells 
Observations of an age-related decrease in the proportion of peripheral blood 
CD56
bright
 NK cells led to the proposition that CD56
dim
 NK cells might be derived 
from CD56
bright
, but for a long time there was no solid evidence of this (Borrego et al. 
1999, Chidrawar et al. 2006). In fact, some speculated that the opposite 
developmental relationship might exist, given that CD56
dim
 CD16
+
 NK cells have 
been shown to convert to CD56
bright 
CD16
-
 NK cells and acquire their functional 
characteristics in vitro when stimulated with certain combinations of cytokines (Loza 
and Perussia 2004, Mailliard et al. 2005, Takahashi et al. 2007). Conversion of 
CD56
bright
 to CD56
dim
 CD16
+
 NK cells was finally observed by Chan et al. in 2007, 
who cultured CD56
bright
 NK cells from peripheral blood with synovial fibroblasts. The 
conversion was found to be dependent on NK cell-fibroblast contact mediated by 
interaction of NK cell CD56 with fibroblast growth factor receptor 1 on fibroblasts. 
The resulting NK cells had surface markers typical of the peripheral blood CD56
dim
 
subset, were highly cytotoxic and displayed a poor IFNγ response to PMA/ionomycin. 
Perhaps more importantly, the study went on to demonstrate that the natural direction 
of development in vivo is bright to dim, since CD56
dim
 NK cells injected into NOD-
SCID mice gave rise only to CD56
dim
 NK cells, whereas CD56
bright
 NK cells gave rise 
to both bright and dim subsets. CD56
bright
 NK cells are also enriched shortly after 
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HSC transplant in humans (Cooley et al. 2007). In addition, CD56
dim
 NK cells have a 
reduced telomere length compared to the CD56
bright
 subset, indicating that they are at 
a later stage of differentiation (Chan et al. 2007, Romagnani et al. 2007, Björkström 
et al. 2010). Overall the balance of evidence now suggests that the CD56
bright
 subset is 
indeed a developmental precursor to the CD56
dim
. 
A number of studies have reported functional intermediates between CD56
bright 
CD16
-
 
and CD56
dim
 CD16
+
 NK cells. Changes in the repertoire of surface receptors have 
been linked to progressive functional changes, during what is apparently an ongoing 
developmental process occurring in “mature” NK cells (see figure 1-v). For instance, 
CD56
bright
 CD16
+
 cells, induced by cytokine stimulation or incubation with T cells, 
are likely to represent NK cells about to transition to CD56
dim 
(Romagnani et al. 2007, 
Béziat et al. 2011). Found in efferent lymph nodes, they exhibit both the cytokine 
responsesiveness of CD56
bright
 CD16
- 
NK cells and cytotoxicity resembling CD56
dim
 
NK cells (Romagnani et al. 2007, Takahashi et al. 2007, Béziat et al. 2011). Subsets 
with intermediate phenotypes have also been identified within the CD56
dim 
population, characterised by expression of markers such as CD62L, CD94 and 
NKG2A, which are also highly expressed on the CD56
bright
 population. CD62L is 
expressed only on a small proportion of CD56
dim
 NK cells, which have a similar 
polyfunctional phenotype to that of CD56
bright
 CD16
+
 NK cells (Juelke et al. 2010). 
CD56
dim
 CD62L
+
 NK cells have high proliferative and cytotoxic capcity and produce 
large quantities of IFNγ in response to cytokines, interaction with DCs and ligation of 
activating receptors (Juelke et al. 2010). CD94 and NKG2A are found on around 50% 
of CD56
dim
 NK cells and are typically expressed together, consistent with their 
functional interaction (Béziat et al. 2010, Yu et al. 2010). As CD56
dim
 NK cells 
mature, they gain KIR and CD57 and lose NKG2A (Béziat et al. 2010, Björkstrom et 
al. 2010, Yu et al. 2010).  Each of these steps is associated with a decrease in 
proliferative capacity and IFNγ production in response to cytokine stimulation (Béziat 
et al. 2010, Björkstrom et al. 2010, Yu et al. 2010). Cytotoxicity towards most 
susceptible targets, including K562, is already fully achieved in NKG2A
+
 CD56
dim 
NK cells, though only NKG2A
-
 KIR
+
 NK cells kill HLA-E positive targets (Béziat et 
al. 2010, Yu et al. 2010). Most NK cells gain KIR before losing NKG2A (Béziat et al. 
2010). However, some NK cells lose NKG2A before gaining KIR and are 
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hyporesponsive as a result of NK cell education (Cooley et al. 2007, Béziat et al. 
2010). 
 
 
Figure 1-v: CD56
bright
 CD16
-
 NKG2A
+
 NK cells differentiate into CD56
dim
 CD16
+
 NKG2A
-
 NK 
cells. “Mature” NK cells are thought to pass through a series of developmental stages before reaching a 
terminally differentiated CD56
dim
 NKG2A
-
 KIR
+
 state. CD56
bright
 NK cells gain CD16 then 
downregulate expression of CD56 and lose CD62L. This is followed by gain of KIRs and finally loss 
of NKG2A. Molecules acquired at a particular stage of differentiation are shown in green and those 
that are lost or downregulated are indicated in red. 
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1.2 The Role of T cells and NK Cells in Multiple Sclerosis 
Multiple sclerosis (MS) is a presumed autoimmune disease of the central nervous 
system (CNS), involving myelin loss, axonal damage and brain atrophy (Hauser and 
Oksenberg 2006). Symptoms include limb weakness or loss of dexterity, visual 
disturbance, fatigue and cognitive deficits such as memory loss and impaired 
problem-solving ability.  Initially, most patients experience relapsing-remitting 
disease (RRMS), i.e. episodes of acute worsening in symptoms followed by periods of 
partial or complete recovery (Hauser and Oksenberg 2006, Wakerley et al. 2008). 
However, approximately 10% of patients experience progressive degeneration without 
first going through a relapsing-remitting stage (Wakerley et al. 2008). This is known 
as primary progressive MS (PPMS). 
Relapses are associated with breakdown of the blood-brain barrier (BBB) and 
formation of lesions in both white and grey matter, where infiltrating leukocytes 
accumulate causing inflammation and demyelination (Brück 2005, Hauser and 
Oksenberg 2006, Popescu and Lucchinetti 2012). The myelin sheath and 
oligodendrocytes which form it are subject to attack; this is presumed to involve 
infiltrating T cells and macrophages, although in some post-mortem 
neuropathological studies, T cells may not be abundant (Jurewicz et al. 1998, Barnett 
and Prineus 2004, Hill et al. 2004, Jurewicz et al. 2005, Zeis and Schaeren-Wiemers 
2008, Goverman 2009). Oligodendrocytes have many processes, each of which wraps 
multiple times around a different axon, encasing it in a lipid-rich myelin sheath which 
provides electrical insulation (Baumann and Pham Dinh 2001). Demyelination 
reduces neuronal conductivity and leaves the axons themselves vulnerable to immune 
attack (Bitsch et al. 2000, Neumann et al. 2003, Hauser and Oksenberg 2006, Melzer 
et al. 2009). 
Symptoms during relapse are caused mainly by inflammation and demyelination 
(Brück 2005). Once inflammation has subsided, axons can be remyelinated, 
explaining why function can be recovered during remission (Lassman et al. 2001, 
Brück 2005). However, axons which are not remyelinated are vulnerable to further 
degeneration even once inflammation has subsided (Bitsch et al. 2000, Kornek et al. 
2000). Damage to neurons is irreversible and once substantial damage has 
accumulated, the CNS becomes unable to compensate and patients enter the 
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secondary progressive (SP) phase of disease, during which they become progressively 
more disabled (Neumann et al. 2003, Brück et al. 2005). The rate of disability 
progression correlates with cerebellar atrophy and the degree of axonal damage, both 
in lesions and in normal appearing white matter (Lossef et al. 1996, De Stefano et al. 
1998, Fu et al. 1998).  
1.2.1 Genetic and Environmental Risk Factors are Associated with 
Development of MS 
Around 85,000 (approximately 1 in 900) people in the UK have MS, two thirds of 
whom are female (Multiple Sclerosis International Federation, Atlas of MS database 
[online], http://www.atlasofms.org/index.aspx, accessed August 25
th
 2012). 
Prevalence is similar in other European countries, North America, Australia and New 
Zealand, with considerably lower rates in Asia and South America. Mean age of onset 
is between 24 and 33 years.  
This suggests that differences in susceptibility are partly caused by genetic factors. 
However, susceptibility to MS cannot be determined by the presence or absence of 
any one individual gene, allele or polymorphism. The strongest genetic association 
with MS occurs within the HLA gene complex on chromosome 6p21.  In particular, 
one common Northern European haplotype, HLA-DQB1*0602, -DQA1*0102, -
DRB1*1501, -DRB5*0101, has consistently been associated with susceptibility to 
MS (Spurkland et al. 1991, Allen et al. 1994, Amirzargar et al. 1998, Barcellos et al. 
2003, Fernández et al. 2004). The risk is thought to be associated primarily with the 
HLA-DQB1*0602 and DRB1*1501 alleles and both of these may need to be present 
in order to confer susceptibility (Caballero et al. 1999, Oksenberg et al. 2004, Caillier 
et al. 2008, Lincoln et al. 2009). Possession of two copies of this haplotype confers an 
even greater susceptibility and increases the likelihood of more aggressive forms of 
disease (Barcellos et al. 2003). Other HLA haplotypes and specific alleles have also 
been proposed to positively or negatively influence risk of MS (Allen et al. 1994, 
Ligers et al. 2001, Cocco et al. 2012). However, due to a high level of linkage 
disequilibrium between HLA alleles, it remains difficult to determine just how many 
of these alleles are genuine functional determinants of disease (Etzensperger et al. 
2008).  
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Genome-wide association studies (GWAS) have identified a number of other non-
HLA alleles that are overrepresented in MS patients. Most of these have relatively 
modest effects on susceptibility and possession of several may be required in order to 
predispose to disease (Baranzini 2011). One of the most established associations 
outside of the HLA region is with certain alleles of IL2RA that favour production of 
the soluble rather than the membrane-bound form of the receptor, which promotes 
proliferation and activation of CD4
+
 effector T cells (International Multiple Sclerosis 
Genetics Consortium et al. 2007, ANZgene 2009, De Jager et al. 2009a, Maier et al. 
2009a, Maier et al. 2009b). An allele of IL7RA associated with an increase in the 
proportion of soluble IL7R is also a risk factor for MS (Gregory et al. 2007, 
International Multiple Sclerosis Genetics Consortium et al. 2007, Lundmark et al. 
2007, De Jager et al. 2009a). Expression of both IL7 and IL7R is increased in 
cerebrospinal fluid (CSF) of MS patients compared to other neurological disease and 
responses to myelin basic protein (MBP) and myelin oligodendrocyte protein (MOG) 
are enhanced by IL-7 in T cells from MS patients but not healthy controls (Traggiai et 
al. 2001, Lundmark et al. 2007).  
Another genetic risk factor for MS is a glycine to serine single nucleotide 
polymorphism in the DNAM-1 (CD226) gene, a mutation which has also been 
associated with several other autoimmune diseases (Hafler et al. 2009, Wieczorek et 
al. 2009, Patsopoulos et al. 2011). DNAM-1 is expressed on most T cells, NK cells, 
monocytes and some B cells (Hafler et al. 2009). It binds to poliovirus receptor or 
nectin 2 and co-stimulates T and NK cell responses and also functions as an adhesion 
molecule promoting transendothelial migration of leukocytes (Shibuya et al.1996, 
Bottino et al. 2003, Reymond et al. 2004, Tahara-Hanaoka et al. 2004). Blocking of 
DNAM-1 delays EAE onset and reduces its severity (Dardalhon et al. 2005).  
Other loci identified by GWAS include the costimulation molecules CD58 (LFA-3), 
CD40 and CD86, IL12B (a component of both IL-12 and IL-23 cytokines), and the 
transcription factors T-bet and STAT3 (International Multiple Sclerosis Genetics 
Consortium et al. 2007, ANZgene 2009, De Jager et al. 2009b, Patsopoulos et al. 
2011). A general increase in MS prevalence with distance from the equator has led to 
the suggestion that environmental factors such as sunlight and pathogens may play a 
role. A role for sunlight is further supported by decreased MS susceptibility in those 
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with outdoor occupations (Freedman et al. 2000, Westberg et al. 2009). Migration 
studies suggest that exposure to sunlight in childhood is particularly important in 
protecting against MS and the association of birth month with likelihood of MS has 
led to speculation that vitamin D levels in utero may also have an effect (Alter et al. 
1966, Dean and Elian 1997, Hammond et al. 2000, Willer et al. 2005). Sunlight is 
important for the synthesis of vitamin D. UVB radiation causes photolysis of 7-
dehydrocholesterol to pre-vitamin D3, which spontaneously isomerises to vitamin D3 
in the skin (Kamen and Tangpricha 2010). This is then hydroxylated twice to produce 
the active form of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol). Calcitriol 
mediates most of its effects via binding to the vitamin D receptor (VDR), a ligand-
activated transcription factor that binds to vitamin D response elements (VDRE) in 
gene promoters (Ramagopalan et al. 2010). VDREs are found at many putative MS-
related loci, including IRF8, STAT3, VCAM-1, CXCR4, CXCR5, NFκB1, CD40, 
CLEC16A and members of the TNF/TNFR superfamilies (Ramagopalan et al. 2010, 
DiSanto et al. 2012). 
Higher vitamin D intake and serum levels of calcitriol have been associated with 
reduced risk of MS and with reduced relapse rate amongst RRMS patients (Munger et 
al. 2004, Munger et al. 2006, Pierrot-Deseilligny et al. 2008, Soilu-Hänninen et al. 
2008 , Correale et al. 2009, Ascherio et al. 2010, Simpson et al. 2010). The serum 
level of calcitriol correlates with the ability of Tregs to suppress T effector 
proliferation in vitro, and higher calcitriol levels also favour skewing towards Th2 
instead of Th1 (Smolders et al. 2009). VDR binds to and activates Forkhead box P3 
(FoxP3) in T regs stimulated with calcitriol, enhancing their ability to suppress T cell 
proliferation (Kang et al. 2012).  It also downregulates IL-12 and IL-23 expression in 
DCs, causing them to induce Th2 or Treg polarisation instead of Th1 or Th17 (Daniel 
et al. 2008).Vitamin D is essential for development of functional invariant (i)NKT 
cells and has a variety of other immunosuppressive effects, including upregulating 
expression of IL-10, TGFβ and IL-5, inhibiting DC maturation, downregulating the 
CNS-homing receptor CCR6 on T cells, inhibiting NK and T cell proliferation, 
promoting T cell apoptosis and inhibiting NK cell cytotoxic function (Leung 1989, 
Merino et al. 1989, Penna and Adorini 2000, Griffin et al. 2001, Spach et al. 2004, 
Spach et al. 2006, Pedersen et al. 2007, Yu and Cantorna 2008, Correale et al. 2009, 
Chang et al. 2010, Lysandropoulos et al. 2011).   
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Smoking is also a major risk factor for MS, particulary PPMS, though the mechanism 
is not known (Hernán et al. 2001, Riise et al. 2003, Hedström et al. 2009, Healy et al. 
2009). It also increases the likelihood of progression to SPMS amongst RRMS 
patients (Hernán et al. 2005, Healy et al. 2009, Pittas et al. 2009).  
 
In summary, the epidemiology of MS is complex, with both genetic and 
environmental factors likely to play a role.  
1.2.2 CD4+ T cells Infiltrate the CNS and Promote Recruitment and 
Activation of Other Leukocytes, leading to Myelin and Axonal Damage  
Due to the inaccessibility of brain tissue in MS, much of our understanding of disease 
mechanisms is based on animal models such as experimental autoimmune 
encephalomyelitis (EAE). EAE is induced by administration of immunogenic white 
matter, protein or myelin antigen peptides from myelin components such as myelin 
oligodendrocyte protein (MOG), myelin basic protein (MBP) or proteolipid protein 
(PLP) or by adoptive transfer of T cell clones specific for these epitopes combined 
with an adjuvant (Gold et al. 2006). This model showed in the 1980s that activated 
autoreactive CD4
+
 T cells are necessary and sufficient to initiate EAE (Ben-Nun et al. 
1981). By extrapolation, it had been widely believed that CD4
+
 T cells are responsible 
for initiating human MS, although this has more recently been debated, as disease 
may occur in the presence of predominant CD8 infiltrates or in the virtual absence of 
lymphocytes (Babbe et al. 2000, Huseby et al. 2001, Barnett and Prineas 2004, Gold 
et al. 2006, Goverman 2009) (see figure 1-vi).  
The type of CD4
+
 T cell that may induce MS is a matter of debate. MS was originally 
considered a stereotypical Th1-mediated autoimmune disease, based on preferential 
CNS infiltration of IFNγ- but not IL-4- expressing T cells following peptide 
immunisation and on the lack of EAE induction in IRF-1-deficient mice (Merrill et al. 
1992, Renno et al. 1994, Tada et al. 1997, Juedes et al. 2000). However, since the 
discovery of Th17 cells, several studies have shown that these are also capable of 
initiating MS-like disease in mice and implied that they may be more crucial than Th1 
(Cua et al. 2003, Langrish et al. 2005, Kebir et al. 2007, Reboldi et al. 2009). The 
relative importance of the two subsets is still a matter of debate, though it seems likely 
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that both might play a role either in initiation or perpetuation of CNS inflammation 
(O’Connor et al. 2008). Th1 and Th17 cells have been shown to initiate distinct types 
of EAE and, given the heterogenous nature of MS, it seems likely that different 
subsets may be responsible for initiating human MS in different individuals (Kroenke 
et al. 2008, Stromnes et al. 2008, Jäger et al. 2009).  
However, T cell plasticity should also be taken into account. When Th17 polarisation 
is induced by IL-23 stimulation of human peripheral blood T cells in vitro, a subset of 
these cells also produces IFNγ and expresses both the Th1 transcription factor T-bet 
and the Th17 transcription factor RORγt (Kebir et al. 2009). The frequency of these 
IFNγ, IL-17 co-expressing cells is higher amongst T cells derived from MS patients, 
particularly those who are in relapse and large numbers of T cells co-expressing these 
cytokines have been detected in MS brain tissue. IFNγ induces strong upregulation of 
ICAM-1 on BBB endothelial cells, which facilitates adhesion and transmigration of 
both Th1 and Th17 cells (Kebir et al. 2009). The Th17 cytokines IL-17 and IL-22 also 
promote migration of human T cells through the BBB, by decreasing expression of 
the tight junction proteins occludin and zonula occludens-1 and promoting expression 
of chemokines including CCL2 and IL-8 (Kebir et al. 2007). Consequently, T cells 
co-expressing IFNγ and IL-17 migrate into the CNS more efficiently compared to 
those expressing either IFNγ or IL-17 alone and play an important role in the 
widespread recruitment of other leukocytes which follows (Kebir et al. 2009).  
In order to cross the BBB, T cells must first be activated in the lymph nodes by 
dendritic cells presenting their cognate antigen (Goverman 2009, Inoue et al. 2012). 
Activated T cells upregulate chemokine receptors and integrins, allowing them to 
migrate towards the CNS and adhere to vascular endothelial cells of the BBB (Hauser 
and Oksenberg 2006, Bauer et al. 2009, Holmann et al. 2011, Inoue et al. 2012). 
Activated T cells roll along blood vessel walls until they encounter chemokines on the 
surface of the endothelial cell, which trigger signalling via the cognate chemokine 
receptors, leading to enhanced binding affinity and clustering of integrins (Carrithers 
et al. 2000, Kerfoot and Kubes 2002, Engelhart 2008, Holman et al. 2011). This 
facilitates stronger binding to the endothelial cell, causing the leukocyte to migrate 
across the vessel wall. Leukocytes are thought to enter the CNS at post-capillary 
venules in the meninges and via the choroid plexus epithelium, the barrier between 
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blood and CSF, both of which constitutively express P-selectins, one of the molecules 
that facilitates leukocyte rolling (Carrithers et al. 2000, Kivisäkk et al. 2003, Döring 
et al. 2007). The very late antigen-4 (VLA-4) integrin in particular is important for 
migration into the CNS parenchyma, since blocking antibodies effectively attenuate 
leukocyte infiltration in both EAE and MS (Yednock et al. 1992, Baron et al. 1993, 
Brocke et al. 1999, Theien et al. 2001, Kerfoot and Kubes 2002, Kivisäkk et al. 
2009a). 
During EAE, CD4
+
 T cells accumulate initially in the subarachnoid space, where they 
are reactivated by resident APCs, proliferate and release pro-inflammatory cytokines 
(Govermann 2009, Kivisäkk et al. 2009b). This causes upregulation of adhesion 
molecules on parenchymal vasculature, enabling them to migrate into the 
parenchyma. Infiltrating CD4
+
 T cells create an inflammatory environment within the 
brain, which promotes infiltration and activation of CD8
+
 T cells and macrophages 
(Kebir et al. 2007, Goverman 2009). Activated Th17 cells produce the neutrophil 
attractant CXCL8 and GM-CSF which induces maturation of microglia, CNS-specific 
APCs with similarity to macrophages (Aloisi et al. 2000, Codarri et al. 2011).  
Meanwhile, IFNγ activates macrophages and induces expression of MHC class II and 
co-stimulatory molecules on parenchymal micoglia allowing them to become 
competent antigen-presenting cells (Menèndez Iglesias et al. 1997, Goverman 2009). 
Th1 cells specifically enhance the ability of microglia and macrophages to induce Th1 
rather than Th2 responses and stimulate them to produce TNFα (Renno et al. 1995, 
Aloisi et al. 2000, Juedes et al. 2000). IFNγ also induces IFNγ-inducible protein 10 
(IP-10) and monokine induced by IFN-gamma (Mig) production by macrophages, 
microglia and astrocytes (Balashakov et al. 1999, Simpson et al. 2000). Together with 
the aforementioned disruption of the BBB by both Th1 and Th17 cytokines, 
accumulation of chemokines in lesions and in the CSF results in recruitment of much 
larger numbers of leukocytes to the CNS, including macrophages, neutrophils, 
memory and naïve B cells and CD4
+ 
and CD8
+
 T cells (Glabinski et al. 1997, 
Balashakov et al. 1999, Sørensen et al. 1999, Simpson et al. 2000, Kebir et al. 2007, 
Carlson et al. 2008). 
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Figure 1-vi: CD4
+
 T cells initiate CNS inflammation and demyelination. T cells are activated in the 
periphery and upregulate integrins required to adhere to and cross the BBB or blood-CSF barrier. Once 
inside the CNS, myelin-specific CD4
+
 T cells are reactivated by APCs in the perivascular space and 
produce cytokines and chemokines which increase BBB permeability and promote migration and 
activation of other leukocytes such as macrophages, CD8
+
 T cells and B cells. Leukocytes migrate into 
the parenchyma and cause damage to myelin-forming oligodendrocytes and axons by releasing 
graznzymes, ROS, TNFα and MMPs. 
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Infiltrating leukocytes produce a number of tissue-degrading enzymes including 
ADAM-12 and MMPs (Bar-Or et al. 2003, Vos et al. 2003, Toft-Hansen et al. 2004). 
These degrade components of the subendothelial basal lamina, increasing BBB 
permeability and facilitating migration into the brain parenchyma (Rosenberg et al. 
1992, Leppert et al. 1995, Stüve et al. 1996, Anthony et al. 1998, Lou et al. 1999, 
Zhang et al. 2011). MMPs, especially MMP9, also contribute to neuronal cell death 
and axonal damage (Vos et al. 2000, Newman et al. 2001). Several MMPs have been 
shown to cleave MBP, including macrophage-derived MMP12 (Gijbels et al. 1993, 
Chandler et al. 1995, Chandler et al. 1996, Vos et al. 2003, Toft-Hansen et al. 2004). 
MMP9 also has a protective role, cleaving the neuron-glial antigen 2 proteoglycan 
which inhibits oligodendrocyte maturation and therefore remyelination (Larsen et al. 
2003).  
Activated macrophages and microglia induce apoptotic pathways in oligodendrocytes 
and neurons by production of TNFα and FasL, to which these cell types are 
particularly sensitive; (Selmaj and Raine 1988, D’Souza et al. 1996, Becher et al. 
1998, Li et al. 2002, Jurewicz et al. 2005). They also produce high levels of toxic 
ROS and RNS which mediate various forms of damage such as lipid peroxidation, 
tyrosine nitrosylation, and DNA strand breaks (Merrill et al. 1993, Zhang et al. 1994, 
De Groot et al. 1997, van der Veen and Roberts 1999, Willenborg et al. 1999, Hill et 
al. 2004, Li et al. 2005, Jack et al. 2007). MBP-specific T cells activate microglia to 
upregulate MHC class II and ICAM-1, secrete TNFα and phagocytose axons and 
antibody-coated oligodendrocytes (Gimsa et al. 2000, Zeis and Schaeren-Wiemers 
2008). Macrophages and microglia present myelin products to T cells, further 
perpetuating the inflammatory response. Microglia secrete IL-12 and preferentially 
induce Th1 rather than Th2 cytokines (Krakowski and Owens 1997, Stalder et al. 
1997). They also release IL-1β, IL-3, IL-6, TNF-α, VEGF, lymphotoxin, macrophage 
inhibitory protein (MIP)-1α and matrix metalloproteinases (MMPs) (Stoll et al. 2002). 
Microglia also selectively phagocytose apoptotic leukocytes, a function which is 
strongly enhanced in the presence of IFNγ (Chan et al. 2001). Phagocytosis of 
apoptotic cells by microglia causes them to downregulate expression of TNFα and IL-
12 and reduces their ability to activate MBP-specific T cells (Magnus et al. 2001).  
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IL-15 produced by B cells, monocytes, astrocytes and microglia upregulates NKG2D 
and granzymes in CD8
+
 T cells, enhancing their cytotoxicity towards glial cells 
(Saikali et al. 2010, Schneider et al. 2011). Cytotoxic CD8
+
 T cells attack neurons and 
the supporting oligodendrocytes via granzyme release, ligation of the death receptor 
Fas (CD95) and production of soluble factors such as TNF-α (Goverman 2009, 
Melzer et al. 2009, Meuth et al. 2009). Oligodendrocytes are lysed by antigen-specific 
CD8
+
 T cells via an MHC class I-dependent mechanism (Jurewicz et al. 1998). 
Activated CD4
+
 and CD8
+
 T cells also gather along axons and kill neurons (Giuliani 
et al. 2003, Nitsch et al. 2004). T cell degranulation induces calcium oscillations in 
the neuron, followed by a sustained increase in calcium concentration, triggering 
nitric oxide production leading to cell death (Malipiero et al. 1999, Nitsch et al. 
2004). This process is dependent on activation of the glutamate recpeptor N-methyl-
D-aspartate (Malipiero et al. 1999, Nitsch et al. 2004).  
Once myelin, oligodendroglial and axon damage has begun, antigen presentation is 
enhanced, due to availability of soluble antigens and release of antigen presenting 
cells such as astroglial cells from suppression by neurons (Melzer et al. 2009). 
Activated macrophages, microglia and CD8
+
 T cells suppress neuronal excitability, 
which together with cytokine release, causes an upregulation of MHC class I 
expression, making them vulnerable to further attack by CD8
+
 T cells (Neumann et al. 
2003, Wang et al. 2008, Melzer et al. 2009, Meuth et al. 2009). 
B cells may also have a role in pathogenesis. Anti-MOG antibodies are increased in 
the CNS of MS patients and have been shown to cause myelin destruction in EAE 
(Genain et al. 1999, Berger et al. 2003, Hafler et al. 2005, Lalive et al. 2006, Menge 
et al. 2011). In addition, high concentrations of IgM in the CSF are associated with 
more rapid disease progression (Perini et al. 2006). Antibody deposited on 
oligodendrocytes is recognised by Fc receptors on macrophages, leading to 
phagocytosis of the oligodendrocyte (Scolding and Compston 1991). Antibodies can 
also direct formation of a membrane attack complex and subsequent complement-
mediated lysis (Mead et al. 2002). It appears that B cells are able to mature within the 
CNS in response to specific antigen (Corcione et al. 2004). In some patients, memory 
B cells cluster into follicular structures in the meninges of the brain (Magliozzi et al. 
2007). These follicles are typically found adjacent to large lesions and are associated 
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with more extensive cortical pathology and rapid disease progression. There has been 
considerable controversy around whether or not the B cells within these ectopic, sub-
meningeal follicles transcribe reactivated Epstein-Barr virus (EBV) (Serafini et al. 
2007, Willis et al. 2009, Serafini et al. 2010). This is of considerable interest, both 
with respect to the role of the anti-viral response in neuropathology and with respect 
to the consideration of infectious agents in the aetiology of the disease.   
IFNγ, TNFα and IL-1β produced by microglia and infiltrating leukocytes activate 
astrocytes, which can have both protective and detrimental consequences (Liberto et 
al. 2004). Astrocytes are the most abundant cell type in the CNS, representing around 
90% of cells in the human brain (Nair et al. 2008). They store glycogen, regulate local 
pH and ion homeostasis and modulate neurotransmission by release of 
neuromodulators into the synaptic cleft and uptake of neurotransmitters such as 
glutamate (Martin 1992, Kang et al. 1998, Brown and Ransom 2007, Nair et al. 
2008). Despite being of neural, rather than haematopoetic origin, astrocytes also have 
some properties of immune cells (Nair et al. 2008). Upon stimulation with IFNγ, 
astrocytes upregulate MHC class II, CD40, CD80 and CD86 and acquire antigen 
presenting function (Nikcevich et al. 1997, Aloisi et al. 1998). Astrocytes are less 
efficient antigen presenting cells than microglia, however antigen presentation by 
astrocytes preferentially stimulates differentiation into Th2 cells, which may have a 
protective function in MS (Aloisi et al. 1998). Astrocytes secrete both pro- and anti-
inflammatory cytokines, including IL-1β, IL-6, IL-10, IL-12, IL-17, IL-23, TNFα and 
TGFβ (Nair et al. 2008). Their endfeet surround blood vessels, allowing them to 
modulate BBB function. IL-1β, IL-6 and TNFα increase BBB permeability, while 
TGFβ and VEGF restore its integrity (Liberto et al. 2004, Nair et al. 2008). 
Astrocytes also secrete the chemokines MCP-1, RANTES, IL-8, IP-10, stromal 
derived factor 1 (SDF-1) and fractalkine (Glabinski et al. 1997). Astrocytes activated 
with IFNγ and TNFα upregulate ICAM-1 and VCAM-1, which bind LFA-1 and 
VLA-4 respectively on activated leukocytes, facilitating their extravasation and 
migration through the parenchyma (Sobel et al. 1990, Tan et al. 1998, Gimenez et al. 
2004). However, astrocytes also inhibit microglial IL-12 secretion and upregulate 
cytotoxic T-lymphocyte-antigen 4 on activated CD4
+
 T cells, causing them to take on 
a more regulatory function (Aloisi et al. 1997, Gimsa et al. 2004, Trajkovic et al. 
2004).  
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Severe damage to the CNS can cause “reactive astrogliosis” and glial scar formation 
(Smith and Eng 1987, Liberto et al. 2004). Astrocytes upregulate production of the 
intermediate filaments glial fibrillary acidic protein, vimentin and nestin, proliferate 
and extend processes, binding the cells tightly together to form a dense glial scar 
(Liberto et al. 2004). Glial scars block migration of oligodendrocytes and axons to 
repair lesions (Nair et al. 2008). Astrocyte-derived ephrin-B2 creates a basal lamina 
around the damaged area, thereby physically blocking axon growth (Bundesen et al. 
2003). Astrocytes also express neurocan and brevican proteoglycans which inhibit 
axon growth and fibroblast growth factor 2, which promotes oligodendrocyte 
proliferation and survival but inhibits maturation (Yamada et al. 1997, Asher et al. 
2000, Nair et al. 2008). Reactive astrocytes also produce ROS, NO and TNFα which 
may contribute to neuron and oligodendrocyte damage (Liberto et al. 2004).  
However, astrocytes also perform important protective functions following neuronal 
damage, as evidenced by prolonged inflammation, continued influx of leukocytes and 
increased neuronal damage following neuronal injury when astrocytes are depleted 
(Bush et al. 1999). Activated astrocytes at the edge of lesions express tissue inhibitor 
of matrix metalloproteinases (TIMP)-1, which might prevent expansion of the lesion 
by the destructive action of MMPs (Pagenstecher et al. 1998). Following injury, 
increased sequestration of glutamate by astrocytes and conversion to glutamine 
protects neurons and oligodendrocytes from damage (Liberto et al. 2004). Astrocytes 
also produce glutathione-S transferase-µ and ceruloplasmin which protect against 
oxidative damage, and a number of factors promoting neuron and oligodendrocyte 
survival and neurogenesis, such as brain-derived neurotrophic factor (BDNF), nerve-
derived growth factor, neurotrophin 3, platelet-derived growth factor (PDGF) and 
LIF, which are upregulated following damage (Levison et al. 1996, Kuhlow et al. 
2003, Schwartz and Nishiyama 2004, Nair et al. 2008). Secretion of MCP-1 and SDF-
1 recruits neural progenitor cells to the site of injury and promotes maturation of 
neural and oligodendrocyte progenitors (Calderon et al. 2006, Maysami et al. 2006, 
Xu et al. 2007). CXCL1-expressing astrocytes interact with oligodendrocytes, 
activating CXCR2 signalling which is important for survival and differentiation of 
oligodendrocytes and promotes remyelination (Padovani-Claudio et al. 2006). 
Activated astrocytes also produce IL-6 and IL-11, which are thought to promote 
oligodendrocyte survival, maturation and myelin synthesis (Schonrock et al. 2000, 
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Valerio et al. 2002, Zhang et al. 2006). Therefore astrocytes may be an important 
determining factor in perpetuation or repair of damage to the CNS. 
1.2.3 Disease Initiation Requires Activation of Peripheral T Cells – Potential 
Role of Viruses and Impaired Immunoregulatory Mechanisms 
Autoreactive CD4
+
 and CD8
+
 cells are present at similar frequencies in peripheral 
blood of MS patients and healthy controls (Crawford et al. 2004). However, the 
activity of these cells is believed to be controlled in healthy individuals by Tregs. 
Furthermore, T cells specific for myelin epitopes would not normally be expected to 
encounter their cognate antigen in the lymph nodes or blood. Since only activated T 
cells cross the intact BBB, cells restricted to CNS-specific epitopes such as MOG 
should not be able to enter under normal conditions (Steinmann 2007). Given that the 
current paradigm involves an important role for antigen-specific cells in disease 
initiation, this raises the question of how they come to enter the CNS in the first place. 
Either they are somehow being activated in the periphery, allowing them to cross the 
intact BBB, or the BBB is first compromised by other factors. T cells do not need to 
be specific for CNS antigens in order to enter the CNS and it is thought that small 
numbers of lymphocytes perform an immunosurveillance function in the ventricular 
and subarachnoid CSF (Hickey et al. 1991, Holman et al. 2011). However, the CNS is 
a highly immunosuppressive environment and infiltrating leukocytes will only initiate 
an immune response if they are restimulated with their cognate antigen within the 
CNS (Govermann 2009, Holman et al. 2011). One possibility is that infection or 
physical damage to the brain tissue induces an inflammatory response which if not 
adequately controlled, might compromise the integrity of the BBB and permit 
infiltration of other cells, including those specific for CNS antigens. Damage to the 
CNS might also result in escape of myelin antigens into the periphery, where they 
could be presented to autoimmune T cells (Steinmann 2007). Another possibility is 
non-specific polyclonal activation of B and T cells by bacterial or viral superantigens 
(Suspedra and Martin 2005).  
Alternatively, myelin-reactive T cells might be activated by molecular mimicry. Many 
viruses contain peptides with close similarity to CNS antigens. In particular the 
peptide between residues 82 and 99 of myelin basic protein, a major target of T cell 
responses during MS, resembles peptides from EBV, cytomegalovirus, influenza A, 
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Hepatitis A, adenovirus, herpes simplex virus 1 and various papilloma viruses 
(Steinman 2007). It has been postulated that activation of myelin-specific T cells by 
viruses in the periphery, causing them to upregulate chemokine receptors and 
integrins, might facilitate their migration into the CNS where they initiate 
inflammation and mount a response against the related self-antigen.  
As discussed above, the notion of an aetiological role for EBV infection is being 
reappraised in the light of debate about possible EBV-positive cells in MS post-
mortem brain tissue.  Several studies have demonstrated EBV seropositivity in around 
99% of MS patients (Bray et al.1983, Hahr et al. 2006, Levin et al. 2010). In addition, 
reactivation of EBV has been associated with increased clinical activity (Wandinger et 
al. 2000). It should be noted that latent EBV infection also occurs in 90-95% of the 
healthy population, most of whom will never develop MS (Haahr and Höllsberg 
2006). Higher serum levels of EBV-specific antibodies or prior development of 
mononucleosis, however, are associated with increased risk of developing MS 
(Lindberg et al. 1991, Ascherio et al. 2001, Levin et al. 2005, De Lorenze et al. 2006, 
Thacker et al. 2006, Lünemann et al. 2010). Individuals with a history of 
mononucleosis who also carry HLA-DR15 are reported to have a ten-fold increased 
risk of MS compared to those with neither (Nielsen et al. 2009). HLA-DR15 
conferred only a 2.4-fold increase when there was no prior mononucleosis, suggesting 
that infection plays a role in genetically susceptible people (Nielsen et al. 2009). 
Strikingly, antibodies recognising one particular epitope of Epstein-Barr nuclear 
antigen 1 increased the risk of MS 24-fold in HLA-DRB1*1501
+
 individuals 
(Sundström et al. 2009). Thus, it appears that MS may be associated with a loss of 
latency and/or an excessive immune response to EBV, though it remains to be 
conclusively proven whether this truly plays a role in MS induction and in how many 
people.  
Regardless of whether or not viruses are important, the fact that they are not unique to 
MS patients suggests that disease initiation requires a perturbation in the balance 
between activation and regulation of the immune response. In accordance with this, 
several studies have reported reduced frequency and function of CD4
+
 Tregs, CD8
+
 
CD28
-
 suppressor cells and iNKT cells in peripheral blood of MS patients (Crucian et 
al. 1995, Viglietta et al. 2004, Haas et al. 2005, Korn et al. 2007, Venken et al. 2007, 
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O’Keeffe et al. 2008, Frisullo et al. 2009, Mikulkova et al. 2010). MS patients also 
have a defect in thymic export of newly generated T cells, resulting in a decreased 
ratio of naïve: memory T cells (Hug et al. 2003, Duszczysyn et al. 2010). Circulation 
of newly generated naïve Tregs is reported to be important for maintaining function of 
all Tregs in the blood, therefore this thymic defect is proposed to be one of the causes 
of impaired Treg-mediated suppression in MS patients (Haas et al. 2007). Since NK 
cells can also have immunosuppressive functions, it is possible that perturbation of 
NK cell function may also play a role in MS (as discussed in chapter 1.2.5). Modest 
genetic associations with so many immune-related loci suggest that there may be 
many factors contributing to this imbalance and that the processes leading to disease 
initiation may vary between patients. 
1.2.4 Current Therapies for MS have Benefits and Limitations 
For a number of years, the main first-line treatments for RRMS have been interferon-
β (IFNβ) and glatiramer acetate (GA). IFNβ comes in two forms: IFNβ1a is 
essentially the same as endogenous human IFNβ, whereas IFNβ1b has a slightly 
altered sequence and lacks glycosylation, which may play a role in stabilising the 
molecule (Clerico et al. 2007). These treatments are usually self-administered 
intravenously once or twice weekly, though IFNβ1a can also be injected 
intramuscularly (Clerico et al. 2007, Racke et al. 2010). All three of these therapies 
reduce development of new lesions and reduce relapse rate by approximately one 
third on average, but show only a small reduction in progression of disability 
(Johnson et al. 1995, PRISMS 1998, Khan et al. 2001, Clanet et al. 2002, Fletcher et 
al. 2002, Martinelli Boneschi et al. 2003, Haas and Firzlaff 2005, Goldberg et al. 
2009, Uitdehaag et al. 2011). Many patients show no improvement and effectiveness 
may deteriorate due to development of autoantibodies (PRISMS 2001, Traboulsee et 
al. 2008). Injection site reactions and flu-like symptoms are very common, 
particularly amongst pateints treated with IFNβ1a (Fletcher et al. 2002, Clerico et al. 
2007, Schwid and Panitch 2007). Muscle weakness, depression and leuko- or 
thrombocytopenia have also been reported in around 10- 20% of IFNβ-treated 
patients, partcicularly those on higher dosage (Clanet et al. 2002, Fletcher et al. 2002, 
Clerico et al. 2007). In addition, adherence to these therapies is poor due to the need 
for regular (at least weekly) injections (Clerico et al. 2007, Fernández et al. 2012). 
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GA is a synthetic co-polymer of alanine, glutamic acid, lysine and tyrosine, which 
binds to MHC class I and II and induces suppressive function in GA-specific CD8
+
 
cytotoxic regulatory T cells, causing them to kill activated CD4
+
 T cells presenting 
GA via HLA class I (Tennakoon et al. 2006, Racke et al. 2010). It upregulates FoxP3 
expression and promotes IL-10 production by Tregs (Putheti et al. 2003, Hong et al. 
2005). It also converts monocytes and microglia to a “type II” phenotype, producing 
IL-10 instead of IL-12 and TNFα and promoting Th2 polarisation of naïve CD4+ T 
cells (Kim et al. 2004, Weber et al. 2004). GA-specifc CD4
+
 T cells can penetrate the 
CNS and produce BDNF (Aharoni et al. 2003, Chen et al. 2003, Ziemssen et al. 
2005). They also secrete IL-10 and TGF-β within the CNS and induce production of 
these anti-inflammatory cytokines by resident microglia and astrocytes (Aharoni et al. 
2003). 
PI3K signalling induces production of IL-1R antagonist in monocytes in response to 
both IFNβ and GA (Molnarfi et al. 2005, Carpintero et al. 2010). IFNβ also induces a 
variety of effects via activation of JAK/STAT pathways (Boxel-Dezaire et al. 2010). 
It inhibits breakdown of the BBB and migration of leukocytes into the CNS by 
suppressing MMP9, upregulating TIMPs and inhibiting expression of CCR7 on DCs 
(Leppert et al. 1996, Stüve et al. 1996, Karabudak et al. 2004, Boz et al. 2006, 
Comabella et al. 2009, Yen et al. 2010). It inhibits production of TNFα and 
lymphotoxin, both of which are toxic to oligodendrocytes (Selmaj and Raine 1988, 
Selmaj et al. 1991, Soliven et al. 1991, Abu Khabar et al. 1992, McRae et al. 1998). It 
also inhibits proliferation and production of IFNγ and TNFα and induces IL-10 and 
IL-4 production in MBP-reactive T cell lines (Kozovska et al. 1999, Weber et al. 
1999). IFNβ1a-treated patients have higher levels of IL-10 in both serum and CSF, 
which correlate with clinical response (Rudick et al. 1998). IFNβ treatment also 
increases frequency and function of CD4
+
 Tregs, CD8
+
 CD28
-
 Tsuppressor cells and 
CD56
bright
 NK cells (Namdar et al. 2000, Javed and Reder 2006, de Andres et al. 
2007, Saraste et al. 2007, Korporal et al. 2008, Aristimuno et al. 2010, Martín-
Rodriguez et al. 2010, Martín-Rodriguez et al. 2011).  
IFNβ modulates antigen presentation in several ways. Firstly, it antagonises IFNγ-
induced MHC class II upregulation and induces apoptosis of mature (but not 
immature) DCs by activation of caspase 3 and induction of caspase 11 expression 
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(Ling et al. 1985, Inaba et al. 1986, Fertsch et al. 1987, Panitch et al. 1989, Yen and 
Ganea 2009). It downregualtes expression of IL-12, IL-23 and IL-1β and upregulates 
IL-27 in DCs, thereby promoting Treg induction and inhibiting Th1 and Th17 
differentiation in naïve T cells (McRae et al. 1998, Ramgolam et al. 2009). IL-12 
production in monocytes is also downregulated (Karp et al. 2000). IFNβ increases the 
number of monocytes expressing CD86, a co-stimulatory molecule favouring Th2 
induction, whilst decreasing the number of B cells expressing CD80, which promotes 
Th1 induction (Genç et al. 1997).  It also modulates the interaction between microglia 
and T cells, promoting IL-10 production and inhibiting expression of TNFα, IL-1β, 
IL-4, IL-12 and IL-13 (Chabot and Yong 2000).  
Oral alternatives for first-line therapy have recently been trialled, the most promising 
of which is fingolimod. Fingolimod (FTY20) is a structural analog of sphingosine. It 
is rapidly phosphorylated in vivo to produce fingolimod-phosphate, which binds to 
four of the five sphingosine-1-phosphate receptors (S1PRs), S1PR1 and S1PR3-5 
(Mandala et al. 2002, Chun and Hartung 2010). S1PR1 is upregulated during clonal 
expansion of activated T cells, prompting T cell egression from lymph nodes into 
peripheral blood, where the concentration of S1P is higher (Matloubian et al. 2004, 
Pappu et al. 2007). Although fingolimod-phosphate initially activates receptor-
signalling, it also causes receptor internalisation and degradation, leading to a 
decrease in cell surface S1P receptor expression (Matloubian et al. 2004). By 
inhibiting responsiveness to S1P, fingolimod-phosphate causes retention of recently 
activated and central memory T cells and B cells within thymus and secondary 
lymphoid tissue, thereby preventing subsequent migration to the CNS (Mandala et al. 
2002, Xie et al. 2003, Brinkmann et al. 2004, Matloubian et al. 2004). Accordingly, a 
reduction in Th17 cells has been observed in peripheral blood of fingolimod-treated 
patients (Brinkmann 2009). Fingolimod-phosphate is also likely to have direct effects 
within the central nervous system, since fingolimod is able to cross the BBB (Foster et 
al. 2007). S1PRs are expressed on various CNS cell types, including neurons, 
oligodendrocytes, astrocytes and microglia and S1P signalling has an important role 
in many neural functions (Chun and Hartung 2010). Fingolimod promotes survival 
and proliferation of oligodendrocytes and modulates extension and retraction of 
processes, effects which are likely to modulate remyelination (Coelho et al. 2007, 
Mirion et al. 2008). It also promotes neuronal survival by upregulation of BDNF and 
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induces ERK signalling and migration in astrocytes (Mullershausen et al. 2007, 
Osinde et al. 2007, Deogracias et al. 2012). Based on known effects of S1P signalling, 
it is likely that fingolimod also modulates other aspects of neural biology such as 
neural process extension, astrogliosis and migration of neural stem/progenitor cells to 
sites of damage (Chun and Hartung 2010). In addition, fingolimod has effects on 
vascular endothelial cells which may alter vascular permeability (Chun and Hartung 
2010). 
Fingolimod is generally well-tolerated in comparison to IFNβ and is reportedly more 
effective (Cohen et al. 2010). Hypertension and an increased susceptibility to 
respiratory infections were reported during phase III trials, but serious side-effects 
were rare (Kappos et al. 2010). Relapse rate was reduced by around 50% compared to 
placebo, with around two-thirds of patients remaining relapse-free after 48 months 
(Kappos et al. 2010). Appearance of new gadolinium-enhancing lesions was also 
reduced considerably. However, fingolimod has only recently been approved and the 
true efficacy and safety can be more effectively assessed over time once it becomes 
widely available. 
Several monoclonal antibodies are also available for treatment of MS: natalizumab 
(Tysabri), alemtuzumab, dacluzimab and rituximab. Most of these have higher 
efficacy compared to IFNβ and GA and can be administered less frequently, but are 
more expensive and associated with a higher level of risk. For this reason, they are 
mainly used in patients with highly active disease. The most widely used antibody 
treatment is Tysabri, which is administered to RRMS patients by monthly intravenous 
infusions. Tysabri binds to the α4 subunit of the α4β1 integrin VLA-4 on 
lymphocytes, monocytes and DCs, thereby blocking its interaction with VCAM, 
inhibiting leukocyte adhesion to vascular endothelial cells and preventing migration 
across the BBB (Yednock et al. 1992, Baron et al. 1993, Carrithers et al. 2000, Putzki 
et al. 2010, Gan et al. 2012). It also causes downregulation of both alpha and beta 
integrin subunits on the surface of B, T, NK and NKT cells and DCs (Harrer et al. 
2011, de Andrés et al. 2012). Downregulation of VLA-4 on DCs inhibits their ability 
to induce antigen-specific T cell responses (de Andrés et al. 2012). Cell counts in the 
CSF are reduced during Tysabri treatment and the cytokine profile is altered, with 
decreased expression of IL-1b, IL-6, IL-8, IFNγ, IL-23, osteopontin and 
84 
 
proinflammatory chemokines and increased IL-10 (Khademi et al. 2009, Mellergard 
et al. 2010). However, Treg function is not restored and the frequency of activated T 
cells and concentration of both pro- and anti-inflammatory cytokines in peripheral 
blood is increased (Khademi et al. 2008, Stenner et al. 2008, Kivisäk et al. 2009, 
Putzki et al. 2010, Ramos-Cejudo et al. 2011). In vitro stimulation with Tysabri does 
not affect T cell proliferation or cytokine profile, suggesting that the changes seen in 
the blood are due to sequestration of cells that would otherwise have migrated to the 
CNS, rather than immunomodulation (Ramos-Cejudo et al. 2011).  
Tysabri is much more effective than IFNβ and GA, reducing the relapse rate by 68%, 
risk of progression over two years by 42% and lesions by 92% (Polman et al. 2006). 
The most common side-effects are fatigue and allergic reaction, though the increase in 
these over the placebo group was relatively modest (Polman et al. 2006). Overall, it is 
better tolerated than other antibody treatments and severe side-effects are rare. 
However, Tysabri causes progressive multifocal leukoencephalopathy (PML) in 
around 1 in 500 patients, a serious and often fatal condition caused by reactivation of 
JC virus, resulting in rapid and severe damage to the CNS (Bloomgren et al. 2012). 
Risk increases with treatment duration and is higher in patients with anti-JC virus 
antibodies and those who have undergone prior immunosuppressive therapy. Amongst 
patients with these risk factors who had undergone at least two years of Tysabri 
therapy, just over 1% developed PML (Bloomgren et al. 2012). Considering the 
serious and potentially fatal nature of PML, this level of risk may be unacceptable for 
many patients, so for those who test positive for JC antibodies this is often not a 
suitable long-term treatment option. 
Rituximab (α-CD20) binds to the B cell surface antigen CD20, causing depletion of B 
cells by a combination of apoptosis induction, ADCC and complement-mediated 
cytotoxicity (Barun and Bar-Or 2012). This leads to reduced proliferation and 
cytokine production by CD8
+
 and CD4
+
 (Th1/Th17) cells and reduced T cell 
infiltration of the CNS (Cross et al. 2006, Barun and Bar-Or 2012). In a RRMS trial, 
it reduced new lesion formation and halved the number of patients experiencing 
relapses, however the mean annualised relapse rate was not significantly different 
(Hauser et al. 2008). Side-effects were mostly infusion-related rather than rituximab-
specific and there was no increase in the frequency of severe adverse events (Hauser 
85 
 
et al. 2008). These results suggest that the drug is relatively safe, but may be 
ineffective in a substantial proportion of patients, though it has not been extensively 
tested in MS.  
Dacluzimab binds to IL2Rα (CD25) and blocks binding of IL-2 to high affinity 
(CD25/CD122/CD132) IL2R complexes (Martin 2012). It downregulates the co-
stimulation molecule CD40L and prevents transpresentation of IL-2 to antigen-
specific T cells via CD25 during interaction with DCs, thereby inhibiting T cell 
activation (Snyder et al. 2007, Wuest et al. 2011). However, the most important effect 
of daclizumab treatment may be a 7-fold increase in the frequency of peripheral blood 
CD56
bright
 NK cells, which are thought to mediate killing of activated T cells 
(Bielekova et al. 2006, Wynn et al. 2010). Daclizumab also upregulates expression of 
granzymes A and K and enhances cytotoxic function of the CD56
bright
 subset (Jiang et 
al. 2011). Data so far indicates that use of dacluzimab as a combination treatment 
with IFNβ is safe and reduces lesion formation more effectively than IFNβ alone 
(Wynn et al. 2010). However, trials so far have been either very small or of limited 
duration, so the long-term efficacy and safety of dacluzimab in MS patients remains 
to be elucidated (Martin 2012).  
Alemtuzumab binds to CD52 on the surface of mature leukocytes, inducing ADCC by 
NK cells and neutrophils (Klotz et al. 2012). This results in rapid and long-lasting 
depletion of T cells and a more transient depletion of B cells and monocytes. 
Alemtuzumab also enhances secretion of BDNF, PDGF and ciliary neurotrophic 
factor (Jones et al. 2010). In a clinical trial it was found to halve the relapse rate, 
significantly inhibit disease progression and in some cases to reverse it (Coles et al. 
2011, Coles et al. 2012). However, around 20% of patients develop autoimmune 
disease. These are most commonly thyroid disorders, but there have also been 
incidences of idiopathic thrombocytopenic purpura, a potentially fatal autoimmune 
condition which inhibits blood clotting (Cossburn et al. 2011, Coles et al. 2012).  
Most of these treatments are only effective during the relapsing-remitting phase of 
disease. Progressive MS and aggressive RRMS may be treated with mitoxantrone. 
Mitoxantrone intercalates into DNA, causing cross-linking and double-strand breaks 
and inhibits the DNA repair enzyme topoisomerase II (Fox 2006). It has a broad 
immunosuppressive effect by inhibiting proliferation and inducing cell death in B 
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cells, T cells, DCs and monocytes (Chan et al. 2005, Neuhaus et al. 2005). It also 
stimulates suppressive function in APCs, causing them to inhibit T cell proliferation 
and B cell antibody production and promote Treg rather than T effector function 
(Fidler et al. 1986a, Fidler et al. 1986b, Neuhaus et al. 2005). In RRMS patients, 
mitoxantrone reduces relapse rate by 65-80% and development of new lesions by 80% 
(Hartung et al. 2002, Krapf et al. 2005, Le Page et al. 2008). It also stabilises or 
reverses disability progression (Hartung et al. 2002, Le Page et al. 2008). Common 
side-effects of mitoxantrone therapy include nausea/vomiting, alopecia, menstrual 
disorders and susceptibility to urinary and respriratory tract infections (Hartung et al.  
2002, Cohen and Mikel 2004). Rare cases of serious infection and leukaemia have 
also been reported and there is a dose-dependent risk of cardiotoxicity (Cohen and 
Mikel 2004, Fox 2006, Goffette et al. 2005, Le Page et al. 2008, Le Page et al. 2011). 
Due to its toxicity, duration of mitoxantrone therapy is usually limited to 2-3 years 
(Fox 2006). 
In summary, though there are a number of therapies available for MS, most either 
have limited efficacy or high risks. Tysabri has proven effective and safe in the short 
term but the increasing risk over time means it is not an appropriate long-term 
solution for many patients. In order to develop more effective and safer therapies it is 
important to understand the immunological mechanisms involved in the disease. The 
majority of research into MS has so far focussed on CD4
+
 and CD8
+
 effector T cells. 
However, there is increasing evidence that other leukocytes including NK cells have a 
role in the disease. 
1.2.5 Evidence of a Role for NK Cells in Multiple Sclerosis 
1.2.5.1 NK Cells Influence Development of EAE 
NK cell depletion studies with anti-NK1.1 antibody in the EAE model have indicated 
both pathogenic (Shi et al. 2000, Winkler-Pickett et al. 2008) and protective (Zhang et 
al. 1997, Xu et al. 2005) roles for NK cells. The exact reason for these discrepancies 
is unclear, though differences in the method of EAE induction and dose, timing and 
route of administration of NK-cell depleting antibodies could all have an impact 
(Winkler-Pickett et al. 2008). Notably, the form of EAE induced in the studies where 
NK cell depletion ameriolated disease was considerably more severe, with a much 
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higher clinical disease score in control mice compared to the other studies. Therefore 
it seems that the role of NK cells may vary depending on the exact nature of disease. 
None of the depletion methods used in these studies were specific to NK cells. All 
three studies used an anti-NK1.1 antibody, which also depletes a subset of T cells. 
Winkler-Pickett et al. obtained similar results using anti-asialo GM, which does not 
deplete NK1.1
+  
T cells, but may have damaging effects on both T cells and 
macrophages, and using anti-Ly49H, which depletes only a subset of NK cells. The 
study by Zhang et al. used an anti-NK1.1 antibody in both WT and β2m-/- mice, which 
do not have NK1.1
+
 T cells. However, the latter mice also lack all CD8
+
 T cells and 
CD4
-
 CD8
-
 T cells, and the effect of depleting NK cells in this environment will not 
necessarily be the same as in an immunocompetent mouse. Nonetheless, the combined 
data do strongly suggest that NK cells influence development of EAE. 
EAE studies have also provided some mechanistic insights into the role of NK cells. 
Firstly, NK cells must be depleted prior to disease induction in order to suppress EAE, 
suggesting that they are more important in initiation, rather than maintenance, of 
inflammation (Winkler-Pickett et al. 2008). Immunisation with MOG increases the 
number of NK cells in the draining lymph node, where they might influence antigen 
presentation by DCs. T cells isolated from draining lymph nodes of NK cell-depleted 
mice were severely impaired in their ability to proliferate and produce cytokines in 
response to MOG peptide and fewer T cells infiltrated the CNS of NK cell-depleted 
mice (Winkler-Pickett et al. 2008).  
IL-18
-/-
 mice are defective in mounting Th1 and antibody responses and are resistant 
to EAE (Shi et al. 2000). As described in chapter 1.1.6, IL-18 promotes co-
stimulatory function and IFNγ production in NK cells and the presence of IL-18-
stimulated NK cells during T cell priming promotes Th1 differentiation (Mailliard et 
al. 2005). In accordance with this, adding exogenous IL-18 to these mice restored Th1 
responses and disease susceptibility only when NK cells were present (Shi et al. 
2000). Transfer of NK cells from IL-18-sufficient mice also reversed the Th1 defect, 
but only when the donor mice expressed IFNγ (Shi et al. 2000). 
Similar effects were seen in mice treated with IL-21. IL-21 injected prior to, but not 
after, EAE induction increased the disease severity, however this effect was abrogated 
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by depletion of NK cells, suggesting that activated NK cells can enhance disease 
initiation (Vollmer et al. 2005). IL-21 doubled NK cell IFNγ production on a per cell 
basis. EAE induction by transfer of autoreactive T cells was also inhibited when the 
donor mice had been treated with IL-21 prior to MOG immunisation. Though this 
could be due to direct effects of IL-21 on T cells, it may indicate that IL-21-activated 
NK cells are enhancing priming/ Th1 polarisation of encephalatogenic T cells. The 
studies by Vollmer and Shi both used anti-NK1.1 antibodies for NK cell depletion, 
however effects of NKT cells were excluded using CD1d
-/-
 mice. 
In the study by Zhang et al., where NK cells were protective, serum levels of TNFα 
and IFNγ were much higher in NK cell-depleted mice, implying a suppressive effect 
of NK cells on pro-inflammatory cytokine production (Zhang et al. 1997). Antigen-
induced proliferation of MOG-specific T cells was higher when incubated with APCs 
from NK cell-depleted mice, indicating that NK cells were negatively regulating APC 
function, in contrast to the data from the Shi and Winkler-Pickett studies (Zhang et al. 
1997). NK cells also selectively kill encephalitogenic PLP-specific T cells (Xu et al. 
2005).  
The role of NK cells within the CNS has also been investigated during EAE (Huang et 
al. 2006, Hao et al. 2010). In these studies, green fluorescent protein (GFP) was 
inserted into the CX3CR1 gene, creating CX3CR1
+/GFP
 mice, in which CX3CR1
+
 cells 
could be tracked by fluorescent imaging, and CX3CR1
GFP/GFP 
mice, which express 
GFP instead of CX3CR1. CX3CR1 is a receptor for fractalkine (CX3CL1), which is 
expressed in the inflamed CNS (Pan et al. 1997). It is important for recruitment of NK 
cells to the CNS, but is not required for infiltration of T cells, monocytes, 
macrophages or iNKT cells (Huang et al. 2006). CX3CR1
GFP/GFP 
mice had much 
fewer NK cells in the CNS and developed more severe EAE, with extensive 
demyelination and an increased mortality rate (Huang et al. 2006, Hao et al. 2010). 
Anti-NK1.1-mediated NK cell depletion in CX3CR1
+/GFP
 mice resulted in a similar 
exacerbation of disease (Huang et al. 2006). Both CX3CR1 knockout and NK cell 
depletion caused a marked increase in MOG-induced IL-17 production by CD4
+
 T 
cells in the CNS, but NK cell depletion did not significantly effect IL-17 production 
by lymph node CD4
+ 
T cells (Hao et al. 2010). Conversely, NK cell-depleted mice 
had much lower IFNγ production in lymph node CD4+ T cells, but slightly higher 
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production in the CNS. NK cell depletion also led to enhanced proliferation of CD8
+
 
T cells in lymph node but not CNS. This suggests that the role of NK cells in the CNS 
is likely to be different from that in the periphery.  
The profound effect of NK cells on IL-17 production in the CNS is likely to be 
mediated via effects on microglia. Microglia are the most potent APCs for Th17 
induction and this function is enhanced in NK cell-depleted mice (Hao et al. 2010). 
NK cell MIP1α production and microglial MCP-1 production result in reciprocal 
chemoattraction of the two cell types. NK cells are then able to inhibit microglial 
activation and production of cytokines involved in Th17 polarisation (IL-1, IL-6 and 
IL-23). Microglia are also susceptible to lysis by NK cells, owing in part to their low 
expression of the NKG2A ligand Qa1 (Hao et al. 2010). Blockade of NKG2A with an 
anti-NKG2A F(ab’)2 fragment led to marked ameriolation of MOG-induced EAE 
(Leavenworth et al. 2010). This was associated not only with inhibition of microglial 
activation, but also increased numbers of activated NK cells in the CNS, reduced T 
cell infiltration and impaired recall responses to MOG, though it was not clear 
whether the latter was due to reduced activation at the individual cell level or 
increased killing of MOG-specific T cells. NKG2A blockade also resulted in a shift in 
the cytokine profile of splenic, lymph node and CNS-derived CD4
+
 T cells, from pro-
inflammatory IFN-γ and IL-17 towards anti-inflammatory IL-4 and IL-10 
(Leavenworth et al. 2010). NK cells might also ameliorate EAE by promoting neural 
regeneration, since NK cells infiltrating the CNS of EAE rats produce high quantities 
of neurotrophic factors such as BDNF and neurotrophin-3 (Hammarberg et al. 2000). 
1.2.5.2 Genetic Factors Affecting NK Cell Function have been Associated with 
Susceptibility to MS 
Identification of HLA class I and KIR genes associated with increased or decreased 
susceptibility to MS indicates a potential role for NK cells in development of human 
MS. HLA alleles containing the Bw4 motif recognised by KIR3DL1, such as HLA-
B*44, are underrepresented amongst MS patients, as is HLA-Cw5, a ligand for 
KIR2DL1 and KIR2DS2 (Yeo et al. 2007, International MHC and Autoimmunity 
Genetics Network et al. 2009, Lorentzen et al. 2009, Bergamaschi et al. 2010, Healey 
et al. 2010). Conversely, HLA-A3, a ligand for KIR3DL2, is associated with 
increased risk of MS (Fogdell-Hahn et al. 2000, Harbo et al. 2004). Whether these 
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associations are related to modulation of T cell function or of NK cells, or both, is 
unclear. Information on the contribution of KIR genotype to MS susceptibility is 
relatively sparse, however there do appear to be some associations. KIR2DS1 protects 
aginst MS in individuals who also possess alleles encoding its ligand HLA-C2 
(Lorentzen et al. 2009, Fusco et al. 2010). Individuals homozygous for a haplotype 
containing the tightly linked 2DL2 and 2DS2 alleles (which lack 2DL3 since this 
segragates to the same locus) have increased susceptibility to MS, as do those 
carrying the KIR2DS4*001 or *002 allele (Fusco et al. 2010, Jelcić et al. 2012). 
These studies do not rule out a possible contribution of KIR
+
 T cells to disease 
modification, however KIRs are central to NK cell biology, whereas they are only 
expressed on a small percentage of T cells.  
Other genetic associations have been identified which might impact upon NK cell 
function, including predispotion towards MS in those possessing a null allele of 
LILRA3, encoding a soluble receptor for MHC class I which is predicted to antagonise 
activating receptors for MHC class I (Koch et al. 2005, Ordóñez et al. 2009). The 
aforementioned association with DNAM-1 could also affect NK cell activation, 
though neither of these receptors is exclusive to NK cells. Given that blocking of 
IL2Rα causes expansion of protective CD56bright NK cells, the MS-associated IL2Rα 
alleles might also modulate NK cell proliferation and function. Variation at the IL7R 
locus might also have effects on CD56
bright
 NK cells, all of which express this receptor 
(Hanna et al. 2004b, Nielsen et al. 2012). 
1.2.5.3 The Role of NK Cells in Human MS Requires Further Investigation 
As described in chapter 1.1.5, NK cells are known to produce many of the cytokines 
associated with MS pathogenesis, including IFNγ, TNFα and GM-CSF. In addition to 
their ability to influence T cell polarisation and kill activated T cells and monocytes, 
there is evidence that NK cells might also have effects on cells of the CNS, such as 
oligodendrocytes, neurons, astrocytes and microglia. Oligodendrocytes in MS white 
matter lesions express high levels of MICA and MICB (Saikali et al. 2007). Primary 
human oligodendrocytes expressing these ligands are susceptibe to NKG2D-
dependent lysis by IL-2-activated autologous NK cells in vitro (Morse et al. 2001, 
Saikali et al. 2007). NK cells also kill autologous resting microglia, which 
constitutively express ligands for NKG2D and DNAM-1 (Lünemann et al. 2008). 
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LPS stimulation of microglia causes them to upregulate MHC class I and 
downregulate NKG2D ligands, making them less susceptible to lysis by NK cells, 
particularly at high doses of LPS (Lünemann et al. 2008). Whether activation by the 
pro-inflammatory cytokine mileu in the inflamed CNS would also protect microglia 
from NK cells is uncertain. NK cells have also been shown to kill human fetal 
astrocytes in culture, leading to subsequent displacement of neurons in mixed glial 
cultures (Morse et al. 2001, Darlington et al. 2008). However, the astrocytes used in 
these studies were heterologous, so it isn’t clear if NK cells would kill astrocytes in 
vivo. Direct killing (or lack of) of human neurons by NK cells has not been 
demonstrated, but murine data indicates that NK cells can kill peripheral, but not 
CNS-derived neurons, since only the former express ligands for NKG2D (Backström 
et al. 2003). 
Presence of NK cells in demyelinating lesions has not been conclusively demonstrated 
in human MS. Although one study suggested that they were present, the antibody used 
to identify NK cells was directed against CD57, which is not in fact specific to NK 
cells (Traugott and Raine 1984). Our research group did not detect substantial 
infiltration of NK cells in MS brain, however since samples are only available post-
mortem, and mostly from patients in a progressive stage of disease, this doesn’t 
exclude the possibility that they are present in the brain of relapsing-remitting patients 
(Durrenberger et al. 2012). Both CD56
dim
 and CD56
bright
 NK cells have been found in 
the CSF of RRMS patients, so it seems likely that they might also penetrate the 
parenchyma (Bielekova et al. 2011).  
A number of studies have investigated changes in NK cell function in MS patients, 
with many of these suggesting that NK cell cytotoxic function might be important in 
preventing inflammation. Benczur et al. (1980) reported a decrease in cytotoxic 
function of NK cells towards K562 targets using peripheral blood lymphocytes as 
effectors, and lack of augmentation by interferon or poly(I:C), though this was 
contradicted by others (Santoli et al. 1981). Some of the patients in the Benczur study 
were on treatment and were not stratified accordingly. Decreased cytotoxicity and 
impaired augmentation by IL-2 was also reported in another study, in which over half 
the patients had the progressive form of MS (Braakman et al. 1986). None of the 
studies differentiated between patients with relapsing-remitting and progressive forms 
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of MS, though all included both in varying proportions. A subsequent study, where 
patients were stratified, indicated that abnormally low lytic activity was a feature of 
progressive, but not relapsing-remitting disease (Vraneš et al. 1989). Lysis of K562 
cells in this study correlated with the frequency of CD56
+
 leukocytes in peripheral 
blood, which was also decreased in progressive patients. This suggests that apparent 
differences in previous studies may also have been due to differences in NK cell 
frequency rather than their individual cytotoxic capacity. 
Impaired NK cell lytic capacity, as determined by in vitro lysis of K562 targets, has 
been observed immediately prior to onset of clinical relapse and appearance of new 
lesions in RRMS patients (Kastrukoff et al. 1998, Kastrukoff et al. 2003). However, 
these so-called valleys in lytic activity did not always result in a relapse, and given the 
apparent cyclical nature of lytic capacity in both patients and controls and the small 
number of patients studied, it is hard to be confident in whether this is really relevant 
to disease.  
All of the studies mentioned so far were also complicated by the use of PBMC rather 
than sorted NK cells as the effector population, since CD33
+
 and CD56
+
 CD3
+
 cells 
are also capable of killing K562 (Kastrukoff et al. 2003), differences in frequencies of 
effector populations could influence results and because differences in NK cell 
cytotoxicity in this assay could be either cell intrinsic or the result of regulation by 
other cell types. Data from our own lab, using the degranulation marker CD107a, 
suggests that NK cells from patients in relapse actually degranulate more in response 
to K562 stimulation compared to patients in remission, though stable patients still had 
higher levels of degranulation than healthy controls (A. Al-Aneezi, unpublished data). 
Furthermore, the frequency of CD69
+
 NK cells is higher in MS patients, suggesting 
that they are in a more activated state (Lünemann et al. 2011).  
1.2.5.4 NK Cell Subsets have been Associated with Protective and Pathogenic 
Roles in Multiple Sclerosis 
Given that NK cells have both pro- and anti-inflammatory functions, some of which 
are associated with particular subsets, it seems likely that different subsets of NK cells 
could have opposing roles in multiple sclerosis. Several subsets have already been 
associated with regulatory roles in MS. 
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Munscahuer et al. (1995) reported a significantly lower frequency of CD8
-
 NK cells 
(CD3
-
 CD56
+
 CD8
-
 ) in PBMCs of untreated RRMS patients compared to controls. 
The frequency of CD16
+
 CD56
+
 CD8
-
 NK cells was also significantly lower, which 
likely indicates a decrease in the CD56
dim
 CD8
-
 NK cell population. Whether the 
CD56
bright
 CD8
-
 population was also reduced is unclear. There was also a slight, but 
non-significant increase in the frequency of CD8
+
 NK cells (again both CD3
-
CD56
+
 
CD8
+
 and CD16
+
 CD56
+
 CD8
+
 populations were altered). In contradiction to this, De 
Jager et al. (2008) reported a decrease in CD8
low
 CD4
-
 lymphocytes in RRMS patients 
compared to healthy controls, and upon further investigation this difference was found 
to be attributable to CD8
+
 NK cells. No clear associations were found between disease 
course and frequency of CD8
+
 NK cells, though the sample size was fairly small 
given the large number of variables. Since the study was not originally designed to 
investigate NK cell subsets specifically, there is no mention of whether or not the 
frequency of CD8
-
 NK cells was also altered. This makes it difficult to assess whether 
the data is due to a decrease in total NK numbers or whether the proportion of NK 
cells expressing CD8 is altered.  
Two studies have reported similar frequencies of CD56
dim
 and CD56
bright
 NK cells in 
MS peripheral blood compared to healthy controls (Lünemann et al. 2011, Martin-
Rodriguez et al. 2011). However, CD56
bright
 NK cells from RRMS patients had 
impaired in vitro proliferative and IFNγ response to IL-12 stimulation, both when 
purified and in the presence of other leukocytes (Lünemann et al. 2011). CD56
bright
 
NK cells, unlike Tregs, are expanded during the third trimester of pregnancy when the 
risk of relapse is decreased, and might contribute to the increased ratio of Th2: Th1 
observed during this time (Airas et al. 2008). They induce caspase-independent 
apoptosis of activated (but not resting) CD4
+
 T cells by releasing granzyme K, which 
causes depolarisation of the mitochondrial membrane and ROS production in the T 
cell (Jiang et al. 2011).  
CD56
bright
 NK cells expand in response to IFNβ therapy, and to an even greater extent 
following dacluzimab (αCD25) therapy (Bielekova et al. 2006, Saraste et al. 2007, 
Vandenbark et al. 2009, Martín-Rodriguez et al. 2010, Wynn et al. 2010, Martín-
Rodriguez et al. 2011). IFNβ (but not daclizumab) also causes a decrease in absolute 
numbers of CD56
dim
 NK cells, though the difference is less substantial (Bielekova et 
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al. 2006, Martín-Rodriguez et al. 2011). The proportion of CD56
bright
 NK cells in the 
CSF is also increased following daclizumab treatment (Bielekova et al. 2011). CD25 
combines with the main IL2R chains CD122 and CD132 to form a receptor with 
higher affinity than the other two chains alone. By blocking CD25, which facilitates 
high affinity binding of IL-2 to the T cells which produced it, there is more IL-2 
available to bind to the intermediate affinity CD122/CD132 IL-2 receptor, which is 
constitutively expressed on NK cells (Martin et al. 2010, Martin 2012). CD56
bright
 NK 
cells express higher levels of CD122 than other lymphocytes, therefore are well-
placed to take advantage of increased IL-2 availability (Bielekova et al. 2006). 
CD56
bright
 expansion is associated with positive outcomes during both daclizumab and 
IFNβ treatment, indicating that these cells may have an important role in suppression 
of autoimmunity (Wynn et al. 2010, Martín-Rodriguez et al. 2011). 
Another study reported a decrease in CD16
+
 CD3
- 
cells (corresponding to the CD56
dim
 
NK cell subset) and CD57
+
 CD3
- 
cells following interferon-β treatment (Perini et al. 
2000). This suggests that the therapy is not only increasing the frequency of 
regulatory NK cells, but also reducing the frequency of more mature, cytolytic NK 
cells. However, no comparison was made to healthy controls in this study.  
NK cells from Japanese MS patients in remission express higher levels of CD95 and 
produce more IL-5 compared to patients in relapse or healthy controls (Takahashi et 
al. 2001). NK cells which are polarised towards this CD95
high
 “NK2” phenotype by in 
vitro culture with IL-4 and α-IL-12 neutralising antibody inhibit IFN-γ and enhance 
IL-4 production by T cells stimulated with PMA and ionomycin. IL-5 is partially, but 
not completely responsible for mediating Th2 polarisation. This may be an important 
regulatory mechanism in some patients, as NK cell-depleted PBMC from patients 
with high CD95 expression contain a higher proportion of MBP-reactive CD4
+
 T cells 
than undepleted PBMC, whereas NK depletion has no effect on MBP response of T 
cells from “CD95low” patients (Takahashi et al. 2004). Low expression of CD11c is 
also associated with expression of IL-5 and GATA-3, although the CD11c
low
 subset 
does not correspond to the CD95
high
 subset (Aranami et al. 2006). Patients with a high 
proportion of CD11c
low
 NK cells had a longer time until their next relapse compared 
to those with predominantly CD11c
high
 NK cells (Aranami et al. 2006). High 
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expression of CD11c correlates with the percentage of HLA-DR
+
 NK cells, which is 
also increased in MS patients (Aranami et al. 2006, Lünemann et al. 2011).  
Stable RRMS patients also have a lower percentage of CX3CR1
+
 NK cells than 
healthy controls, whereas patients with active disease have a marginally higher 
frequency than controls (Infante-Duarte et al. 2005). This was measured as a 
percentage of NK cells rather than percentage of lymphocytes. Since stable MS 
patients also had lower levels of CX3CR1 mRNA in total PBMC, it is most likely that 
there was an overall decrease in frequency of CX3CR1
+
 NK cells, however it is 
unclear whether there was also a corresponding increase in the frequency of CX3CR1
-
 
NK cells. CX3CR1
+
 NK cells have higher cytotoxic activity towards K562 targets 
(Infante-Duarte et al. 2005). Since CX3CR1 is important in mediating migration to 
the CNS in mice, it is possible that these more cytotoxic NK cells are participating in 
destruction of oligodendrocytes and astrocytes in the CNS during relapse and that 
patients able to regulate their numbers might therefore be protected from relapse. 
Alternatively, CX3CR1
+
 NK cells might be promoting inflammation in the periphery, 
perhaps by killing regulatory cells, thereby increasing the likelihood of T cell 
activation and CNS infiltration. The lack of difference between healthy controls and 
patients in relapse suggests that the frequency of this subset is not however a primary 
cause of disease. 
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1.3 Aims 
Given the evidence for both pathogenic and anti-inflammatory functions for NK cells 
in MS, we hypothesised that each of these functions might be performed by specific 
subsets of NK cells and that the frequency of such subsets might be altered in MS 
patients. Altered frequencies of several subsets have already been observed in MS 
patients compared to healthy controls and beneficial effects of therapies have been 
associated with specific types of NK cells. However, these subsets have each been 
identified based on expression of just one marker and it is not clear how the different 
observations are related. The aim of this study was to obtain a more comprehensive 
understanding of NK cell subsets in MS, in the following ways: 
1. Classify NK cell subsets using a combination of markers and identify specific 
subsets which have higher or lower frequency in RRMS patients compared to 
healthy controls (chapter 3). 
2. Investigate the effects of two widely-used MS  therapies (IFNβ and Tysabri) on 
frequencies of NK cell subsets (chapter 3). 
3. Investigate the phenotype and function of subsets of interest, including 
transcriptional profiles, cytokine production and cytotoxic function (chapter 4). 
4. Determine whether pathogenic and/or regulatory NK cells are found in the CNS 
during spontaneous demyelinating autoimmune disease, using the Line 7 mouse 
model of MS (chapter 5). 
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2. METHODS 
2.1 Human PBMC Isolation 
Blood samples were obtained from patients and healthy controls with full informed 
consent and ethical approval. MS and clinically isolated syndrome (CIS) patients were 
recruited from Charing Cross Hospital, West London, by Dr. Fatemah Kamel, Dr. 
Paolo Giannetti and Dr. Pascal Durrenberger. Patients were classified by neurology 
consultants Dr. Richard Nicholas and Dr. Omar Malik. RRMS patients experiencing 
an acute exacerbation in symptoms at the time of sampling were said to be in relapse, 
whereas those with no new visible symptoms were said to be in remission. CIS 
patients are defined in the clinic patient notes and database as those that have been 
referred to the MS Clinic due to a single, isolated attack of symptoms that may be MS 
related (such as blurred vision) but have not yet received a confirmed diagnosis of 
MS. A significant proportion of these will subsequently be confirmed as MS cases 
following further relapse and clinical confirmation according to McDonald criteria 
(www.nationalmssociety.org/download.aspx?id=29943). As such, analysis of 
CIS patients is considered to offer an invaluable insight into the early immunological 
events in a long-term, chronic disease. Sixteen healthy controls (see table 2-vii), 
twelve CIS patients (table 2-viii), twelve untreated RRMS patients (table 2-ix), twelve 
RRMS patients on interferon-β therapy (table 2-x) and eight on Tysabri therapy (table 
2-xi) were analysed for peripheral blood frequencies of NK cell subsets. Only patients 
who had not been treated with steroids for a relapse within the last two months were 
included. Patients on IFNβ or Tysabri therapy had been on therapy for at least 2 
months prior to sampling. Eleven of the twelve untreated patients had never been on 
disease-modifying treatment for MS and one (MSU2) had ceased treatment with GA 
one year prior to sample acquisition.  
Blood samples were collected in sodium heparinised vacutainers (Becton Dickinson, 
UK) and PBMC isolated by Histopaque density gradient centrifugation as follows. 
Blood was mixed with an equal volume of sterile phosphate buffered saline (PBS) 
(Invitrogen, UK) and overlayed onto 15ml room temperature Histopaque (Sigma-
Aldrich, UK) in a 50ml centrifuge tube, then centrifuged at 800g for 20 minutes 
(acceleration 5, brake 1). PBMC were removed from the Histopaque/plasma interface 
using  sterile Pasteur pipettes and transferred into fresh 50ml tubes, which were then 
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filled to the top with PBS and centrifuged at 350g for 10 minutes (acceleration 9, 
brake 9). Following removal of supernatant, PBMC were washed twice more with 
PBS, first at 300g, then at 200g for platelet removal. Cells were resuspended in 10ml 
FACS buffer and mixed thoroughly prior to counting with trypan blue (Sigma-
Aldrich, UK) for exclusion of dead cells.  
2.2 Flow Cytometry Evaluation of Human PBMC (Surface 
Staining) 
Cells were centrifuged once more at 300g and supernatant removed completely, using 
a 1000μl pipette to remove residual liquid from the inverted tube. Cells were blocked 
using 1:10 diluted human FcR blocking reagent (Miltenyi Biotec, UK) in 100µl 
FACS buffer per 10
7
 cells, for 15 minutes at 4ºC. Cells were resuspended in FACS 
buffer at a concentration of 1x 10
7
 cells/ml and 50µl (5 x 10
5
) cells were added to 
each well of a 96 well plate containing 100μl pre-mixed antibodies in FACS buffer. 
Antibody cocktails for experimental and fluorescence minus one controls (FMOs) 
were prepared on the morning of the experiment prior to adding cells, in order to 
maintain a consistent staining duration. For each FMO, one antibody was removed 
and replaced with an isotype control, in order to control for both non-specific binding 
and spectral overlap. (For full list of antibodies see table 2-iii.) PBMC plus antibody 
cocktails were mixed briefly by pulse vortexing and incubated for 30 minutes at 4ºC 
in the dark. Cells were then washed twice with FACS buffer, resuspended in 1% 
paraformaldehyde (Sigma-Aldrich, UK), stored at 4ºC and acquired on a BD FACS 
Aria II flow cytometer within 48 hours (50,000 lymphocytes were acquired per 
sample). Single antibody-stained cells were also acquired in order to perform 
compensation. Compensation was performed using BD FACSDiva software and 
further data analysis was carried out using FlowJo 7.5 (Treestar, USA). 
Lymphocytes were gated according to forward and side-scatter and doublets were 
excluded using the forward scatter-width parameter. For multiparameter subset 
frequency analysis, cells were gated as shown in figure 2-i and categorised into ten 
subsets (summarised in figure 2-ii). 
2.3 PBMC Stimulation and Intracellular Cytokine Staining 
PBMC were resuspended at a concentration of 1 x 10
6 
cells/ml in culture medium and 
incubated for 6 hours (37ºC, 5% CO2) in the presence of 50ng/ml PMA, 1µg/ml 
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ionomycin (Sigma-Aldrich, UK) and 1µl/ml (1000x) monensin (Biolegend, UK). 
Cells were transferred to a 50ml centrifuge tube and washed twice with FACS buffer. 
Fc receptor-blocking was performed as described in section 2.2, before diluting cells 
to 2 x 10
7
 cells/ml in FACS buffer. Cells were then transferred to FACS tubes (1 x 10
6
 
PBMC/ tube) and stained with antibodies against surface markers as described in 
section 2.2. Intracellular staining was performed using Cytofix/Cytoperm buffer and 
Perm/Wash solution (diluted 1:10 in H2O) from the BD Cytofix/Cytoperm 
fixation/permeabilization kit (Becton Dickinson, UK). Following surface staining, 
cells were washed twice with FACS buffer, resuspended thoroughly in 250µl 
Cytofix/Cytoperm buffer and incubated at 4ºC for 20 minutes. After washing twice 
with 1ml per tube (1x) Perm/Wash solution, supernatant was removed thoroughly and 
cells were resuspended in 100µl (1x) Perm/Wash solution. Fluorochrome conjugated 
anti-cytokine antibodies and isotype controls were added and samples incubated at 
4ºC in the dark for 30 minutes. Cells were washed twice with (1x) Perm/Wash 
solution and resuspended with 100µl 2% paraformaldehyde. Samples were stored at 
4ºC in the dark and acquired the following day on BD FACS Aria II flow cytometer. 
(100,000 lymphocytes were acquired per sample). Data analysis was performed as 
described in section 2.2. 
2.4 Cell Sorting for RNA 
PBMC were isolated from 40ml of blood obtained from healthy female volunteers and 
Fc-receptor blocking was performed as described in section 2.2. 5 x 10
5
 PBMC were 
added to pre-prepared antibody mixes in FACS tubes for compensation (single stains) 
and gating (all five antibodies and FMOs for CD56, CD8, CD27 and CD57). The rest 
of the cells were stained in a 50ml centrifuge tube. 130µl FACS buffer, 10µl CD56, 
10µl CD27, 20µl CD8 PerCP-Cy5.5, 20µl CD57 FITC and 10µl CD3 APC were 
added per million PBMC. Cells were incubated at 4ºC for 30 minutes in the dark, then 
washed twice and resuspended in FACS buffer. PBMC for sorting were diluted to 
approximately 5 x 10
6
/ml and filtered through a 100µM filter into sterile 
polypropylene FACS tubes (both from Becton Dickinson, UK). Cells were sorted on 
the BD FACS Aria II fluorescence activated cell sorter using the 70 micron nozzle 
and “4-way purity” mode, with a sample incubation temperature of 4ºC. Voltages and 
compensations were set using single-stained cells prior to acquiring the FMO control 
tubes, which were used for setting gates. Lymphocytes were identified according to 
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forward and side scatter and doublets were excluded by plotting forward scatter-area 
vs. forward scatter-width. NK cells were defined as CD56
+
 CD3
-
 singlets. CD56
dim
 
CD8
+
 CD57
+
 CD27
-
 and CD56
dim
 CD8
-
 CD57
-
 CD27
-
 NK cell populations were 
defined using FMOs. In order to enhance purity, cells were sorted into far left and far 
right positions only, which are furthest from the waste stream and flow rate was set so 
as to sort no more than 2000 events per second. First, ≥ 2000 cells of each subset were 
sorted into polypropylene FACS tubes containing 300µl FACS buffer, then 
resuspended by repeatedly running buffer down the sides of the tube followed by 
vortexing. These samples were then acquired on the FACS Aria II to check their 
purity (see figure 2-iii). The remainder of the PBMC were then sorted into cold 
polypropylene tubes containing 300µl lysis buffer RLT Plus (Qiagen, UK) 
supplemented with 2-Mercaptoethanol (Sigma-Aldrich, UK). Once sorting was 
complete, samples were made up to a volume of 350µl (or a multiple of 350µl, if 
volume already over 350µl) with lysis buffer RLT Plus and resuspended by running 
buffer lysis buffer down side of tube. Suspensions were then transferred to 1.5ml 
Eppendorf tubes and vortexed thoroughly in order to homogenize samples. Lysates 
were stored at -80ºC until required for RNA extraction. 
2.5 RNA Extraction 
RNA was extracted from sorted NK cells using the RNeasy Plus Micro Kit (Qiagen, 
UK), as follows. Buffer RPE was diluted with 4 volumes of 99% molecular grade 
ethanol (Sigma-Aldrich, UK). Lysates were thawed and briefly vortexed before 
transferring 350µl to gDNA Eliminator spin columns inside 2ml collection tubes. 
Following centrifugation for 30 seconds at 16,000g, columns were discarded and 
350µl 70% ethanol was added to the flow-through and mixed by pipetting. Flow-
through was then transferred to RNeasy MiniElute spin columns in 2ml collection 
tubes and centrifuged at 16,000g for 30 seconds. Flow-through was discarded using a 
pipette and column was then washed with 700µl buffer RW1, followed by 500µl 
buffer RPE by centrifuging for 30 seconds, 16,000g and discarding flow-through. 
500µl 80% ethanol was then added to the spin column and centrifuged for 2 minutes 
at 16,000g. Collection tube and flow-through were discarded and column was 
transferred to a fresh 2ml collection tube. Columns were then centrifuged for 5 
minutes at 16,000g with lids open in order to remove residual ethanol from spin 
column membrane. Columns were placed in 1.5ml collection tubes and 20µl RNase-
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free water was added directly onto the spin column membrane, ensuring that the 
membrane was fully covered. Columns were then centrifuged at 16,000g for 2 
minutes to elute RNA. RNA concentrations were determined using a NanoDrop 
spectrophotometer (Thermo Scientific, UK). 
2.6 Reverse Transcription 
Reverse transcription was performed using the RT
2
 Nano PreAMP cDNA Synthesis 
Kit (Qiagen, UK). The following were added to PCR tubes: 2µl (5x) gDNA 
elimination buffer, 20ng RNA and RNase-free water up to a volume of 10µl. Contents 
were mixed by gentle pipetting, followed by brief centrifugation. Samples were 
incubated for 5 minutes at 42ºC, then immediately chilled on ice for at least one 
minute. RT cocktail was prepared as shown in table 2-i. 
10μl RT cocktail was then added to each sample, mixed well by pipetting and briefly 
centrifuged. Samples were incubated at 42ºC for 30 minutes for reverse transcription, 
then immediately at 95ºC for 5 minutes to stop the reaction. cDNA was then pre-
amplified for use in quantitative(q) RT-PCR arrays or individual qRT-PCR reactions. 
Table 2-i: Reagents for reverse transcription reaction 
Reagent Volume per reaction (μl) 
BC3 (5x reverse transcription buffer 3) 4 
P2 (Primer and external control mix) 1 
RE (cDNA enzyme synthesis mix) 1 
RI (RNase inhibitor) 1 
RNase-free water 3 
 
2.7 Quantitative RT-PCR Arrays 
Nano PreAMP cocktail was prepared by mixing 12.5μl RT2 PreAMP PCR master mix 
per reaction with 7.5μl RT2 PreAMP pathway primer mix Human Th17 for 
Autoimmunity and Inflammation. 5µl cDNA and 20µl Nano PreAMP cocktail were 
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added to 0.2ml PCR tubes, mixed gently by pipetting and centrifuged before 
performing PCR as follows: 10 minutes at 95ºC (to activate HotStart Taq DNA 
polymerase), followed by 12 PCR cycles (95ºC for 15 seconds, 60ºC for 2 minutes). 
Samples were placed on ice briefly, then 2μl side reaction reducer was added, mixed 
and centrifuged. Samples were incubated in a thermal cycler at 37ºC for 15 minutes to 
eliminate residual primers, followed by 95ºC for 5 minutes to stop the reaction. 84μl 
of RNAse/DNase-free water (Sigma-Aldrich, UK) was added to each sample and 
mixed. Samples were then stored at -20ºC until use. 
For qPCR array, 102µl pre-amplified cDNA was mixed with 1350µl (2x) RT
2
 SYBR 
Green ROX qPCR Mastermix (Qiagen, UK) and 1248µl RNase/DNase-free water 
(Sigma-Aldrich, UK) in a 50ml centrifuge tube. 25µl of this mixture was added to 
each well of the Human Th17 for Autoimmunity & Inflammation RT² Profiler PCR 
Array (Qiagen, UK). Plate was sealed and centrifuged for 1 minute at 1000g to 
remove bubbles, before running qPCR on  Mx3000P (Stratagene, UK), as follows:  
1. Activation of HotStart DNA Taq polymerase (1 cycle, 10 minutes, 95ºC) 
2. Amplification: 40 cycles of (95ºC for 15 seconds, 60ºC for 1 minute) 
3. Automated dissociation curve 
 
Threshold was set at 0.13 for all samples and Ct values exported to Excel for analysis. 
Values were uploaded to the SABiosciences PCR Array Data Analysis Web Portal 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) for calculation of 
fold changes in gene expression (by ΔΔCt method) and clustergram generation. Gene 
expression was normalised to four of the five housekeeping genes provide in the 
array: HPRT1, RPL13A, GAPDH and ACTB. (β2-microglobulin was excluded as its 
expression was not consistent with that of the other housekeeping genes or between 
the two NK cell subsets.) Statistical significance of fold differences of ≥1.2 between 
gene expression in the CD56
dim
 CD27
-
 CD8
+
 CD57
+
 subset and the CD56
dim
 CD27
-
 
CD8
-
 CD57
-
 subset was determined by paired Wilcoxon signed rank test (performed 
using GraphPad Prism version 5). 
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2.8 Individual qRT-PCR Assays 
Reverse transcription was performed as described in section 2.6. Primers for human 
GAPDH, HPRT1, granzyme A, granzyme B, perforin, interferon-γ, Tbx21, RORC, 
IL12RB1, IL12RB2, CD127, IL23R, IL-23A, IL-17D, IL-27 and S1PR1 were 
purchased from Qiagen, UK. Primer cocktail was prepared by mixing primers for 6 or 
8 genes of interest with primers for GAPDH and HPRT1. PreAMP cocktail was 
prepared by mixing 12.5μl RT2 PreAMP PCR master mix (Qiagen, UK) per reaction 
with 7.5μl primer cocktail.  cDNA and no-RT controls (RNA which had not 
undergone reverse transcription) were preamplified as described in section 2.7, with 
the following modification: only 8 PCR cycles were performed. For qRT-PCR, 
1050µl RT
2
 SYBR Green Mastermix (Qiagen, UK) was mixed with 882µl 
RNase/DNase-free water and 84µl primer cocktail, then aliquoted into a 96-well PCR 
plate (24µl/well). 1µl/ well cDNA (in triplicate) or no-RT control (singlet) was added 
to the plate, which was then sealed, centrifuged and run on the Mx3000P as described 
in section 2.7, for 50 PCR cycles. Data was analysed using GraphPad Prism version 5 
and statistical significance determined by Wilcoxon signed rank test. 
2.9 K562 Killing Assays 
PBMC from six healthy female donors were stained with antibodies and sorted for 
CD56
dim
 CD27
-
 CD8
+
 CD57
+
 and CD56
dim
 CD27
-
 CD8
+
 CD57
-
 NK cells as described 
in chapter 2.4, with the following modifications: samples were incubated at room 
temperature during sorting and sorted into polypropylene FACS tubes containing 
200µl culture medium.  
1 x 10
7
 K562 cells were thawed from liquid nitrogen on day of experiment, washed 
and resuspended in 20ml culture medium and incubated at 37ºC, 5% CO2 for 2-4 
hours prior to assay.  
NK cells were diluted to a concentration of 60,000 cells/ml in culture medium and 
resuspended thoroughly by repeatedly running buffer down the sides of the tube, then 
vortexing. K562 cells were centrifuged, resuspended in 10ml culture medium and 
counted twice with trypan blue for exclusion of dead cells, then diluted to a 
concentration of 30,000 cells/ml. Experimental wells (100µl K562 + 100µl NK cells), 
K562 controls (100µl K562 + 100µl culture medium) and NK cell controls (100µl NK 
cells + 100µl culture medium) were set up in triplicate in a 96-well round-bottomed 
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tissue culture plate (total 1000 K562 and 2000 NK cells per well). Plates were 
centrifuged (250g, 5 minutes) in order to optimise cell contact, and then incubated for 
2 hours at 37°C, 5% CO2. TO-PRO-3 (Invitrogen, UK) was diluted 1in 100 in PBS to 
produce a working solution, of which 1µl was added per well immediately after 
incubation. Countbright counting beads (Invitrogen, UK) were vortexed thoroughly 
and 10µl was added to each well. Contents of each well were mixed thoroughly, 
transferred to FACS tubes and acquired immediately on the BD FACS Aria II. Data 
was analysed using FlowJo verion 7.5 and Microsoft Excel. K562, NK cell and bead 
populations were identified by forward and side scatter and apoptotic cells identified 
according to uptake of TO-PRO-3 dye, which only enters cells when cell surface 
membrane integrity is compromised. Cell death was calculated as follows: 
Expected number of viable cells = 3000 / (beads added/ beads acquired) 
Actual number of viable cells = total K562 events – number of TO-PRO-3+ K562 
Raw percentage cell death = 100 x (expected number of viable cells – actual number 
of viable cells) / expected number of viable cells 
Normalised percentage cell death = 100 x (mean experimental cell death – mean 
control cell death) / (100 – mean control cell death) 
2.10 Preparation and Staining of Cells from Line 7 mice 
Line 7 mice were scored twice weekly according to their degree of paralysis (see table 
2-i). Mice which had reached a clinical score of 2- 3 were selected for sacrifice. 
Mice were injected intraperitoneally with 250μl euthatal (Mirion, UK). Following 
removal of the spleen, mice were perfused with sterile PBS into the left ventricle 
whilst the heart was still beating, until all blood was removed from circulation. This 
ensured that leukocytes isolated from the CNS included only those that had crossed 
the BBB. (This part of the procedure requires a Home Office license and was 
therefore carried out by Dr. Karen Chu, Dr. Daniel Lowther, Dr. Deborah Chong or 
Marie-Laure Aknin.) Splenocytes were flushed out into medium using syringe and 
needle and transferred to 15ml centrifuge tube, then centrifuged (300g, 10 minutes) 
and resuspended in fresh medium. Cells were kept at room temperature until ready to 
use, then washed once with PBS. 
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Table 2-ii: Scoring of clinical disease in Line 7 mice 
Score Description 
0 No clinical signs 
1 Limp tail 
2 Loss of righting reflex or waddling gait 
2.5 Slight hind limb paralysis 
3 Paralysis of one hind limb 
4 Paralysis of both hind limbs 
5 Total limb paralysis 
6 Moribund 
 
Brain and spinal cord were dissected out and placed in 1ml Dulbecco’s modified 
Eagle medium (DMEM) + Glutamax (Invitrogen, UK) with 25μl 100mg/ml 
collagenase and 10μl 100mg/ml DNase (Sigma-Aldrich, UK). Tissue was chopped up 
using scissors and further disrupted by repeatedly taking up and releasing with 1ml 
syringe, then incubated at 37ºC, 5% CO2 for 2 hours.  CNS suspension was then 
passed through a 70μM cell strainer into petri dish. Remaining liquid was gently 
pushed through strainer using plunger from 1ml syringe. Filtered CNS was then 
transferred to 15ml tube and centrifuged (300g, 10mins) prior to careful aspiration of 
supernatant using a stripette. 30% Percoll (Sigma-Aldrich, UK) was made up in 
DMEM+glutamax and 70% Percoll was made up in PBS. Sample was resuspended in 
4ml 30% Percoll and overlayed onto 4ml 70% Percoll, with 3ml Hanks balanced 
saline solution (Sigma-Aldrich, UK) overlayed on top. Sample was centrifuged at 
400g for 30 minutes with no brake. Fatty layer from upper interface was removed 
using Pasteur pipette and discarded. Using a fresh Pasteur pipette, cell layer from 
lower interface was transferred to a fresh 15ml centrifuge tube then washed once with 
PBS. 
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Spleen and CNS samples were mixed with ACK buffer for erythrocyte lysis, 
centrifuged once (300g, 10 minutes) and washed once with PBS, then resuspended in 
1ml PBS (CNS) or 10ml PBS (spleen) before counting with trypan blue for exclusion 
of dead cells. Cells were incubated with 1:1000 diluted live/dead yellow viability dye 
(Invitrogen, UK) for 30 minutes at 4ºC, then washed with FACS buffer. Cells were 
then blocked with 1:1000 diluted α-CD16/32 (e-bioscience, UK) in FACS buffer for 
10 minutes at 4ºC, washed and resuspended in FACS buffer, then incubated with 
antibodies against surface antigens (see table 2-iv) for 30 minutes at 4ºC in V-
bottomed plates. Cells were washed twice with FACS buffer then fixed with 1% 
paraformaldehyde. Samples were stored at 4ºC and acquired on FACS Aria II within 
72 hours. Doublet exclusion was performed by gating lymphocyte population on 
forward scatter-width and live/dead yellow
+
 apoptotic cells were also excluded.  
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2.11 Buffers and Medium: 
 
FACS buffer: 
500ml sterile PBS (Invitrogen, UK) supplemented with 50ml fetal bovine serum 
(Biosera, UK). 
Culture medium: 
500ml RPMI 1640 + GlutaMax (Invitrogen, UK) supplemented with 50ml fetal 
bovine serum (Biosera, UK). 
ACK (erythrocyte lysis) buffer:  
8.29 g Ammonuim chloride NH4Cl (0.155 mM)  Sigma-Aldrich UK 
1 g Potassuim Bicarbonate KHCO3 (1 mM)   Sigma-Aldrich UK  
37.2 mg NA2EDTA (0.1 mM)    Sigma-Aldrich UK 
in 1 litre of ddH2O.  
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Figure 2-i: Gating strategy for enumeration of NK cell subsets. Lymphocytes were gated based on 
forward- and side scatter (A) and doublets were excluded by gating out cells with high forward scatter-
width (FSC-W) (B). NK cells were defined as CD56
+
 CD3
-
 cells within the singlet population (C). NK 
cells were then divided into four populations based on expression of CD56 and CD8 (D). These 
populations were subdivided according to expression of CD27 and CD57 (E and F). CD56
dim
 CD8
-
 and 
CD8
+
 NK cells were each divided into three subpopulations (E), whereas CD56
bright
 CD8
-
 and CD8
+
 
NK cells lacked CD57 expression and were therefore divided into two subpopulations (F). CD27
+
 
CD57
+
 NK cells were not present amongst any of the aforementioned populations. Gating is shown on 
PBMC from a healthy control and is representative of gating strategy for all controls, CIS and MS 
patients. 
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Figure 2-ii: Classification of NK cells into ten subsets. CD56
bright
 NK cells from peripheral blood of 
both healthy controls and patients did not express CD57 and therefore were classified into just four 
subsets: CD27
+
 CD8
-
, CD27
+
 CD8
+
, CD27
-
 CD8
-
 and CD27
-
 CD8
+
. CD8, CD27 and CD57 were all 
found on a subpopulation of CD56
dim
 NK cells, however CD27 and CD57 expression were mutually 
exclusive, therefore CD56
dim
 NK cells were divided into six subsets: CD27
+
 CD8
+
, CD27
+
 CD8
-
, 
CD57
+
 CD8
+
, CD57
+
 CD8
-
, CD27
-
 CD57
-
 CD8
+
 and CD27
-
 CD57
-
 CD8
-
. The frequencies of these ten 
subsets were compared in peripheral blood of healthy controls, CIS patients and MS patients 
(untreated, interferon-β-treated and Tysabri-treated). 
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Figure 2-iii: Sorted NK cell subsets have high purity. PBMC were stained with antibodies against 
CD3, CD56, CD8, CD27 and CD57. CD56
dim
 CD27
-
 CD8
+
 CD57
+
 and CD56
dim
 CD27
-
 CD8
-
 CD57
-
 
NK cell subsets were sorted using a FACS Aria II cell sorter for extraction of RNA and use in killing 
assays. A minimum of 2000 cells per subset were sorted into FACS buffer and reacquired on the FACS 
Aria to check purity before commencing cell sorting for assay. Plots are representative of 13 cell sorts 
performed using PBMC from healthy female donors, with a purity of ≥98%. 
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Table 2-iii: Antibodies for detection of human antigens 
Antigen Fluorochrome Clone Isotype Supplier Cat. 
Number 
CD3 APC HIT3a Mouse 
IgG1, κ  
BD 555342 
CD3 V500 UCHT1 Mouse 
IgG1, κ 
BD 561416 
CD8 PerCP-Cy5.5 SK1 Mouse 
IgG1, κ 
BD 341050 
CD27 APC-H7 M-T271 Mouse 
IgG1, κ 
BD 560222 
CD56 V450 B159 Mouse 
IgG1, κ 
BD 560360 
CD57 FITC NK-1 Mouse 
IgM, κ 
BD 555619 
CD57 Alexa Fluor 
647 
HCD57 Mouse 
IgM, κ 
Biolegend 322308 
CD95 PE DX2 Mouse 
IgG1, κ 
BD 555674 
CD127 PE hIL-7R-M21 Mouse 
IgG1, κ 
BD 557938 
IL12RB1 PE 69310 Mouse 
IgG1 
R&D FAB839P 
IL12RB2 PE 305719 Mouse 
IgG1 
R&D FAB1959P 
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NKG2A 
(CD159a) 
PE Z199 Mouse 
IgG2b 
BC IM3291U 
NKG2D 
(CD314) 
PE 1D11 Mouse 
IgG1, κ 
BD 557940 
NKp30 PE Z25 Mouse 
IgG1 
BC IM3709 
NKp44 Alexa Fluor 
647 
p44-8.1 Mouse 
IgG1, κ 
BD 558564 
NKp44 PE p44-8.1 Mouse 
IgG1, κ 
BD 558563 
NKp46 PE 9E2/NKp46 Mouse 
IgG1, κ 
BD 557991 
IL-17  PE eBio64DEC17 Mouse 
IgG1, κ 
e-bioscience 12-7179 
IL-22 PE 22URTI Mouse 
IgG1, κ 
e-bioscience 12-7229 
IFNγ PE 4S.B3 Mouse 
IgG1, κ 
e-bioscience 12-7319 
BC = Beckmann Coulter, BD = Becton Dickinson, R&D = R&D Systems. FITC = fluorescein 
isothyocyanate, PE= phycoerythrin, APC = allophycocyanin 
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Table 2-iv: Antibodies for detection of murine antigens 
Antigen Fluorochrome Clone Isotype Supplier Cat. 
Number 
CD3 FITC 145-2C11 Armenian 
hamster IgG1, κ 
Beckton 
Dickinson 
553062 
NKG2D APC CX5 Rat IgG1 e-bioscience 17-5882 
NKp46 eFluor 450 29A1.4 Rat IgG2a e-bioscience 48-3351 
 
Table 2-v: Excitation and detection wavelegths of fluorochromes and dead cell dyes measured on 
FACS Aria II 
Fluorochrome or 
Dye 
Excitation 
Wavelength (nm) 
Detection 
Wavelength (nm) 
Bandpass Filter 
Tolerance 
FITC 488 525 50 
PE 488 575  25 
PerCP-Cy5.5 488 710  50 
APC/ Alexa Fluor 
647 
633 670  14 
APC-H7 633 780 60 
V450/ efluor450 405 450  40 
V500 405 525 50 
TO-PRO-3 633 670 14 
Live/dead yellow 405 610 20 
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Table 2-vi: Primer list for Th17 for Autoimmunity & Inflammation RT² Profiler PCR Array 
Unigene Refseq Symbol Description 
Hs.508524 NM_014412 CACYBP Calcyclin binding protein 
Hs.72918 NM_002981 CCL1 Chemokine (C-C motif) ligand 1 
Hs.303649 NM_002982 CCL2 Chemokine (C-C motif) ligand 2 
Hs.75498 NM_004591 CCL20 Chemokine (C-C motif) ligand 20 
Hs.534347 NM_002990 CCL22 Chemokine (C-C motif) ligand 22 
Hs.251526 NM_006273 CCL7 Chemokine (C-C motif) ligand 7 
Hs.156445 NM_000734 CD247 CD247 molecule 
Hs.591629 NM_006139 CD28 CD28 molecule 
Hs.374990 NM_001773 CD34 CD34 molecule 
Hs.504048 NM_000732 CD3D CD3δ molecule (CD3-TCR complex) 
Hs.3003 NM_000733 CD3E CD3ε molecule (CD3-TCR complex) 
Hs.2259 NM_000073 CD3G CD3γ molecule (CD3-TCR complex) 
Hs.631659 NM_000616 CD4 CD4 molecule 
Hs.592244 NM_000074 CD40LG CD40 ligand 
Hs.85258 NM_001768 CD8A CD8α molecule 
Hs.517106 NM_005194 CEBPB 
CCAAT/enhancer binding protein (C/EBP), 
beta 
Hs.143929 NM_022570 CLEC7A C-type lectin domain family 7, member A 
Hs.1349 NM_000758 CSF2 Colony stimulating factor 2 (GM-CSF) 
Hs.2233 NM_000759 CSF3 Colony stimulating factor 3 (G-CSF) 
Hs.531668 NM_002996 CX3CL1 Chemokine (C-X3-C motif) ligand 1 
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Hs.789 NM_001511 CXCL1 Chemokine (C-X-C motif) ligand 1  
Hs.522891 NM_000609 CXCL12 Chemokine (C-X-C motif) ligand 12 
Hs.590921 NM_002089 CXCL2 Chemokine (C-X-C motif) ligand 2 
Hs.89714 NM_002994 CXCL5 Chemokine (C-X-C motif) ligand 5 
Hs.164021 NM_002993 CXCL6 Chemokine (C-X-C motif) ligand 6  
Hs.154210 NM_001400 S1PR1 Sphingosine-1-phosphate receptor 1 
Hs.247700 NM_014009 FOXP3 Forkhead box P3 
Hs.524134 NM_002051 GATA3 GATA binding protein 3 
Hs.643447 NM_000201 ICAM1 Intercellular adhesion molecule 1 
Hs.56247 NM_012092 ICOS Inducible T-cell co-stimulator 
Hs.856 NM_000619 IFNG Interferon, gamma 
Hs.193717 NM_000572 IL10 Interleukin 10 
Hs.674 NM_002187 IL12B Interleukin 12B (p40) 
Hs.567294 NM_005535 IL12RB1 Interleukin 12 receptor, beta 1 
Hs.479347 NM_001559 IL12RB2 Interleukin 12 receptor, beta 2 
Hs.845 NM_002188 IL13 Interleukin 13 
Hs.654378 NM_000585 IL15 Interleukin 15 
Hs.41724 NM_002190 IL17A Interleukin 17A 
Hs.278911 NM_013278 IL17C Interleukin 17C 
Hs.655142 NM_138284 IL17D Interleukin 17D 
Hs.272295 NM_052872 IL17F Interleukin 17F 
Hs.654970 NM_018725 IL17RB Interleukin 17 receptor B 
Hs.129959 NM_032732 IL17RC Interleukin 17 receptor C 
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Hs.150725 NM_017563 IL17RD Interleukin 17 receptor D 
Hs.390823 NM_153480 IL17RE Interleukin 17 receptor E 
Hs.83077 NM_001562 IL18 
Interleukin 18 (interferon-gamma-inducing 
factor) 
Hs.126256 NM_000576 IL1B Interleukin 1, beta 
Hs.89679 NM_000586 IL2 Interleukin 2 
Hs.567559 NM_021803 IL21 Interleukin 21 
Hs.287369 NM_020525 IL22 Interleukin 22 
Hs.98309 NM_016584 IL23A Interleukin 23, alpha subunit p19 
Hs.677426 NM_144701 IL23R Interleukin 23 receptor 
Hs.302036 NM_022789 IL25 Interleukin 25 
Hs.528111 NM_145659 IL27 Interleukin 27 
Hs.694 NM_000588 IL3 Interleukin 3  
Hs.73917 NM_000589 IL4 Interleukin 4 
Hs.2247 NM_000879 IL5 Interleukin 5  
Hs.654458 NM_000600 IL6 Interleukin 6 
Hs.709210 NM_000565 IL6R Interleukin 6 receptor 
Hs.591742 NM_002185 IL7R Interleukin 7 receptor 
Hs.624 NM_000584 IL8 Interleukin 8 
Hs.459265 NM_002201 ISG20 
Interferon stimulated exonuclease gene 
20kDa 
Hs.207538 NM_002227 JAK1 Janus kinase 1 
Hs.656213 NM_004972 JAK2 Janus kinase 2 
Hs.2936 NM_002427 MMP13 Matrix metallopeptidase 13 (collagenase 3) 
117 
 
Hs.375129 NM_002422 MMP3 
Matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
Hs.297413 NM_004994 MMP9 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
Hs.713650 NM_012340 NFATC2 
Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 
Hs.654408 NM_003998 NFKB1 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1 
Hs.256022 NM_005060 RORC RAR-related orphan receptor C (RORγ) 
Hs.50640 NM_003745 SOCS1 Suppressor of cytokine signaling 1 
Hs.527973 NM_003955 SOCS3 Suppressor of cytokine signaling 3 
Hs.463059 NM_003150 STAT3 
Signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
Hs.80642 NM_003151 STAT4 
Signal transducer and activator of 
transcription 4 
Hs.437058 NM_003152 STAT5A 
Signal transducer and activator of 
transcription 5A 
Hs.524518 NM_003153 STAT6 
Signal transducer and activator of 
transcription 6, interleukin-4 induced 
Hs.371720 NM_003177 SYK Spleen tyrosine kinase 
Hs.272409 NM_013351 TBX21 T-box 21 (T-bet) 
Hs.645227 NM_000660 TGFB1 Transforming growth factor, beta 1 
Hs.537126 NM_001039661 TIRAP 
Toll-interleukin 1 receptor (TIR) domain 
containing adaptor protein 
Hs.174312 NM_138554 TLR4 Toll-like receptor 4 
Hs.241570 NM_000594 TNF Tumor necrosis factor 
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Hs.591983 NM_004620 TRAF6 TNF receptor-associated factor 6 
Hs.388927 NM_003403 YY1 YY1 transcription factor 
Hs.534255 NM_004048 B2M Beta-2-microglobulin 
Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
Hs.728776 NM_012423 RPL13A Ribosomal protein L13a 
Hs.592355 NM_002046 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
Hs.520640 NM_001101 ACTB Actin, beta 
Table is adapted from version on SABiosciences website found at: 
http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-073A.html 
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Table 2-vii: Age and gender of healthy controls used for comparison of subset frequencies 
Healthy Control Number Age Gender 
HC1 37 F 
HC2 52 M 
HC3 52 M 
HC4 43 F 
HC5 25 F 
HC6 40 F 
HC7 46 M 
HC8 40 M 
HC9 31 F 
HC10 53 F 
HC11 29 F 
HC12 60 F 
HC13 37 F 
HC14 26 F 
HC15 29 F 
HC16 29 F 
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Table 2-viii: Age and gender of CIS patients 
Patient Number Age Gender 
CIS1 47 M 
CIS2 50 F 
CIS3 48 M 
CIS4 38 M 
CIS5 41 F 
CIS6 49 F 
CIS7 34 F 
CIS8 29 F 
CIS9 32 F 
CIS10 36 F 
CIS11 38 F 
CIS12 34 F 
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Table 2-ix: Age, gender and disease status of untreated MS patients 
Patient Number Age Gender Relapse or 
Remision 
MSU1 54 F Relapse 
MSU2 45 F Relapse 
MSU3 35 F Remission 
MSU4 29 F Remission 
MSU5 63 F Remission 
MSU6 37 M Remission 
MSU7 53 F Remission 
MSU8 40 M Remission 
MSU9 44 F Remission 
MSU10 52 M Remission 
MSU11 47 F Remission 
MSU12 55 F Remission 
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Table 2-x: Age, gender and disease status of patients on interferon-β therapy 
Patient Number Age Gender Relapse or 
Remision 
MSI1 41 F Relapse 
MSI2 36 M Relapse 
MSI3 47 F Relapse 
MSI4 39 F Relapse 
MSI5 55 F Remission 
MSI6 43 F Remission 
MSI7 26 F Remission 
MSI8 37 F Remission 
MSI9 57 F Remission 
MSI10 37 M Remission 
MSI11 48 F Remission 
MSI12 40 M Remission 
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Table 2-xi: Age, gender and disease status of Tysabri-treated patients 
Patient Number Age Gender Relapse or 
Remission 
MST1 30 F Remission 
MST2 35 F Remission 
MST3 51 F Remission 
MST4 34 M Remission 
MST5 50 F Remission 
MST6 24 M Remission 
MST7 46 F Remission 
MST8 34 F Remission 
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Table 2-xii: Summary of age and gender of patient and control groups 
Patient or 
Control Group 
Mean Age Age Range Number of 
Males 
Number of 
Females 
Healthy 
controls 
39.3 25 - 60 4 12 
CIS 39.7 29 - 50 3 9 
Untreated 
RRMS 
46.2 29 - 63 3 9 
IFNβ-treated 
RRMS 
42.2 26 - 57 3 9 
Tysabri-treated 
RRMS 
38.0 24 - 51 2 6 
Patient and control groups exhibited no significant difference in the mean or variance in age 
(determined by one-way ANOVA and Bartlett’s test for equal variance). All groups had a male: female 
ratio of 1:3. 
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3. RRMS PATIENTS EXHIBIT DIFFERENCES IN 
FREQUENCIES OF SPECIFIC NK CELL SUBSETS  
Given the contradictory findings regarding the role of NK cells in MS and its animal 
models, I hypothesised that the overall influence of NK cells might be determined by 
relative frequencies of NK cell subsets with different functions. Several studies have 
already alluded to involvement of particular types of NK cell in downregulating 
inflammatory activity during MS. These include the CD56
bright
 subset, which expands 
during pregnancy and in response to IFNβ and daclizumab therapies and CD95+ NK 
cells which are reported to have a higher frequency in the blood of MS patients in 
remission than either patients in relapse or healthy controls (Takahashi et al. 2001, 
Bielekova et al. 2006, Saraste et al. 2007, Airas et al. 2008, Vandenbark et al. 2009, 
Martín-Rodríguez et al. 2010, Wynn et al. 2010, Martín-Rodríguez et al. 2011). 
Killing of activated T cells has been proposed as a mechanism by which CD56
bright
 
NK cells regulate autoimmunity (Bielekova et al. 2006, Jiang et al. 2011), though 
they may also suppress disease by other mechanisms such as release of anti-
inflammatory cytokines. NK cells from patients with high expression of CD95 are 
reported to specifically inhibit IFNγ production but not proliferation of MBP-specific 
T cells, though it is unclear whether this is by a direct mechanism or via effects on 
APCs (Takahashi et al. 2004). Though these two subsets appear to be capable of 
suppressing relapses amongst MS patients, there is no evidence that MS is related to a 
deficiency in these NK cell populations. It is expansion of these subsets to levels 
higher than those typical of healthy controls that has a protective role during MS 
(Takahashi et al. 2001, Vandenbark et al. 2009, Martín-Rodríguez et al. 2011). 
One subset of NK cells in which MS patients may have a deficiency is the CD8
+
 
subset. This subset has been reported to have a decreased frequency in both RRMS 
patients and patients with clinically isolated syndrome (CIS) (De Jager et al. 2008). 
However, an earlier study suggested that it was CD8
-
 NK cells that were decreased in 
frequency in untreated MS patients compared to controls (Munschauer et al. 1995). 
No-one has so far performed a comprehensive investigation of NK cell subsets in MS. 
Therefore my aim was to gain a better understanding of changes in NK cell subset 
frequencies in MS patients compared to healthy controls using a combination of 
surface markers (as opposed to previous studies which have identified subsets using 
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one marker at a time). In addition to comparing the frequencies of NK cell subsets in 
peripheral blood of RRMS patients to that of healthy controls, I also studied subset 
frequencies in CIS patients, individuals who have had a single demyelinating episode 
and are likely to develop MS in future, in order to give an insight as to whether any 
imbalance in subset frequencies was present at an early stage of disease. Given that 
IFNβ has previously been reported to have effects on the frequency of CD56bright NK 
cells, I was keen to find out more about the effect of this treatment on NK cell subsets. 
I also investigated whether Tysabri (natalizumab), one of the most successful 
treatments for highly active MS, affected the frequency of NK cell subsets; its 
function is normally evaluated only in terms of T cell ingress across the blood brain 
barrier and there has been relatively little consideration of effects on peripheral innate 
or adaptive immune phenotype. 
The first step was to select suitable markers to include in the panel. In doing this, I 
sought to include all the most relevant markers, whilst balancing this with the need for 
adequate resolution of positive and negative (or bright and dim) populations, which 
may be compromised by spectral overlap when too many markers are used together.  
The most widely-studied functional distinction amongst NK cells is that between 
CD56
dim
 and CD56
bright
 subsets, so this was a natural starting point for my 
classification, especially given the association of CD56
bright
 NK cells with 
amelioration of MS in response to disease-modifying therapies (Wynn et al. 2010, 
Martín-Rodríguez et al. 2011). The contrasting data on changes in CD8
+
 and CD8
-
 
NK cell frequencies in MS patients made this marker my next choice for inclusion in 
the panel. The differences reported in CD95 expression in Japanese MS patients along 
with its functional association with IL-5 production and inhibition of T cell IFNγ 
production (Takahashi et al. 2001, Takahashi et al. 2004) led me also to consider 
including this marker. Next, I considered markers which have been associated with 
distinct functional properties in healthy subjects and chose CD27 and CD57 as 
markers of interest. A reduction in the percentage of CD57
+
 NK cells has previously 
been observed in MS patients treated with IFNβ, however it was not clear how these 
frequencies compared to that of healthy controls (Perini et al. 2000). The association 
of CD57 with increased maturity and cytotoxic function (Chattopadhyay et al. 2009, 
Björkström et al. 2010, Lopez-Vergѐs et al. 2010) made this marker an ideal choice. 
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Conversely, CD27 is associated with lower cytotoxic function and enhanced 
responsiveness to cytokines, properties that have also been associated with the 
CD56
bright
 subset (Silva et al. 2008, Vossen et al. 2008). Unlike CD56 and most of the 
other markers used to distinguish human NK cell subsets, CD27 expression also 
distinguishes NK cell subsets in mice (Hayakawa and Smyth 2006) and might 
therefore provide an opportunity to link differences observed in MS patients to 
functional roles in disease models.  
Staining for CD95, with two different phycoerythrin-conjugated antibody clones 
showed that there were not distinct positive and negative populations amongst 
peripheral blood NK cells, although there were amongst peripheral blood T cells. This 
rendered it unsuitable for inclusion in my classification. Indeed, one might suggest 
that close scrutiny of the FACS plots in the paper by Takahashi et al. (2001) does not 
allow delineation of distinct positive and negative populations, though the data have 
been interpreted and cited with this interpretation. Therefore I proceeded in designing 
a panel with the other four markers (CD56, CD8, CD27 and CD57), with CD3 for 
exclusion of iNKT and NK-like T cells.  
3.1 Expression and Co-expression of CD8, CD27 and CD57 on 
CD56
dim 
and CD56
bright
 NK Cells 
Various combinations of fluorochromes were tested in order to combine the markers 
in such a way that spectral overlap did not prevent identification of the positive and 
negative populations for CD8 and CD27, which were expressed only at low levels on 
NK cells in comparison to T cells. Once a suitable panel had been chosen, it was 
tested on healthy controls in order to evaluate which markers were or were not 
expressed together and to devise a classification system. Expression of each marker 
(CD8, CD27 and CD57) on CD56
bright
 and CD56
dim
 subsets and their frequency of co-
expression with the other markers is summarised in figure 3-i. CD8 was typically 
expressed on 30-40% of NK cells, with a slightly higher frequency in the CD56
dim
 
compared to the CD56
bright
 population. There did not appear to be any relationship 
between expression of CD8 and that of either CD27 or CD57. CD27 was expressed on 
around 10-20% of NK cells and was more frequent amongst CD56
bright
 NK cells. 
Meanwhile, CD57 was expressed on around 50% of CD56
dim
 NK cells and was absent 
from the CD56
bright
 population. Expression of CD27 and CD57 was mutually 
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exclusive. Based on this information, a gating strategy was devised which divided NK 
cells into ten subsets as shown in chapter 2, figures 2-i and 2-ii. 
 
 
Figure 3-i: Co-expression pattern of NK cell surface markers. Multiparameter flow cytometry was 
performed on PBMC from ten healthy donors using antibodies directed against CD3, CD56, CD8, 
CD27 and CD57. Lymphocytes were identified based on forward and side scatter and NK cells were 
defined as CD56
+
 CD3
-
 lymphocytes. The mean percentage of cells expressing CD8, CD27 or CD57 
(columns) was calculated for all NK cells, for CD56
dim
 and CD56
bright
 subsets and for NK cells 
expressing each of the other markers (rows). CD57 was expressed only on CD56
dim
 NK cells and was 
never expressed in combination with CD27.  
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3.2 Confirmation of Differences in Frequency of NK Cell 
Subsets in RRMS Patients and the Effects of IFNβ 
Treatment 
Before analysing the multiparameter data, I wanted to find out if there was any 
difference in the overall frequency of NK cells in MS or CIS patients compared to 
healthy controls.  
No significant difference was observed in the frequency of NK cells in MS patients 
versus controls and neither IFNβ nor Tysabri treatment had a significant effect on NK 
cell frequency (see figure 3-ii). 
 
Figure 3-ii: Total NK cell frequency does not differ between MS patients and controls and is not 
significantly influenced by interferon-β or Tysabri therapy. PBMC were isolated from 12 untreated, 
12 IFNβ-treated and 8 Tysabri-treated MS patients (with mean ages of 46, 42 and 38 respectively), 12 
CIS patients (mean age 40) and 16 healthy controls (mean age 39). All groups were gender matched 
with a 3:1 female: male ratio. Lymphocytes were gated according to forward and side scatter and 
doublets excluded. The frequency of NK cells (CD56
+
 CD3
-
) within the lymphocyte gate (with mean 
and SEM) is shown (A) in RRMS and CIS patients compared to healthy controls and (B) in IFNβ- and 
Tysabri-treated patients compared to untreated RRMS patients. Kruskal Wallis tests indicated no 
significant difference between MS patients, CIS patients and controls (A) or between treated and 
untreated MS patients (B). 
 
Next, I wanted to see if I could replicate the data of De Jager et al., who reported 
fewer CD8
+
 NK cells in blood of MS patients and to see if IFNβ or Tysabri treatment 
affected the frequency of CD8
+
 NK cells.  
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I did not find any significant difference in the frequency of CD8
+
 NK cells within the 
whole lymphocyte population (figure 3-iii A), however, amongst the NK cell 
population, there was a significantly higher proportion of CD8
+
 cells in peripheral 
blood of both CIS and RRMS patients compared to healthy controls (figure 3-iii B). 
This difference was reversed in patients treated with either IFNβ or Tysabri.    
 
Figure 3-iii: Untreated RRMS and CIS patients have a higher proportion of CD8
+
 compared to 
CD8
-
 NK cells. PBMC were isolated from 12 untreated, 12 IFNβ-treated and 8 Tysabri-treated MS 
patients (with mean ages of 46, 42 and 38 respectively), 12 CIS patients (mean age 40) and 16 healthy 
controls (mean age 39). All groups were gender matched with a 3:1 female: male ratio. Lymphocytes 
were gated according to forward and side scatter with doublet exclusion and NK cells were identified 
as CD3
-
 CD56
+
. The frequency of CD8
+
 NK cells (with mean and SEM) is shown (A) as a percentage 
of all lymphocytes and (B) as a percentage of NK cells. Significant differences were determined by 
Kruskal Wallis test followed by Dunn’s multiple comparison test of RRMS and CIS versus healthy 
(left) or IFNβ and Tysabri versus no treatment (right). Significant differences are indicated by 
*(p<0.05) or ** (p<0.01).  
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I then compared the overall frequencies of CD56
bright
 and CD56
dim
 NK cells amongst 
peripheral blood lymphocytes of untreated and treated MS patients and controls. 
There were no disease- or treatment-related differences in the overall frequency of 
CD56
dim
 NK cells (figure 3-iv A), however there were differences in the frequency of 
CD56
bright 
NK cells (figure 3-iv B). Untreated RRMS patients had a significantly 
lower frequency of CD56
bright 
NK cells than healthy controls. CIS patients had a 
frequency between that of healthy controls and MS patients. 
Consistent with previous studies, the frequency of CD56
bright
 NK cells was higher in 
IFNβ-treated patients. However, there was a high level of variability amongst IFNβ-
treated patients, with some having similar frequencies to untreated MS patients, while 
others had frequencies considerably higher than healthy controls. Therefore, I decided 
to compare the frequency of this subset in IFNβ-treated patients who were in relapse 
at the time the sample was taken to those who were in remission. Though the 
difference in frequency of CD56
bright
 NK cells amongst all lymphocytes did not reach 
statistical significance, the percentage of NK cells which were CD56
bright
 was 
significantly lower in patients who were in relapse compared to those in remission 
(figure 3-iv C). 
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Figure 3-iv: Untreated RRMS patients have a reduced frequency of CD56
bright
 NK cells which is 
reversed by IFNβ treatment. (A) and (B): PBMC were isolated from 12 untreated, 12 IFNβ-treated 
and 8 Tysabri-treated MS patients (with mean ages of 46, 42 and 38 respectively), 12 CIS patients 
(mean age 40) and 16 healthy controls (mean age 39) and analysed by flow cytometry. All groups were 
gender matched with a 3:1 female: male ratio. Lymphocytes were gated according to forward and side 
scatter and doublets excluded. The frequency of (A) CD56
dim
 NK cells and (B) CD56
bright
 NK cells in 
MS and CIS patients versus controls (left) and in untreated versus IFNβ or Tysabri-treated pateints 
(right) is indicated as a percentage of lymphocytes (with mean and SEM). Significant differences were 
determined by Kruskal Wallis and Dunn’s multiple comparison tests. (C) IFNβ-related expansion of 
CD56
bright
 NK cells is restricted to patients in remission. Blood samples were taken from age and 
gender-matched IFNβ-treated patients, four of whom were in relapse and eight of whom were in 
remission. Frequency of CD56
bright
 NK cells was compared by Mann-Whitney U test. Significant 
differences ((A), (B) and (C)) are indicated by * (p <0.05), ** (p<0.01) or *** (p<0.001). 
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3.3 Multiparameter Analysis Reveals Differences in NK Cell 
Subset Frequencies that are not Restricted to the CD56
bright
 
Population 
I then went on to analyse the frequencies of the ten subsets classified according to 
expression of CD56, CD8, CD27 and CD57. The CD56
bright 
population was divided 
into four subsets: CD8
-
 CD27
-
, CD8
- 
CD27
+
, CD8
+
 CD27
-
 and CD8
+
 CD27
+
. Three of 
these subsets had a significantly lower frequency in MS patients compared to controls 
and the other subset (CD8
+
 CD27
+
) had a low frequency in both (figure 3-v A). In 
both CIS and RRMS patients, the CD56
bright
 CD8
-
 CD27
-
 population was 
approximately half the size of that in healthy controls. This subset was the only subset 
that was significantly increased in IFNβ-treated patients (figure 3-v B). However, all 
four CD56
bright
 subsets had significantly higher frequency in IFNβ-treated patients 
who were in remission compared to those who were in relapse (figure 3-v C). 
The CD56
dim
 subset was divided into six subsets, according to expression of CD8, 
CD27 and CD57 as described in chapter 2 (see figure 2-ii). The CD56
dim
 CD8
+
 CD27
-
 
CD57
+
 subset constituted a significantly higher proportion of NK cells in MS patients 
compared to healthy controls, with an intermediate frequency in CIS patients (figure 
3-vi). The CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset had a slightly lower frequency in MS 
patients than controls. The Kruskall-Wallis test indicated a significant difference for 
this subset, however the post-test did not identify a difference between either patient 
group and controls once corrected for multiple comparisons. This indicates that there 
is likely to be some difference, but a larger sample size is needed to elucidate whether 
this subset is reduced in frequency in MS patients, CIS patients or both. 
This subset is however significantly increased in IFNβ-treated compared to untreated 
MS patients (figure 3-vii). Conversely, IFNβ significantly decreased the frequency of 
CD56
dim
 CD8
+
 CD57
+
, CD8
+
 CD27
+ 
and CD8
-
 CD27
+
 NK cell subsets. Tysabri-
treated patients also had a significantly lower frequency of the CD56
dim
 CD8
+
 CD57
+
 
subset. Other subsets were not significantly altered in Tysabri-treated individuals, but 
this may have been due to the relatively small sample size. Unlike CD56
bright
 NK 
cells, none of the CD56
dim
 subsets had significantly different frequencies in IFNβ-
treated patients in relapse compared to those in remission (figure 3-viii).  
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Figure 3-v: CD56
bright
 subset frequencies are altered in MS patients. PBMC were isolated from 12 
untreated, 12 IFNβ-treated and 8 Tysabri-treated MS patients (with mean ages of 46, 42 and 38 
respectively), 12 CIS patients (mean age 40) and 16 healthy controls (mean age 39). All groups were 
gender matched with a 3:1 female: male ratio. CD56
bright
 NK cells were classified into four subsets 
(CD8
-
 CD27
+
, CD8
-
 CD27
-
, CD8
+
 CD27
+
 and CD8
+
 CD27
-
) and flow cytometry was performed to 
compare frequencies of these subsets in peripheral blood.  Mean and SEM were plotted and significant 
differences in the frequency of each subset in (A) RRMS and CIS patients compared to healthy controls 
and (B) IFN-β and Tysabri-treated compared to untreated RRMS patients, were determined by 
Kruskal-Wallis test followed by Dunn’s multiple comparison test. (C) Significant differences between 
age and gender-matched IFNβ-treated patients in relapse (n=4) and those in remission (n=8) were 
identified by Mann-Whitney U test. Significant differences are denoted as: * p<0.05 or ** p<0.01. 
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Figure 3-vi: MS patients have a higher frequency of CD56
dim
 CD8
+
 CD27
-
 CD57
+
 NK cells. PBMC 
were isolated from twelve untreated RRMS patients with a mean age of 46, twelve CIS patients with a 
mean age of 40 and sixteen healthy controls with a mean age of 39 and analysed by flow cytometry. All 
groups were gender matched with a 3:1 female: male ratio. CD56
dim
 NK cells were classified into six 
subsets based on expression of CD8, CD27 and CD57, as described in chapter 2.  Frequency of each of 
these subsets in patients and controls is shown with mean and SEM. Statistical significance was 
determined by Kruskal Wallis test followed by Dunn’s multiple comparison test. ** indicates a 
statistically significant difference (p<0.01) compared to healthy controls. Kruskal Wallis test also 
indicated a significant difference (p<0.05) in the frequency of the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset, 
but this was not confirmed by Dunn’s multiple comparison test.  
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Figure 3-vii: Interferon-β alters frequencies of several CD56dim NK cell subsets. PBMC were 
isolated from 12 untreated RRMS patients with a mean age of 46, 12 IFNβ-treated patients with a mean 
age of 42 and 8 Tysabri-treated patients with a mean age of 38 and analysed by flow cytometry. All 
groups were gender matched with a 3:1 female: male ratio. CD56
dim
 NK cells were divided into six 
subsets based on expression of CD8, CD27 and CD57, as described in chapter 2.  Frequency of each of 
these subsets in untreated and IFNβ- or Tysabri-treated patients is shown with mean and SEM. 
Statistically significant differences were determined by Kruskal Wallis test followed by Dunn’s 
multiple comparison test and are indicated by * (p<0.05), ** (p<0.01) or *** (p<0.001). 
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Figure 3-viii: Frequencies of CD56
dim
 subsets are not significantly different in relapse compared 
to remission. PBMC from interferon-β-treated patients were incubated with antibodies against CD3, 
CD56, CD8, CD27 and CD57 and analysed by flow cytometry. CD56
dim
 NK cells were divided into six 
subsets based on expression of CD8, CD27 and CD57, as described in chapter 2. Frequency of these 
subsets (mean and SEM) is shown in age and gender-matched IFNβ-treated patients experiencing 
disease exacerbation (relapse) (n=4) and those in remission (n=8). Mann-Whitney U test detected no 
significant difference in frequency of any of the six subsets. 
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3.4 Subset Frequencies in Healthy Adults do not Differ 
Significantly in Relation to Age or Gender 
Age-related changes in the frequency of NK cells and of particular NK cell subsets 
have been reported previously in peripheral blood of healthy donors. Both the 
absolute number and percentage of NK cells in peripheral blood increase with age 
(Borrego et al. 1999, Le Garff-Tavernier et al. 2010). The proportion of NK cell 
subsets also appears to change over time, with an accumulation of NK cell 
populations that are thought to be more developmentally mature in elderly subjects. 
For instance, the ratio of CD56
dim
 to CD56
bright
 NK cells is reported to increase with 
age, due to a decline in absolute numbers of CD56
bright
 NK cells (Chidrawar et al. 
2006, Le Garff-Tavernier et al. 2010) and an increase in absolute frequency of the 
CD56
dim
 subset (Borrego et al. 1999). A negative correlation between CD56
bright
 NK 
cell frequency and age has also been demonstrated in MS patients (Martín-Rodríguez 
et al. 2010). Older individuals also have fewer NK cells expressing CD94 and 
NKG2A and more expressing KIR (Lutz et al. 2005). CD57, which has also been 
associated with increased maturity of NK cells, was initially found to increase 
significantly with age amongst T cells but not NK cells (Borrego et al. 1999), 
however a subsequent study suggested that NK cells also contained a higher 
proportion of CD57
+
 cells in older subjects (Le Garff-Tavernier et al. 2010). These 
associations were typically based on comparisons of elderly subjects (60+ or 80+) 
with adults aged 18-60, and do not demonstrate age-related differences amongst the 
under 60s (Borrego et al. 1999, Chidrawar et al. 2006, Le Garff-Tavernier et al. 
2010).  
Given these previous associations of subset frequencies with age and the inferred 
relationship with developmental maturity, I was curious to know whether my subsets 
of interest were altered across the age range that was included in my study and 
whether any slight differences in the age distribution of patient groups were likely to 
affect my results. Though there did appear to be a slight decrease in CD56
bright 
NK cell 
frequency with age in healthy subjects, this was not significant over the age range of 
24-60 that was examined (figure 3-ix B).There was also no change in the overall 
frequency of NK cells in the lymphocyte population and no change in either the 
CD56
dim
 CD8
+
 CD57
+
 subset or the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset. 
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Figure 3-ix: No significant gender- or age-related differences in the frequency of NK cells or NK 
cell subsets were detected. Overall NK cell frequency and frequency of CD56
bright
, CD56
dim
 CD8
-
 
CD27
-
 CD57
-
 and CD56
dim
 CD8
+
 CD27
-
 CD57
+
 NK cell subsets in peripheral blood lymphocytes was 
compared (A) in male versus female age-matched healthy controls (n=8) and (B) in healthy individuals 
of different ages (age 24-60, n=16). The relationship between age and frequency of CD56
bright
 NK cells 
was tested by linear regression, but the trend was not statistically significant (R
2
 = 0.1586, 95% CI of 
slope = -0.6025 to 0.08324, p = 0.1266). 
 
 
(A) (B) 
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Given the higher incidence of MS amongst females compared to males, I also wanted 
to know if there was any difference between males and females in the frequency of 
these subsets, which might potentially affect susceptibility to MS. However, no 
significant differences were observed between male and female healthy controls 
(figure 3-ix A). 
3.5 Discussion 
Though I did not observe differences in the overall frequency of NK cells in 
peripheral blood of MS patients in relation to either disease or therapy, a number of 
differences were observed in frequencies of particular subsets of NK cells, consistent 
with the hypothesis that an imbalance in the proportions of regulatory versus pro-
inflammatory NK cell subsets might contribute to MS pathogenesis and that changes 
in this balance may be an important mechanism of action of MS therapies such as 
Tysabri and IFNβ, or biomarkers of their efficacy. 
First, I have confirmed the observation that CD56
bright
 NK cells are expanded in IFNβ-
treated patients (Saraste et al. 2007, Vandenbark et al. 2009, Martín-Rodríguez et al. 
2010, Martín-Rodríguez et al. 2011) and extended this to show that this expansion of 
CD56
bright
 NK cells is only observed amongst patients who are in remission. I also 
noticed that those IFNβ-treated patients with stable MS (who had not had any relapses 
in the last year) had a particularly high frequency of CD56
bright
 NK cells, however the 
number of patients was not sufficient to perform a gender-matched statistical 
comparison. This is consistent with a previous report that CD56
bright
 NK cells are 
preferentially expanded in patients who show clinical responses to IFNβ therapy 
(Martín-Rodríguez et al. 2011). Contrary to previous reports, which implied that 
untreated MS patients had a similar frequency of CD56
bright
 NK cells to healthy 
controls (Vandenbark et al. 2009, Lünemann et al. 2011, Martín-Rodríguez et al. 
2011), I found that there was a statistically significant decrease in the frequency of the 
CD56
bright
 subset both as a percentage of NK cells and as a percentage of lymphocytes 
in untreated RRMS patients. A decreased ratio of CD56
bright
: CD56
dim
 NK cells was 
also observed in CIS patients, suggesting that changes in subset frequencies occur 
early in disease. Therefore, it is possible that alterations in NK cell subset frequencies 
might have a role in initiation of disease, though we do not have direct evidence of 
this. It would be interesting to follow up these CIS patients over time and see whether 
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there is any relationship between NK cell subset frequencies at this early stage of 
disease and how rapidly they progress to MS, if at all. 
In contrast to De Jager et al., I did not find any significant decrease in the percentage 
of CD8
+
 NK cells in the peripheral blood lymphocyte population of either CIS or 
RRMS patients compared to healthy controls. Although my sample size was smaller, 
the discrepancy between the studies is not likely to be due to lack of statistical power, 
since the proportion of NK cells that expressed CD8 in my study was in fact higher in 
both CIS and MS patients than in controls. I also observed a reduction in the 
frequency of NK cells expressing CD8 in both IFNβ- and Tysabri-treated patients. 
However, the aim of my study was to go beyond simply confirming or refuting prior 
observations regarding the frequency of single-marker-defined NK cell subsets such 
as CD56
bright
 or CD8
+
. After elucidating the relationship in expression of key NK cell 
markers CD8, CD27 and CD57, I devised a panel that enabled me to dissect NK cells 
into ten different subsets, and compared the frequency of these ten subsets in 
untreated MS and CIS patients to that of healthy controls as well as patients on 
therapy. When the CD56
bright
 population was subdivided into four subsets based on 
expression of CD8 and CD27, three of these subsets were found to constitute a 
significantly smaller proportion of NK cells in RRMS patients compared to healthy 
controls. The two CD56
bright
 CD8
-
 subsets both had a mean frequency in MS patients 
of approximately half that of healthy controls and the CD8
-
 CD27
-
 subset also had a 
significantly lower frequency in CIS patients. This subset is particularly interesting, 
since it was also substantially and significantly expanded in IFNβ-treated patients. 
Though treatment-related differences in frequency of the other CD56
bright
 subsets did 
not reach statistical significance, the trend across all CD56
bright
 subpopulations was 
broadly similar and all four were significantly higher in IFNβ-treated patients who 
were in remission compared to those in relapse. Therefore, all these subsets might 
play a role in regulating disease activity during IFNβ treatment and possibly also 
protect against development of MS.  
The overall percentage of CD56
dim
 NK cells within the lymphocyte population was 
not significantly different in MS patients compared to controls and was not altered in 
relation to treatment. However, when the CD56
dim
 subset was subdivided according to 
expression of CD8, CD27 and CD57, some differences were observed. The most 
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interesting subset was the CD56
dim
 CD8
+
 CD27
-
 CD57
+
 subset, which represented a 
significantly higher proportion of NK cells in untreated RRMS patients than in 
healthy controls. The frequency of this subset was also significantly lower in both 
IFNβ- and Tysabri-treated patients. This suggests that therapies for MS may not only 
boost numbers of immunoregulatory CD56
bright
 NK cells, but also reduce the 
frequency of NK cell subsets that are associated with inflammation. Naturally, this 
data cannot confirm whether or not this subset is actively contributing to pathogenesis 
or whether its expansion in MS patients is an inconsequential by-product of 
inflammation. However, it suggests that the function of this particular subset warrants 
further investigation. Since CD57 has been associated with increased cytotoxic 
function (Chattopadhyay et al. 2009, Lopez-Vergѐs et al. 2010) and CD8 with 
resistance to activation-induced cell death (Addison et al. 2005), one might 
hypothesise that the CD56
dim
 CD8
+
 CD57
+
 subset directly participates in killing of 
neurons and oligodendrocytes in the CNS and/or contributes to inflammation by 
killing of Tregs. 
IFNβ treatment has striking effects on the proportions of NK cells subsets. IFNβ-
treated patients have a significantly lower percentage not only of CD56
dim
 CD8
+
 
CD57
+
 NK cells, but also of CD56
dim
 CD8
+
 CD27
+
 and CD8
-
 CD27
+
 NK cells. 
Meanwhile, the CD56
dim
 subset lacking all three markers (CD8
-
 CD27
-
 CD57
-
) has a 
significantly higher frequency in IFNβ-treated patients. The latter subset had a slightly 
lower frequency in untreated patients compared to healthy controls, suggesting that its 
frequency is regulated in the opposite manner to the CD8
+
 CD57
+
 subset and I 
hypothesised that this subset might have functional characteristics more similar to that 
of the CD56
bright
 subset and also play a role in suppressing inflammation. However, it 
is not clear if these changes in NK cell subset frequencies are a primary effect of IFNβ 
treatment that may be responsible for some of the changes observed in other leukocyte 
populations, or whether direct effects of IFNβ on other cell populations lead to 
secondary effects on NK cells. Therefore it would be interesting to study patients 
longitudinally from the point at which they commence IFNβ treatment, in order to 
determine whether changes in the phenotype and frequency of NK cells and other 
leukocytes, including T cells and APCs, occur in a particular order. 
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Analysis of differences between untreated and treated patients is difficult since 
patients with more active MS are more likely to be given therapy, therefore the IFNβ-
treated group contained a higher number of subjects who were in relapse than the 
untreated group. However, the differences observed between IFNβ-treated and 
untreated patients do not appear to be related to disease activity, since IFNβ-treated 
patients in relapse had subset frequencies that were either closer to that of healthy 
controls (as was the case for CD56
bright
 subsets) or the same as IFNβ-treated patients 
in remission (CD56
dim
 subsets). Therefore, if anything, the relative lack of untreated 
patients in relapse may have made the effects of therapy appear less substantial than 
they would if patients were studied longitudinally. The difficulty in obtaining samples 
from untreated patients who were in relapse may also have hindered identification of 
differences between untreated MS patients and healthy controls. For instance, as 
mentioned, one of the CD56
dim
 subsets appeared to be reduced in MS patients but this 
did not quite reach statistical significance in the post-hoc test. Ideally, the analysis 
would be extended to increase overall sample size as well as to include more patients 
in relapse and with highly active disease. This would also allow comparison of subset 
frequencies between untreated patients with active versus benign MS and relapse 
versus remission. It would be interesting to see if the same differences between 
relapse and remission observed in IFNβ-treated patients also apply to untreated 
patients.  
It would also be interesting to investigate the mechanism by which IFNβ alters NK 
cell subset frequency. Expansion of the CD56
bright
 subset, for instance, might be 
related to IL-2. IFNβ downregualtes IL2Rα expression on lymphocytes both in vitro 
and in vivo (Noronha et al. 1993, Leppert et al. 1996, Genç et al. 1997). Blocking of 
IL-2Rα by daclizumab has been shown to expand the CD56bright subset by reducing 
binding of IL-2 to receptors on the T cells that produced it, leaving more IL-2 
available for binding to IL-2 receptors on CD56
bright
 NK cells (Bielekova et al. 2006, 
Martin et al. 2010). Therefore IL2Rα downregulation by IFNβ might have a similar 
effect. Expansion of the CD56
bright
 subset in daclizumab-treated patients is reportedly 
much more robust than in IFNβ-treated patients (Bielekova et al. 2006, Wynn et al. 
2010), which might reflect more efficient blocking of IL-2/ IL-2Rα interactions than 
is mediated by IFNβ.  
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Tysabri treatment also signficantly reduced the frequency of CD56
dim
 CD8
+
 CD57
+
 
NK cells and may have effects on other subsets which were not statistically significant 
in this small sample. An increase in the total frequency of NK cells has previously 
been observed in peripheral blood of Tysabri-treated patients (Putzki et al. 2010). 
Alterations seen in the blood of Tysabri patients are more difficult to interpret than 
changes related to IFNβ therapy. Tysabri’s main mechanism of action is thought to be 
preventing lymphocytes from entering the CNS by blocking and downregulating the 
VLA-4 integrin required for adhesion to endothelial cells of the BBB (Yednock et al. 
1992, Baron et al.1993, Carrithers et al. 2000, Kivisäkk et al. 2009, Putzki et al. 2010, 
Harrer et al. 2011, Gan et al. 2012). VLA-4 is expressed on NK cells and α-VLA4 has 
been found to suppress NK infiltration of the CNS during EAE (Gismondi et al. 1991, 
Gan et al. 2012). Therefore, changes in NK cell frequencies in peripheral blood could 
be caused either by an overall expansion or contraction of a particular subset or by 
maintenance of cell types in the blood that would otherwise have migrated to the 
CNS. The fact that the only subset for which there was a significant difference in 
Tysabri-treated patients (CD56
dim
 CD8
+
 CD57
+
) was decreased in frequency in 
peripheral blood means that this difference is not likely to be due to effects on the 
migration of the CD56
dim
 CD8
+
 CD57
+
 subset itself. However, the alteration in the 
relative frequency of this subset amongst NK cells and lymphocytes could in theory 
be due to an increase in peripheral blood numbers of other NK cells and leukocytes 
which are no longer able to migrate to the CNS. Therefore it would be useful to know 
if the absolute numbers of each NK cell subset (i.e. per μl of blood) were altered in 
peripheral blood, but we did not have the facility to measure this. It would also be of 
particular interest to see if the CD56
dim
 CD8
+
 CD57
+
  subset and others are present in 
the CSF of RRMS patients, whether their frequency in CSF is related to active disease 
or relapse and whether disease-modifying therapies, especially Tysabri affect CSF 
frequencies of NK cell subsets. 
In summary, I have identified significant changes in the frequencies of specific 
subsets of NK cells in MS patients compared to healthy controls, consistent with the 
hypothesis that MS patients have an imbalance in the relative frequencies of 
regulatory and pro-inflammatory NK cell subsets. These differences include an 
increased frequency of CD56
dim
 CD8
+
 CD57
+
 NK cells and a reduced frequency of 
several CD56
bright
 subsets, in particular the CD8
-
 CD27
-
 subset, which were reversed 
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by IFNβ therapy. Two subsets of CD56dim NK cells (CD56dim CD8+ CD27- CD57+ 
and CD56
dim
 CD8
-
 CD27
-
 CD57
-
) were selected for follow-up in order to identify 
differences that would shed light on the mechanisms by which they might 
differentially modulate inflammation. 
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4. TRANSCRIPTIONAL AND FUNCTIONAL 
DIFFERENCES BETWEEN CD56
DIM
 CD8
-
 CD27
-
 CD57
-
 
AND CD56
DIM
 CD8
+
 CD27
-
 CD57
+
 NK CELLS 
Having identified subsets which had altered frequencies in MS patients compared to 
healthy controls, I sought to learn more about the function of these NK cell subsets. 
The CD56
bright 
subset, which had reduced frequency in untreated MS patients and was 
increased amongst IFNβ-treated patients, has previously been well characterised and 
within the CD56
bright
 population all four subsets showed the same trends in frequency, 
albeit to different extents. Therefore characterisation of CD56
bright
 subsets was not a 
priority. However, within the CD56
dim
 NK cell population, there were subsets that 
appeared to have a reciprocal relationship as biomarkers of disease state: the CD56
dim
 
CD8
+
 CD57
+
 subset was identified as a disease-associated subset, the frequency of 
which was reduced by IFNβ treatment. CD56dim CD27+ NK cell frequency was also 
reduced in IFNβ-treated patients, however there was no evidence that MS patients had 
a higher frequency than healthy controls and the CD27
+
 subsets represent a relatively 
small proportion of NK cells, making it difficult to isolate sufficient cells for 
functional analysis. Conversely, one subset of CD56
dim
 NK cells, lacking CD8, CD27 
and CD57, had a significantly higher frequency in IFNβ-treated patients. This subset 
also appeared to have a slightly lower frequency in MS patients than controls. Since 
the frequencies of CD56
dim
 CD27
-
 CD8
+
 CD57
+
 and CD56
dim
 CD27
-
 CD8
-
 CD57
-
 
subsets appear to have a reciprocal relationship in disease, I decided to compare the 
function and transcriptional profile of these two subsets. Both these subsets constitute 
around 20% of NK cells in healthy controls, a sufficient proportion to enable isolation 
of these subsets for qRT-PCR and killing assays. 
CD57
+
 NK cells are more likely to express KIR and have a decreased proliferative 
response to IL-2, therefore the CD8
+
 CD57
+
 subset is likely to represent a more 
mature effector population (Björkström et al. 2010, Lopez-Vergѐs et al. 2010). CD57+ 
NK cells are reported to be more effective mediators of ADCC and express higher 
levels of granzymes and perforin (Chattopadhyay et al. 2009, Lopez-Vergѐs et al. 
2010). There is limited data on the functional differences between CD8
+
 and CD8
-
 
NK cells, however the CD8
+
 subset is reported to be more effective at killing target 
cells over time as it undergoes a lower rate of activation-induced apoptosis (Addison 
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et al. 2005). Therefore the CD56
dim
 CD8
+
 CD57
+
 subset would be expected to have 
greater cytotoxic function.  
The function of the CD8
-
 CD27
-
 CD57
-
 subset is harder to predict, given that this 
subset lacks not only CD57, associated with cytotoxic function, but also CD27, 
associated with enhanced cytokine production. It is possible that this subset represents 
a population of NK cells with limited functional capacity and that an increased 
frequency of this subset might be protective purely in the sense that there is a lower 
proportion of pathogenic effector NK cells. Therefore I was keen to find out whether 
this subset expressed genes that might indicate a distinct function, for instance in 
immunosuppression.  The frequency of the CD56
dim
 CD27
-
 CD8
-
 CD57
-
 subset 
showed a similar pattern to that of the CD56
bright
 subset. Therefore I hypothesised that 
the function, transcriptional profile and expression of activating, inhibitory and 
cytokine receptors in the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset might be closer to that 
of the CD56
bright
 subset than the CD56
dim
 CD8
+
 CD57
+
 subset. As discussed in chapter 
1, a number of functional and developmental intermediates have been described 
between the CD56
bright
 and CD56
dim
 populations (Romagnani et al. 2007, Takahashi et 
al. 2007, Juelke et al. 2010, Béziat et al. 2011, Hamann et al. 2011) and it is possible 
that the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset also falls into this category. 
4.1 Identification of Transcriptional Differences between CD8- 
CD27
-
 CD57
-
 and CD8
+
 CD57
+
 CD56
dim
 NK Cell Subsets 
In order to identify transcriptional differences between the two subsets, I chose a 
qRT-PCR array (SABiosciences Human Th17 for Autoimmunity and Inflammation) 
that contained primers for a range of pro-inflammatory and anti-inflammatory 
cytokine and chemokine genes, cytokine receptors, signalling molecules and matrix 
metalloproteinases (expression of which might aid migration into the CNS 
parenchyma and contribute to neuronal damage). All the key cytokines known to be 
produced by NK cells were included in this array, including IFNγ, TNFα, GM-CSF, 
IL-5, IL-13 and IL-10. CD56
dim 
CD8
- 
CD27
-
 CD57
-
 and CD56
dim
 CD8
-
 CD27
-
 CD57
+
 
NK cells were isolated by FACS for RNA extraction and qRT-PCR analysis. 
Expression levels for each of these genes are summarised in tables 4-(i-iv).  
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Table 4-i: Cytokine and chemokine expression determined by qRT-PCR array  
Gene Expression in CD8- CD57- Expression in CD8+ CD57+ 
CCL1 - - 
CCL2 +/- +/- 
CCL7 +/- - 
CCL20 +/- +/- 
CCL22 +/- +/- 
CSF2 (GM-CSF) +/- + 
CSF3 +/- +/- 
CX3CL1 - +/- 
CXCL1 + ++ 
CXCL2 +/- + 
CXCL5 + +/- 
CXCL6 +/- +/- 
CXCL12 - +/- 
IFNγ +++ +++ 
IL-1b +/- ++ 
IL-2 +/- - 
IL-3 - - 
IL-4 - +/- 
IL-5 +/- +/- 
IL-6 - - 
IL-8 +++ +++ 
IL-10 + + 
IL-12B - - 
IL-13 +/- +/- 
IL-15 ++ ++ 
IL-17A - - 
IL-17C ++ ++ 
IL-17F +/- - 
IL-18 +++ +++ 
IL-21 - - 
IL-22 - - 
IL-23A +/- +/- 
IL-25 +/- +/- 
IL-27 +/- +/- 
TGF-β +++ +++ 
TNF-α +++ +++ 
PBMC were isolated from seven healthy female donors. cDNA from FACS-sorted NK cell subsets was analysed 
by qRT-PCR array.Genes with a mean Ct value of <25 are defined as high expression (+++), those with mean Ct 
25-30 as medium (++), Ct of 30-35 low (+) if detected in all 7 samples, (+/-) if detected in 2-6 samples or (-) if 
detected in less than 2 samples. 
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Table 4-ii: Expression of cell surface receptors and adaptor molecules determined by qRT-PCR 
array 
Gene Expression in CD8
-
 CD57
-
 Expression in CD8
+
 CD57
+
 
CD3D ++ +++ 
CD3E +++ +++ 
CD3G ++ +++ 
CD247 +++ +++ 
CD4 ++ ++ 
CD8A ++ +++ 
CD28 - - 
CD34 - - 
CD40L ++ ++ 
S1PR1 +++ +++ 
IL12RB1 +++ +++ 
IL12RB2 +++ +++ 
IL17RB ++ ++ 
IL17RC +/- +/- 
IL17RD - +/- 
IL17RE +/- +/- 
IL23R +/- - 
IL6R ++ ++ 
IL7R ++ ++ 
TLR4 ++ ++ 
ICAM1 +++ +++ 
ICOS + + 
PBMC were isolated from seven healthy female donors. cDNA from FACS-sorted NK cell subsets was 
analysed by qRT-PCR array.Genes with a mean Ct value of <25 are defined as high expression (+++), 
those with mean Ct 25-30 as medium (++), Ct of 30-35 low (+) if detected in all 7 samples, (+/-) if 
detected in 2-6 samples or (-) if detected in less than 2 samples. 
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Table 4-iii: Expression of intracellular signalling molecules and transcription factors determined 
by qRT-PCR array 
Gene Expression in CD8
-
 CD57
-
 Expression in CD8
+
 CD57
+
 
CACYBP +++ +++ 
CEBPB +++ +++ 
CLEC7A ++ ++ 
FOXP3 +/- +/- 
GATA3 ++ ++ 
JAK1 +++ +++ 
JAK2 +++ +++ 
NFATC2 +++ +++ 
NFKB1 +++ +++ 
RORC ++ + 
SOCS1 +++ +++ 
SOCS3 ++ ++ 
STAT3 +++ +++ 
STAT4 +++ +++ 
STAT5A +++ +++ 
STAT6 +++ +++ 
SYK ++ ++ 
TBX21 +++ +++ 
TIRAP ++ ++ 
TRAF6 +++ +++ 
YY1 +++ +++ 
PBMC were isolated from seven healthy female donors. cDNA from FACS-sorted NK cell subsets was 
analysed by qRT-PCR array. Genes with a mean Ct value of <25 are defined as high expression (+++), 
those with mean Ct 25-30 as medium (++), Ct of 30-35 low (+) if detected in all 7 samples, (+/-) if 
detected in 2-6 samples or (-) if detected in less than 2 samples. 
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Table 4-iv: Expression of other genes determined by qRT-PCR array 
Gene Expression in CD8
-
 CD57
-
 Expression in CD8
+
 CD57
+
 
ISG20 +++ +++ 
MMP3 - - 
MMP9 ++ ++ 
MMP13 - - 
PBMC were isolated from seven healthy female donors. cDNA from FACS-sorted NK cell subsets was 
analysed by qRT-PCR array.Genes with a mean Ct value of <25 are defined as high expression (+++), 
those with mean Ct 25-30 as medium (++), Ct of 30-35 low (+) if detected in all 7 samples, (+/-) if 
detected in 2-6 samples or (-) if detected in less than 2 samples. 
 
Data was uploaded to the SABiosciences data analysis portal for calculation of fold 
changes in gene expression in the CD56
dim
 CD8
+
 CD57
+
 subset compared to the 
CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset and for generation of a clustergram showing 
relationships in expression of different genes (figure 4-i). Genes that had a fold 
change of at least +/-1.2 in the CD8
+
 CD57
+
 subset compared to the CD8
-
 CD57
-
 
subset were subjected to statistical analysis. Genes which had significantly higher 
expression in the CD8
+
 CD57
+
 subset are summarised in table 4-v. Genes which had 
significantly higher expression in the CD8
-
 CD57
-
 subset are summarised in table 4-
vi.  
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Figure 4-i: Clusters of co-regulated genes are associated with CD56
dim
 CD8
-
 CD27
-
 CD57
-
 and 
CD8
+
 CD27
-
 CD57
+
 NK cell subsets. PBMC were isolated from seven healthy female donors. cDNA 
derived from FACS-sorted NK cell subsets was analysed by qRT-PCR array.  Clustergram shows all 
genes that were consistently expressed in at least one subset (see tables 4-(i-iv)). Genes are clustered 
according to similar relative expression levels in each sample. Upper box (purple) shows a cluster of 
co-expressed genes with higher expression in CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells. Lower box (blue) 
shows a cluster of co-expressed genes with higher expression in CD56
dim
 CD8
+
 CD57
+
 NK cells. 
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Table 4-v: Genes with significantly higher expression in the CD56
dim
 CD8
+
 CD57
+
 NK cell subset 
Gene Fold change 
CD8A 49.08 
CD3D 3.33 
CD3G 2.70 
SOCS3 1.54 
IFNγ 1.54 
IL12RB1 1.42 
S1PR1 1.38 
NFATC2 1.37 
STAT3 1.36 
TBX21 (T-bet) 1.34 
CD247 (CD3ζ) 1.32 
PBMC were isolated from seven healthy female donors. cDNA derived from FACS-sorted NK cell 
subsets was analysed by qRT-PCR array. All genes shown were significantly different (p<0.05) as 
determined by Wilcoxon matched pairs test, which was performed for all genes with a mean fold 
change of at least 1.2 as determined by ΔΔCt method with normalisation to four housekeeping genes. 
 
Table 4-vi: Genes with significantly higher expression in the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cell 
subset 
Gene Fold change 
RORC 5.60 
IL7R 4.06 
IL12RB2 2.53 
IL-18 1.55 
ICAM1 1.30 
NFKB1 1.21 
PBMC were isolated from seven healthy female donors. cDNA derived from FACS-sorted NK cell 
subsets was analysed by qRT-PCR array. All genes shown were significantly different (p<0.05) as 
determined by Wilcoxon matched pairs test, which was performed for all genes with a mean fold 
change of at least 1.2 as determined by ΔΔCt method with normalisation to four housekeeping genes.  
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The biggest fold change was in expression of RORC, the hallmark transcription factor 
associated with driving the expression of IL-17 and IL-22 (Manel et al. 2008, Cella et 
al. 2009, Cupedo et al. 2009), which had significantly higher expression in the CD8
-
 
CD57
-
 subset. NFκB, a key transcriptional mediator in response to certain cytokines 
and TLR stimulation (Pahl 1999), was also modestly but significantly increased in the 
CD8
-
 CD57
-
 subset. Conversely STAT3, T-bet and NFATC2 (nuclear factor of 
activated T cells, cytoplasmic 2) transcription factors, all of which upregulate and/or 
are upregulated by IFNγ (Lighvani et al. 2001, Szabo et al. 2002, Harris et al. 2005, 
Macian 2005, Bluyssen et al. 2010), had higher expression in the CD8
+
 CD57
+
 subset. 
In line with this, IFNγ itself was also expressed at a higher level in this subset, as was 
suppressor of cytokine signalling 3 (SOCS3), which is activated by STAT3 and 
mediates a negative feedback loop in several cytokine-induced signalling pathways 
including IFNγ (Bluyssen et al. 2010). However, IL-18, a cytokine which co-
stimulates IFNγ production (Fehniger et al. 1999) was expressed at a higher level in 
the CD8
-
 CD57
-
 subset. IL12RB1, the receptor chain shared by the IL-12 and IL-23 
receptors was expressed at a higher level in the CD8
+
 CD57
+
 subset, whereas the 
IL12RB2 chain, unique to the IL-12 receptor, was expressed at a higher level in the 
CD8
-
 CD57
-
 subset, as was IL7R. 
There were also significant differences in expression of adhesion molecules, with 
S1PR1 expressed preferentially in the CD8
+
 CD57
+
 subset and ICAM1 expressed at 
higher levels in the CD8
-
 CD57
-
 subset. Several TCR chains (CD3 δ, γ and ζ) were 
also upregulated in the CD8
+
 CD57
+
 subset compared to the CD8
-
 CD57
-
 subset. 
In addition to the genes listed in table 4-v, IL-23A also had much higher expression in 
the CD8
+
 CD57
+
 NK cell subset, however the Ct value was above the cut-off value of 
35 in one of the donors. Statistical comparison was performed for the remaining six 
donors but there was a high level of variability and overall the difference between the 
two subsets was not significant. 
The PCR array contained a control with primers for sensitive detection of genomic 
DNA, which confirmed that in each sample genomic DNA contamination was either 
absent or sufficiently low not to affect the results when using a Ct of 35 as a cut-off 
point for a positive result. However, it is still preferable to confirm results with a no 
reverse transcription control and I also wanted to see if a significant difference in 
IL23A expression could be detected when Ct values above 35 were included in the 
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analysis. Therefore individual qRT-PCR assays for selected genes were carried out in 
triplicate to confirm differences in gene expression in the context of a separate no 
reverse transcription control for each gene. 
Individual qRT-PCR assays confirmed significantly higher expression of IFNγ, IL-
23A, TBX21 (T-bet), IL12RB1 and S1PR1 in the CD8
+
 CD57
+
 subset (figure 4-ii). 
Significantly higher expression of RORC and IL12RB2 in the CD8
-
 CD57
-
 subset was 
also confirmed. Although expression of IL7R was again higher in the CD8
-
 CD57
-
 
subset, this did not reach statistical significance in the individual qRT-PCR assay. 
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Figure 4-ii: Confirmation of transcriptional differences by individual qRT-PCR assays. The 
cDNA samples previously used for the array analysis (isolated from FACS-sorted CD56
dim
 CD8
-
 
CD27
-
 CD57
-
 and CD56
dim
 CD8
+
 CD57
+
 NK cell subsets of seven healthy donors) were reanalysed by 
individual qRT-PCR assays. Assays were performed in triplicate with no reverse transcription controls 
for each gene.  ΔCt was calculated by normalisation to the mean of the Cts of GAPDH and HPRT1. 
Significant differences (p<0.05) as determined by Wilcoxon matched pairs test are indicated by *. 
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4.2 Cell Surface Expression of Cytokine Receptors 
In order to determine whether the transcriptional differences identified in cytokine 
receptor expression corresponded to differences on the cell surface, I performed flow 
cytometry to examine surface expression of IL12Rβ1, IL12Rβ2 and IL7R (CD127) on 
each of the subsets (figure 4-v). IL-12Rβ1 was expressed at slightly higher levels on 
CD56
dim
 compared to CD56
bright
 NK cells, however there was no apparent difference 
between the CD56
dim
 CD8
-
 CD57
-
 and CD8
+
 CD57
+
 subsets. IL-12Rβ2 expression 
was not detected on any of the subsets. IL7R was expressed on the majority of 
CD56
bright
 NK cells, was virtually absent from the CD56
dim
 CD8
+
 CD57
+
 subset and 
was expressed on only a small percentage of CD56
dim
 CD8
-
 CD57
-
 NK cells.  
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Figure 4-iii: Expression of cytokine receptors. PBMC from four healthy donors were incubated with 
antibodies against CD3, CD56, CD8, CD27, CD57 and IL-12Rβ1, IL-12Rβ2 or IL7R (CD127) or 
isotype controls. (A) and (B) Representative histograms for each subset are shown with mean MFI ratio 
(median fluorescence for receptor of interest divided by median fluorescence FMO isotype control) of 
all four donors. Black line = FMO isotype control, blue line = receptor of interest. (C) Percentage of 
each subset expressing IL7R (representative of 3 donors). 
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4.3 Differences in Expression of Activating and Inhibitory 
Receptors  
Next, I wanted to determine if CD8
+
 CD57
+
 and CD8
-
 CD57
-
 subsets expressed 
different levels of activating and inhibitory receptors on the cell surface. First I 
examined expression of the inhibitory receptor NKG2A. Loss of NKG2A has been 
associated with NK cell maturation and previous reports indicate that it is expressed 
on all CD56
bright
 NK cells and around 50% of CD56
dim
 NK cells (Béziat et al. 2010, 
Yu et al. 2010). The proportion of NK cells expressing NKG2A was significantly 
higher within the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset (figure 4-iii). However, a 
substantial portion of the CD56
dim
 CD8
+
 CD57
+
 population also expressed this 
receptor. As expected, I found that NKG2A was found on nearly all CD56
bright
 NK 
cells. 
I also compared expression of the activating receptors NKG2D, NKp30, NKp44 and 
NKp46 in the CD56
dim
 CD8
+
 CD57
+
 and CD8
-
 CD57
-
 subsets as well as in CD56
bright
 
NK cells (figure 4-iv). NKp30 expression was similar across all three subsets. NKp44 
was expressed at low levels on the CD56
bright
 subset and was not detected on either 
CD56
dim
 subset. NKG2D had slightly higher expression on the CD56
bright
 subset, with 
no difference in expression between the two CD56
dim
 subsets. NKp46 expression was 
highest on CD56
bright
 NK cells and lowest on CD56
dim
 CD8
+
 CD57
+
 NK cells, with an 
intermediate level of expression on CD56
dim
 CD8
-
 CD57
-
 NK cells. 
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Figure 4-iv: The CD8
+
 CD57
+
 subset contains significantly fewer NKG2A
+
 NK cells. PBMC were 
isolated from nine healthy donors and incubated with antibodies against CD3, CD56, CD8, CD27, 
CD57 and NKG2A. (A) Representative flow cytometry plots showing expression of NKG2A in the 
CD56
bright
 subset, the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset and the CD56
dim
 CD8
+
 CD27
-
 CD57
+
 subset.  
(B) Percentage of each NK cell subset expressing NKG2A: each line represents one donor. Significant 
differences determined by repeated measures ANOVA followed by Tukey’s multiple comparison test 
are denoted *** (p<0.001). 
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Figure 4-v: Differences in expression of activating receptors. PBMC from four healthy donors were 
incubated with antibodies against CD3, CD56, CD8, CD27, CD57 and NKp30, NKp44, NKp46 or 
NKG2D. Representative histograms for each subset are shown with mean MFI ratio (median 
fluorescence for receptor of interest divided by median fluorescence of FMO isotype control) of all 
four donors. Black line = FMO isotype control, blue line = α-NKp30, NKp44, NKp46 or NKG2D. 
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4.4 CD56dim CD8- CD27- CD57- NK Cells Produce Similar Levels 
of IFNγ to CD8+ CD57+ NK Cells and do not Produce IL-17 
or IL-22  
CD56
bright
 NK cells make more IFNγ than CD56dim NK cells when stimulated with 
cytokines or PMA and ionomycin (Fehniger et al. 1999, Cooper et al. 2001b, Jacobs 
et al. 2001). One of the features typical of previously identified functional and 
developmental intermediaries between the CD56
bright
 and CD56
dim
 subsets, such as 
CD56
dim
 CD62L
+, is the ability to produce levels of IFNγ commensurate with that of 
the CD56
bright
 subset (Juelke et al. 2010). If CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells are 
another intermediate population, they might be expected to produce a similar level of 
IFNγ in response to cytokines or PMA/ionomycin as the CD56bright subset, whereas 
CD57
+
 NK cells, as a more “mature” population would be expected to produce less. 
However, the CD8
+
 CD57
+
 subset expressed higher levels of IFNγ transcript, 
therefore they might in fact produce more IFNγ. Therefore, I set out to determine 
whether there was any difference in the percentage of cells producing IFNγ or the 
amount of IFNγ that they were producing in response to stimulation with PMA and 
ionomycin.  
There was no significant difference in the percentage of cells producing IFNγ (figure 
4-vi-A). The intensity of IFNγ staining in the CD56bright population was significantly 
higher than that of the CD56
dim
 CD8
- 
CD57
-
 subset (figure 4-vi-B). The amount 
produced by the CD56
dim
 CD8
+
 CD57
+
 subset varied considerably between donors 
and on average was between that of the other two subsets. In this respect, the CD8
-
 
CD57
-
 subset does not therefore have a closer functional association with the 
CD56
bright
 subset.  
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Figure 4-vi: IFNγ production in the CD56dim CD8- CD27- CD57- subset in response to 
PMA/ionomycin stimulation is lower than that of CD56
bright
 NK cells and not significantly 
different to that of the CD56
dim
 CD8
+
 CD57
+
 subset. PBMC from five healthy donors were 
stimulated with PMA/ionomycin in the presence of monensin for 6 hours. (A) Percentage of IFNγ+ 
cells and (B) the level of IFNγ expression (MFI ratio = MFI IFNγ+ population of test sample divided by 
MFI of FMO isotype control). Statistical significance was determined by Friedman test followed by 
Dunn’s multiple comparison test.* denotes p<0.05. (C) Representative flow cytometry plots showing 
IFNγ expression in CD56bright, CD56dim CD8- CD27- CD57- and CD56dim CD8+ CD57+ NK cell subsets 
from the same donor. 
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As mentioned in chapter 4.1, the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset expressed a 
significantly higher level of RORC, a transcription factor that has been associated 
with NK cell subsets found in tonsil that produce IL-22 and/or IL-17 but very little 
IFNγ (Cella et al. 2009, Cupedo et al. 2009). Transcripts for IL-22 and IL-17A were 
not detected in freshly isolated CD56
dim
 CD8
-
 CD57
-
 NK cells (table 4-i). In order to 
determine if these cytokines were expressed in this subset following activation, I 
stimulated PBMC with PMA and ionomycin for 6 hours then performed intracellular 
staining for IL-22 and IL-17A. IL-22 production has previously been observed over 
this same time period in tonsil NK cells (Cella et al. 2009). 
IL-22 and IL-17A were not expressed by the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset or 
by any other peripheral blood NK cell population, though they were detected in a 
subpopulation of T cells (figure 4-vii). 
 
 
Figure 4-vii: CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells do not produce IL-22 or IL-17A. PBMC from 
four healthy donors were stimulated with PMA/ionomycin for 6 hours. Cells were labelled with 
antibodies against CD3, CD56, CD8, CD27 and CD57, fixed and permeabilized, then incubated with α-
IL-22, α-IL17A or isotype control. IL-17A- and IL-22-expressing cells were detected within the T cell, 
but not the NK cell, population. 
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4.5 CD56dim CD8+ CD57+ NK cells are More Cytotoxic than 
CD56
dim
 CD8
- 
CD27
-
 CD57
-
 NK Cells 
Cytotoxicty towards susceptible targets is an important function of NK cells. Both 
CD57 and CD8 have previously been associated with increased cytotoxic function 
(Srour et al. 1990, Lowdell et al. 2002, Addison et al. 2005, Chattopadhyay et al. 
2009, Lopez-Vergѐs et al. 2010), therefore the CD56dim CD8+ CD57+ would be 
expected to have higher cytotoxicity than the CD56
dim
 CD8
-
 CD57
-
 subset. In order to 
test this hypothesis, I first performed qRT-PCR using RNA from FACS-sorted NK 
cell subsets to compare expression of key cytotoxic mediators granzymes A and B and 
perforin, then carried out killing assays to confirm this at a functional level. 
As predicted, granzyme A, granzyme B and perforin all had significantly higher 
expression in the CD56
dim
 CD8
+
 CD57
+
 subset (figure 4-viii).  
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Figure 4-viii: CD8
+
 CD57
+
 NK cells express higher levels of cytotoxic molecules. Expression of 
cytotoxicity genes in CD8
-
 CD57
-
 and CD8
+
 CD57
+
 subsets of CD56
dim
 CD27
-
 NK cells as determined 
by qRT-PCR. PBMC were isolated from seven healthy female donors. RNA was extracted from NK 
cell subsets isolated by FACS and subjected to qRT-PCR analysis for expression of granzyme A, 
granzyme B and perforin. Expression was measured in triplicate with no reverse transcriptase controls 
for each gene.  ΔCt was calculated by normalisation to the mean Ct value for GAPDH and HPRT1 
housekeeping genes. Significant differences (p<0.05) as determined by Wilcoxon matched pairs test are 
indicated by *.  
 
Next I compared the ability of these two NK cell subsets to kill the NK cell-
susceptible K562 erythroleukaemia cell line. FACS-sorted NK cell subsets were 
incubated with K562 cells for 2 hours and the percentage of NK cell-mediated K562 
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cell death and activation-induced NK cell death (normalised to controls for 
spontaneous cell death) was determined by a flow cytometric assay. This assay 
involved the use of a DNA-binding dye (TO-PRO-3), which only enters cells when 
the integrity of the cell membrane is perturbed, as is the case during apoptosis. 
Counting beads enabled determination of the number of dead cells that were lost from 
the target cell gate. This enabled calculation of the total percentage of dead and 
apoptotic cells, which was normalised to controls to account for spontaneous cell 
death, as described in chapter 2.9. The CD56
dim
 CD8
+
 CD57
+
 NK cell subset killed 
significantly more K562 cells than the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset (figure 4-
ix-A). However, there was no significant difference in activation-induced cell death 
(figure 4-ix-B). 
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Figure 4-ix: CD8
+
 CD57
+
 NK cells exhibit higher cytotoxicity towards K562 target cells. PBMC 
were isolated from six healthy female donors. CD56
dim
 CD8
-
 CD27
-
 CD57
-
 and CD56
dim
 CD8
+
 CD57
+
 
NK cells were isolated by FACS and incubated for 2 hours with K562 at a 2:1 NK cell to K562 ratio. 
Countbright counting beads were used to calculate the number of dead cells that were lost from the 
K562 gate (A) or NK cell gate (B) and TO-PRO-3 DNA-binding dye was used to identify apoptotic 
cells. (A) K562 killing was determined by comparing the relative numbers of viable (TO-PRO-3-
negative) K562 cells in triplicate experimental wells vs. K562-only controls. Paired t test indicated a 
statistically significant difference between CD8
+
 CD57
+
 and CD8
-
 CD57
-
 NK cells (p=0.0085 **). (B) 
The percentage of NK cells lost due to activation-induced cell death was estimated by comparing the 
number of viable NK cells following incubation with K562 to that in NK cell-only controls. Paired t 
test indicated no significant difference in activation-induced NK cell death. 
(A) (B) 
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4.6 Discussion 
In this chapter I have compared transcriptional profiles, cell surface receptor 
expression, cytokine production and cytotoxic function of two subsets of CD56
dim
 NK 
cells and identified both similarities and differences.  
Many of the transcriptional differences identified by qRT-PCR array are related to 
IFNγ signalling. IFNγ-related genes that were upregulated in the CD8+ CD57+ subset 
include T-bet, STAT3, NFATC2, SOCS3 and IL12RB1. T-bet is crucial for IFNγ 
transcription in NK cells and CD4
+
 T cells and its expression is augmented by IFNγ 
(Lighvani et al. 2001, Szabo et al. 2002). STAT3 is activated by a number of 
cytokines including the IL-6 family, IL-10 family, interferons and IL-23 (Schindler 
and Plumlee 2008). It promotes survival and proliferation (Takeda et al. 1998, Akira 
2000, Narimatsu et al. 2001). IFNγ activates both STAT3 and SOCS3, which inhibits 
STAT3-mediated signalling (Bluyssen et al. 2010). SOCS proteins are activated by 
cytokines and growth factors such as IL-2, IL-6, erythropoietin and PDGF and form 
part of a negative feedback loop, suppressing further signalling through cytokine 
receptors (Starr et al. 1997, Cacalano et al. 2001). SOCS3 binds to JAK2 associated 
with receptors that signal via STAT3 and inhibits its tyrosine kinase activity (Sasaki et 
al. 1999, Yoshimora et al. 2012). It also inhibits IL-12 signalling by binding to the 
STAT4 docking site on IL-12Rβ2 (Yamamoto et al. 2003).   
Expression of IFNγ can be induced by a number of mechanisms, including stimulation 
with IL-12 and IL-18 or ligation of activating receptors (Anegón et al. 1988, 
Cassatella et al. 1989, Cuturi et al. 1989, Warren et al. 1995, Fehniger et al. 1999). 
Previous reports have indicated that CD56
bright
 NK cells express higher levels of IL-
12RB2 transcript than CD56
dim
 (Wendt et al. 2006, Lopez-Vergѐs et al. 2010) and that 
CD56
dim
 CD57
+
 NK cells have a lower level than CD56
dim
 CD57
-
 NK cells, which is 
consistent with the data presented here showing that transcription is lower in the CD8
+
 
CD57
+
 subset of CD56
dim
 NK cells. IL-12Rβ2 expression has also been associated 
with “NK2” polarisation and production of IL-5 and IL-13 (Peritt et al. 1998, 
Takahashi et al. 2001), but I did not detect any significant difference in the expression 
of these two cytokines. Curiously, however, I found that IL-12RB1 transcript was 
more abundant in the CD8
+
 CD57
+
 subset. IL-12Rβ1can pair either with IL-12Rβ2 to 
form the high affinity IL-12 receptor or with IL-23R to form the IL-23 receptor 
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(Presky et al. 1996, Parham et al. 2002). However, expression of IL23R was low to 
undetectable in both subsets, therefore it seems unlikely that IL-12RB1 expression in 
the CD8
+
 CD57
+
 subset was linked to preferential formation of IL-23R rather than IL-
12R heterodimers.  
The transcriptional differences in expression of these receptor subunits did not 
translate into differences on the cell surface of resting NK cells. IL-12Rβ2 was not 
detected on the surface of either CD56
dim
 subset, or on the surface of CD56
bright
 NK 
cells. This is consistent with a previous study demonstrating that IL-12Rβ2 is only 
expressed on the cell surface following activation with IL-18 (Mailliard et al. 2005). 
This may be part of the mechanism by which IL-18 synergises with IL-12 for 
induction of IFNγ production. The CD8- CD57- subset also had higher expression of 
IL-18 transcript, therefore it is possible that in response to an appropriate stimulus, 
these cells might produce IL-18 which acts in an autocrine manner to induce surface 
expression of IL-12Rβ2. However, no antibodies were available in order to assess 
whether this subset actually secretes IL-18 protein. IL-12Rβ1 was detected on the 
surface of freshly isolated PBMC, but there was no apparent difference in surface 
expression between the two subsets. This could be due to the lower sensitivity of flow 
cytometry compared to qRT-PCR, especially given that the fluorescence intensity for 
this antibody was low on all subsets. Activation might be required in order to 
upregulate cell surface IL-12Rβ1 levels. The presence of higher levels of transcript 
might enable a more rapid upregulation of cell surface levels on CD8
+
 CD57
+
 NK 
cells when translation or protein transport is increased. CD8
+
 CD57
+
 NK cells might 
also have a higher rate of IL-12Rβ1 protein turnover, resulting in similar levels of 
expression on the surface of resting NK cells, but allowing them to more rapidly 
replace internalised receptors following binding of IL-12 or IL-23. 
Following PMA and ionomycin stimulation, CD8
+
 CD57
+
 NK cells did not produce 
significantly more IFNγ than CD8- CD57- NK cells, despite higher levels of IFNγ 
transcript. However, cytokine production was only measured at one time point and it 
would be interesting to know if there are differences in the kinetics of the response. 
Higher levels of IFNγ transcript in CD56dim compared to CD56bright NK cells have 
previously been associated with the ability to produce IFNγ more rapidly in response 
to activating signals (De Maria et al. 2011). Therefore it seems likely that the CD8
+
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CD57
+
 subset may be activated more rapidly than the CD8
-
 CD57
-
 subset. PMA and 
ionomycin stimulation demonstrated that both subsets have the capacity to produce 
substantial amounts of IFNγ, but given the findings of Fauriat et al. (2010a) regarding 
preferential responsiveness to different stimuli in CD56
bright
 and CD56
dim
 NK cell 
subsets, further investigation is clearly warranted. CD8
+
 CD57
+
 NK cells might 
produce more IFNγ in response to target cells or stimulation of activating receptors 
such as CD16, a characteristic associated with CD56
dim
 NK cells in general (Anfossi 
et al. 2006, Fauriat et al. 2010a). I found that CD8
+
 CD57
+
 NK cells expressed higher 
levels of CD3ζ, an important ITAM-containing adaptor protein that mediates 
signalling via CD16, NKp30 and NKp46 and possibly through CD8 itself (Lanier et 
al. 1989, Pessino et al. 1998, Vitale et al. 1998, Pende et al. 1999, Gibbings and Dean 
Brefus 2009). They also exhibited higher expression of NFATC2, which is induced by 
CD16 stimulation (Arambu et al. 1995). In Th1 cells, NFAT proteins cooperate with 
STAT4, which is activated in response to IL-12R engagement, to induce IFNγ 
expression and with T-bet to promote and maintain Th1 polarisation (Macian 2005).  
However, if the CD56
dim
 CD8
- 
CD27
-
 CD57
-
 subset does indeed resemble the 
CD56
bright
 population, it might produce more IFNγ in response to cytokine 
stimulation. Given the opposing differences in transcripts for each of the IL-12 
receptor components, it would be interesting to see how the two subsets respond to 
IL-12 stimulation and how this compares to the CD56
bright
 subset. It would also be 
interesting to determine the effect of IL-18 co-stimulation on each subset. CD57
-
 NK 
cells are reported to have higher surface expression of IL-18Rα (Lopez-Vergѐs et al. 
2010), so a greater enhancement of IFNγ production by IL-18 might be expected in 
the CD8
-
 CD57
-
 subset. IL-18 might upregulate IL-12Rβ2 surface expression more 
strongly or more rapidly on the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset since these cells 
already express high levels of transcript. Alternatively IL-18 might upregulate 
transcription in the CD8
+
 CD57
+
 subset, abolishing the difference at the mRNA level. 
Though the CD56
dim
 CD8
-
 CD27
- 
CD57
-
 subset did appear to share some 
characteristics with the CD56
bright
 subset, I also considered the possibility that it might 
be related to “NK-22” cells found in human tonsils. Two RORC-expressing subsets 
have been described in human tonsil, both of which produce IL-22 and one of which 
also produces IL-17A (Cella et al. 2008, Cupedo et al. 2009). A similar IL-22 
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producing RORC
+
 subset has also been described in the murine gut (Satoh-Takayama 
et al. 2008). Human NK-22 cells are NKp44
+
 CD127
+
 and have low expression of 
perforin and IFNγ (Cella et al. 2008, Cupedo et al. 2009). I did not detect expression 
of NKp44 on the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset and though IFNγ production 
was significantly lower than CD56
bright
 NK cells and slightly lower than CD56
dim
 
CD8
+
 CD57
+
 NK cells, the high percentage of cells expressing IFNγ was not 
consistent with RORC
+
 tonsil NK cells. More importantly, expression of IL-22 was 
not detected in this subset, or in any peripheral blood NK cell subset when stimulated 
with PMA and ionomycin for the same duration in which IL-22 production was 
observed in the study by Cella et al. 
For the qRT-PCR and killing assays, I did not make comparisons to the CD56
bright
 
subset since I found that sorting of more than two populations compromised purity, 
which was of paramount importance for the PCR assays in particular. However, 
expression patterns of activating and inhibitory receptors were consistent with the 
hypothesis that CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells are a functional intermediate 
between the CD56
bright
 and the CD56
dim
 CD8
+
 CD57
+
 subset. NKG2A, which is 
present on virtually all CD56
bright
 NK cells, was present on a significantly higher 
proportion of CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells compared to CD56
dim
 CD8
+
 
CD57
+
 NK cells. The CD8
-
 CD57
-
 subset also had a level of NKp46 expression in 
between that of CD56
bright
 NK cells (which, consistent with a previous report (Vitale 
et al. 2004), had the highest expression of NKp46) and that of the CD8
+
 CD57
+
 
subset. Lower expression of NKp46 on CD57
+
 NK cells is consistent with the 
findings of Lopez-Vergѐs et al. (2010), however they also reported lower expression 
of NKp30 and NKG2D on CD57
+
 compared to CD57
-
 CD56
dim
 NK cells, which I did 
not observe in the CD8
+
 CD57
+
 subset. CD8
-
 CD57
-
 NK cells had higher levels of 
both IL-12RB2 and IL7R receptor transcripts, which have also previously been 
reported to have higher expression in CD56
bright
 compared to CD56
dim
 NK cells 
(Hanna et al. 2004b, Wendt et al. 2006). However, surface staining revealed that 
actually only a small percentage of CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells expressed 
IL-7 receptor, whereas the majority of CD56
bright
 NK cells expressed it. Another 
transcriptional similarity with the CD56
bright
 subset was lower expression of CD3ζ. 
CD3ζ is expressed at ~3-fold  higher levels in CD56dim compared to CD56bright NK 
cells (Hanna et al. 2004b). The fold-difference that I observed between the two 
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CD56
dim
 subsets was less than this, indicating that the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 
subset probably has an intermediate level of CD3ζ expression, though it is impossible 
to be confident of this without having directly compared all three subsets in the same 
analysis. 
In addition to CD3ζ, I also detected increased mRNA levels of CD3δ and CD3γ in the 
CD8
+
 CD57
+
 subset. CD3δ and CD3γ transcripts have previously been reported to be 
absent from adult peripheral blood NK cells, using less sensitive detection methods on 
NK cell clones or unsorted polyclonal NK cells (Biassoni et al. 1988, Anderson et al. 
1989, Lanier et al. 1992). Since the NK cell populations isolated in my study had very 
high purity, it is unlikely that these transcripts were derived from contaminating T 
cells. CD3δ and/or γ also appear to be expressed in thymic bipotent T/NK cell 
precursors (Sanchez et al. 1994). In addition, both transcripts and protein have been 
detected in the cytoplasm of NK cell clones derived from human fetal liver, however 
the protein is not transported to the cell surface (Lanier et al. 1992, Phillips et al. 
1992). Despite being derived from fetus, these NK cells display the cytotoxic function 
of mature NK cells (Phillips et al. 1992). Therefore expression of CD3δ and CD3γ is 
not restricted to immature progenitors with T cell potential and it is quite conceivable 
that they would also be expressed in adult mature NK cells. If these molecules are 
retained in the cytoplasm of CD56
dim
 CD8
-
 CD27
-
 CD57
- 
NK cells, as they are in fetal 
NK cells, the functional relevance of their expression is questionable. However they 
might contribute to signalling pathways in a similar way to CD3ζ.  
CD56
dim
 CD8
+
 CD57
+
 NK cells also expressed higher levels of IL23A transcript. 
However they did not express the other subunit that makes up functional IL-23 
heterodimers, IL-12B (p40). IL-23 is not a cytokine normally associated with NK 
cells and it would be interesting to find out if there are any circumstances under which 
they also express p40 and actually secrete IL-23, or if IL-23A has some function that 
is independent of the p40 subunit.  
The CD56
dim
 CD8
+
 CD57
+
 NK cell subset expressed higher levels of perforin and 
granzymes A and B, as expected, since higher expression of these molecules has 
previously been reported in CD57
+
 compared to CD57
-
 CD56
dim
 NK cells 
(Chattopadhyay et al. 2009). Cytotoxicity towards K562 is apparently similar in 
CD57
-
 and CD57
+
 subsets of CD56
dim
 NK cells (Lopez-Vergѐs et al. 2010). However, 
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CD8
+
 NK cells are reported to kill more K562 due to their relative resistance to 
activation-induced cell death (Addison et al. 2005). Therefore I hypothesised that the 
CD8
+
 CD57
+
 population would kill more K562 cells than the CD8
-
 CD57
-
 subset. The 
CD8
+
 CD57
+
 subset did indeed kill a higher proportion of K562 cells, however there 
was no significant difference in the rate of activation-induced NK cell death, which 
occurred in both subsets during the 2 hour incubation period. Since increased 
granzyme expression is apparently not sufficient to confer enhanced cytotoxic 
function on CD57
+
 NK cells (Lopez-Vergѐs et al. 2010), the mechanism for this 
increased cytotoxicity remains unclear. However differential expression of signalling 
molecules such as CD3ζ could have a role. 
In conclusion, a number of transcriptional and functional differences have been 
identified between the two CD56
dim
 subsets that were examined. The data so far 
suggests that CD8
+
 CD57
+
 NK cells, as hypothesised, are the more cytotoxic 
population, whereas CD8
-
 CD27
-
 CD57
-
 NK cells show more similarities to the 
CD56
bright
 subset. These results highlight future avenues for investigation that would 
further improve understanding of the functional differences between these subsets. 
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5. NK CELLS DO NOT INFILTRATE THE CNS IN THE 
LINE 7 MURINE MODEL OF MULTIPLE SCLEROSIS 
Since multiple sclerosis is the result of inflammation specifically within the central 
nervous system, an obvious question is whether natural killer cells are playing a direct 
role within the CNS or whether NK cells in the periphery are influencing the 
activation and therefore migration of other cells such as T cells prior to crossing the 
blood-brain barrier. 
Studies of human MS are limited in their ability to determine what is happening inside 
the CNS itself, due to its inaccessibility. CSF is difficult to obtain and brain and spinal 
cord tissue can only be obtained post-mortem. As a result, MS tissue samples are 
usually from patients with advanced, progressive disease, and therefore may not be 
representative of pathology in the earlier relapsing-remitting phase. Furthermore, 
control samples can only be obtained from people who have died due to other causes 
and therefore it is debatable whether they can be said to be healthy.  
Immunohistochemistry and confocal microscopy work performed by my colleague 
Pascal Durrenberger indicated very few NKp46
+
 NK cells present in post-mortem 
CNS samples from either MS patients or controls (Durrenberger et al. 2012). This 
would support the theory that the main role of NK cells in MS is in influencing 
inflammatory processes in the periphery that result in the abnormal migration of T 
cells and other leukocytes into the CNS. However, it does not exclude a possible role 
of NK cells within the CNS during relapsing-remitting MS. Indeed, human NK cells 
have been shown to kill oligodendrocytes, astrocytes and microglia in vitro (Morse et 
al. 2001, Saikali et al. 2007). NK cell cytotoxicity towards microglia is a proposed 
mechanism for inhibition of Th17 polarisation within the CNS during EAE (Hao et al. 
2010). Transgenic CX3CR1
-/-
 mice with a selective NK cell homing deficiency to the 
CNS develop EAE more rapidly and with higher mortality than wild type, which 
suggests that NK cells have an immunoregulatory function within the CNS during 
demyelinating disease (Huang et al. 2006). However, systemic depletion of NK cells 
using an antibody directed against NK1.1 not only alters the proliferation and IL-17 
production of T cells in the CNS, it also increases T cell proliferation in the periphery 
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and causes an increase in the amount of leukocytes infiltrating the CNS (Hao et al. 
2010) , suggesting that NK cells affect disease both inside and outside of the CNS. 
In order to determine whether NK cells might have a role within the CNS at an earlier 
stage of disease, I sought to determine which types of NK cell were present in the 
CNS of Line 7 mice with a demyelinating autoimmune disease resembling MS. These 
humanised transgenic mice generated in the Altmann lab express high levels of HLA-
DRB1*1501 (an HLA class II molecule associated with susceptibility to human MS) 
on an Aβ0 background and a TCR specific for the DR15-restricted epitope MBP 85-
99, cloned from the MS patient-derived Ob1A12 T cell clone (Ellmerich et al. 2005). 
Line 7 mice exhibit a high rate (around 60%) of spontaneous demyelinating disease 
leading to paralysis, without the need for disease induction by injection of myelin 
peptides or myelin-reactive T cells (Ellmerich et al. 2005). The spontaneous nature of 
demyelinating disease in the Line 7 model avoids bias caused by adjuvants required 
for EAE induction. Large numbers of T cells infiltrate the CNS of Line 7 mice and by 
the time disease is clinically evident, epitope spreading has occurred, with T cell 
responses directed at HLA-DR15-restricted epitopes of MBP, MOG and αβ-crystallin 
(Ellmerich et al. 2005). 
Since these mice have a full repertoire of other immune cell-types including B cells, 
NK cells and  T cells in the context of their autoimmune T cell repertoire and the 
development of severe, spontaneous disease, they provide an opportunity for 
reappraisal of the role of CNS NK cells which might be considered to offer 
advantages over the adjuvant-induced EAE models. 
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5.1.1 NKp46+ NK Cells were Not Detected in the CNS of Line 7 Mice 
Using the Line 7 model, I set out to determine which subsets of NK cells, if any, were 
present in the CNS of mice exhibiting symptoms of autoimmune demyelination. Cells 
were extracted from the CNS and spleen of Line 7 mice with moderate clinical 
disease (score 2-3) and stained with antibodies against NK cell markers. Score 2-3 
mice in this model have previously been shown in the lab to exhibit profound 
demyelination and pronounced CNS mononuclear infiltrates. 
Mouse NK cells are commonly defined either as NK1.1
+
 CD3
-
 or as NKp46
+
. NKp46 
was identified as the marker of choice, since one of the NK1.1 antibodies tested 
produced a very low signal in spleen, whilst the other exhibited an unacceptably high 
level of non-specific binding as determined using a matched concentration of 
appropriate isotype control.  
For each of the six mice tested, staining of spleen and CNS were carried out 
simultaneously. In spleen samples, a clear population of NKp46
+
 cells could be 
identified, representing 1-3% of splenocytes (figure 5-i). In CNS samples from the 
same mice however, there was no clear NKp46
+
 population and no discernible 
difference between NKp46 staining and that of the isotype control (figure 5-ii and 5-
iii).  
 
Figure 5-i: NK cells expressing NKp46 are present in the spleen of Line 7 mice. Data is 
representative of six Line 7 mice with moderate clinical disease (score 2-3). Splenocytes were extracted 
by syringe and treated with erythrocyte lysis buffer as described in methods. Cells were stained with 
live/dead yellow dye for exclusion of dead cells followed by (A) rat IgG2a eflour450 (isotype control) 
or (B) rat anti-mouse NKp46 eflour450 for identification of NK cells.  
NKp46 efluor450 IgG2a efluor450 
(A) (B) 
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Figure 5-ii: NKp46
+
 leukocytes are not found in the CNS of Line 7 mice. CNS tissue was extracted 
from three Line 7 mice (two female and one male) with a clinical disease score of 2 (low/moderate). 
Tissue was physically and enzymatically disrupted prior to isolation of leukocytes by Percoll density 
gradient centrifugation. Cells in the leukocyte fraction were stained with live/dead yellow for exclusion 
of dead cells and either rat anti-mouse NKp46 (right) or IgG2a isotype control (left). 
Isotype control Anti-NKp46 
IgG2a efluor450 NKp46 efluor450 
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Figure 5-iii: NKp46
+
 leukocytes are not found in the CNS of Line 7 mice. CNS tissue was extracted 
from three female Line 7 mice with moderate clinical disease (score 2.5 - 3) and physically and 
enzymatically disrupted prior to isolation of leukocytes by Percoll density gradient centrifugation. Cells 
in the leukocyte fraction were stained with live/dead yellow for exclusion of dead cells and rat anti-
mouse NKp46 (right) or IgG2a isotype control (left). (A) and (B) represent mice sacrificed at a score of 
2.5 and sample (C) is from a mouse sacrificed at score 3. 
Isotype control Anti-NKp46 
NKp46 efluor450 IgG2a efluor450 
(A) 
(B) 
(C) 
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5.1.2 Lack of NKp46 Detection was not due to Antibody Sequestration 
To test the hypothesis that sequestration of NKp46 antibody by residual CNS debris 
or non-lymphocytic cells might be preventing the detection of NKp46 on CNS-
derived NK cells, the lymphocyte population was enriched by fluorescence-activated 
cell sorting (FACS) of CNS-derived leukocytes prior to staining with NKp46. 
Forward/side scatter analysis of sorted and unsorted samples revealed that sorting had 
succeeded in enriching the lymphocyte population, although some larger cells were 
still present (figure 5-iv). NKp46 was still not detected in samples that were stained 
with anti-NKp46 after sorting (figure 5-v), suggesting that the failure to detect 
NKp46
+
 lymphocytes was not likely to be caused by antibody sequestration. 
 
Figure 5-iv: Enrichment of lymphocyte population by FACS. Forward and side scatter plots 
showing CNS leukocyte fraction from a female Line 7 mouse with moderate clinical disease (score 2), 
(A) prior to sorting and (B) after sorting. Leukocytes were isolated from physically and enzymatically 
disrupted CNS tissue by Percoll density gradient centrifugation. Cells were incubated with live/dead 
yellow dye, then live lymphocytes were sorted on FACS Aria II according to forward- and side-scatter 
with doublet exclusion and negativity for live/dead yellow dye.  
(A) 
(B) 
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Figure 5-v: NKp46 was not detected in FACS-sorted lymphocytes isolated from the CNS of a 
Line 7 mouse. Leukocytes were isolated from physically and enzymatically disrupted CNS tissue from 
a female Line 7 mouse with a clinical disease score of 2 by Percoll density gradient centrifugation and 
incubated with live/dead yellow dye for exclusion of dead cells. Lymphocytes were identified based on 
forward and side scatter and sorted using the FACS Aria II with doublet and dead cell exclusion. 8 x 
10
4
 sorted lymphocytes were stained with α-CD3 FITC and either rat IgG2a efluor450 or α-NKp46 
efluor450 for identification of NK cells.  
 
5.1.3 NKG2D was also Not Detected on CNS-derived Lymphocytes 
To address the possibility that NK cells are present in the CNS but have 
downregulated expression of NKp46, samples from spleen and CNS were stained 
with an antibody against NKG2D. NKG2D is typically found on all NK cells, 
however it is also found on activated CD8
+
 T cells (Diefenbach et al. 2000) therefore 
would not normally be the marker of choice. NK cells can however be identified by 
co-staining with CD3 for exclusion of NKG2D
+
 T cells.  
In spleen samples, well-defined NKG2D
+
 populations were found amongst both CD3
+
 
and CD3
-
 leukocytes. However, in CNS samples neither CD3
-
 nor CD3
+
 populations 
contained NKG2D
+
 cells (figure 5-vi). In one of the mice, scoring 2.5, there was a 
small proportion of cells that appeared to be weakly positive for NKG2D, but the 
difference from the isotype control was not sufficient to be confident that this was a 
genuine NKG2D
+
 population. 
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Figure 5-vi: NKG2D
+
 lymphocytes were not detected in the CNS of Line 7 mice. Leukocytes were 
isolated from three Line 7 mice with moderate clinical disease (two female and one male, score 2 - 
2.5), by disruption of CNS tissue followed by Percoll density gradient centrifugation, then stained with 
α-CD3 and either α-mouse NKG2D APC (right) or rat IgG1 APC isotype control (left).  
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5.1.4 Discussion 
Neither NKp46 nor NKG2D were detected on cells infiltrating the CNS of Line 7 
mice exhibiting moderate clinical symptoms of demyelinating autoimmune disease.  
The possibility of sequestration of antibody by impurities in the CNS sample was 
considered. NKp46 expression has been detected on human astrocytes (Durrenberger 
et al. 2012), so it is possible that CNS-resident cells or debris from such cells might 
specifically sequester NKp46 antibody. In addition, there is a substantial proportion of 
dead cells in these CNS samples, which have a tendency to bind antibody non-
specifically. However, CD3 staining was still detected in CNS samples, so non-
specific sequestration of antibody seems unlikely. Enriching lymphocytes by cell 
sorting did not make a difference to NKp46 staining, which also suggests that the 
antibody was not being sequestered.  
There are several other possible reasons why these NK cell markers were detected in 
the spleen but not the CNS. NK cells might be absent from the CNS because they are 
not sufficiently activated and/or not expressing the molecules necessary for migration 
across the blood-brain barrier. Alternatively, they might be able to enter the CNS but 
then either undergo apoptosis or downregulate the activating receptors by which we 
would usually identify them.  
Widespread downregulation of NK cell receptors, including NKp46 and NKG2D, is 
observed in certain types of cancer (Costello et al. 2002, Garcia-Iglesias et al. 2009). 
Downregulation of NKG2D has also been observed in transgenic mice expressing 
constitutively high levels of ligands such as MICA or Rae-1 (Oppenheim et al. 2005, 
Wiemann et al. 2005) and several studies have demonstrated downregulation of 
human NKG2D by soluble ligands including MICA, MICB and ULBPs released by 
tumour cells and activated CD4
+
 T cells (Groh et al. 2002, Song et al. 2006, Cao et al. 
2007, Cerboni et al. 2009, Ashiru et al. 2010). NKG2D ligands are expressed on 
activated T cells and macrophages (Molinero et al. 2002, Hamerman et al. 2004) and 
reactive oxygen species produced by phagocytes have been shown to downregulate 
expression of both NKG2D and NKp46 on CD56
dim
 NK cells (Romero et al. 2006). In 
addition, NKG2D is downregulated by the combination of IFN-β and IL-12 produced 
during viral infection (Muntasell et al. 2010). Therefore, receptor expression on CNS 
NK cells could conceivably be influenced by expression of stress-induced ligands in 
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the CNS tissue and on activated infiltrating leukocytes, as well as by the cytokine 
mileu within the inflamed CNS.  
Work carried out in our group indicates a substantial increase in MICA and MICB 
mRNA in white matter lesions of MS patients compared to healthy white matter 
(Hyun-Woong Do, unpublished data). Increased levels of MICA are also found on 
intestinal epithelial cells of patients with Crohn’s disease and in both synovium and 
peripheral blood of rheumatoid arthritis patients (Groh et al. 2003, Allez et al. 2007). 
However, unlike cancer patients, these patients did not exhibit downregulation of 
NKG2D, most likely because of the counteracting influence of cytokines such as IL-
15 and TNFα, which upregulate NKG2D expression (Groh et al. 2003, Allez et al. 
2007). These cytokines are also upregulated in MS and EAE (Hofman et al. 1989, 
Selmaj et al. 1991, Renno et al. 1995, Kivisäkk et al. 1998, Blanco-Jerez et al. 2002, 
Rentzos et al. 2006, Wu et al. 2010), which makes it seem less likely that 
downregulation of NKG2D would take place.  
Meanwhile, NKp46 expression on astrocytes is increased in the CNS of MS patients 
(Durrenberger et al. 2012), which excludes the possibility of generic downregulation 
of this receptor within the CNS. If downregulation of NKp46 was taking place, it 
would have to be by a mechanism specific to NK cells. 
Overall, the most likely possibility is that NK cells are not present in the CNS tissue 
of Line 7 mice at this stage of disease. Prior to extraction of the CNS, mice were 
perfused with PBS to flush out the blood vessels, therefore only NK cells which had 
crossed the BBB would be detected in the sample. It is possible therefore, that NK 
cells have migrated towards the CNS but not penetrated the BBB. Since the data 
presented here represents mice that already had a moderate degree of paralysis (score 
2 – 3), it is also possible that NK cells might enter the CNS at a different stage of 
disease, possibly before onset of visible symptoms. 
During EAE, NK cells have been reported to infiltrate the murine CNS in substantial 
numbers and to have a clinically significant role in regulating inflammation once there 
(Huang et al. 2006, Hao et al. 2010). The contradictory results between these studies 
and ours with regard to the presence of NK cells is most likely due to differences 
between the EAE and Line 7 disease models. For instance, there might be a difference 
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in the activation status of NK cells in the blood, since EAE induction involves use of 
an adjuvant, which is likely to activate NK cells independently of myelin-specific T 
cell responses. There could also be differences in chemokine expression and in the 
degree of selectivity of the BBB.  
It is important to bear in mind that neither murine model is a completely faithful 
representation of human disease. The Line 7 model has more similarity to MS than 
most EAE models in so far as it is spontaneous and involves a humanised HLA/TCR 
combination associated with MS. However it goes without saying that there are 
significant differences in NK cell biology and other aspects of the immune system 
between mice and humans. Furthermore, human MS is a complex disease and 
although HLA-DRB15*01 is a strong genetic risk factor, in reality disease initiation 
and progression in humans is likely to be determined by a range of factors. Some of 
these factors, in particular KIR and HLA class I genotypes, might influence the 
activation state of NK cells, and therefore their ability to cross vascular endothelial 
barriers such as the BBB.  
The data from the Line 7 mice is however consistent with staining of human post-
mortem brain sections carried out by Pascal Durrenberger, which detected very few 
NKp46
+
 lymphocytes in white matter lesions of patients with progressive MS 
(Durrenberger et al. 2012). Of course, if NKp46 downregulation was occurring in the 
Line 7 model, it might also occur in the human CNS, so it is not completely certain 
that there are no NK cells there. Also, these samples are representative of very late 
disease and do not exclude the possibility of NK cell infiltration during the relapsing-
remitting phase. In support of a role for NK cells within the CNS during human MS, 
presence of NK cells has been reported in the CSF of untreated RRMS patients 
(Bielekova et al. 2011). The ratio of NK cells to CD4
+
 and CD8
+
 T cells in the CSF is 
increased during daclizumab treatment due to an increase in the size of the CD56
bright
 
NK cell population, indicating a potential regulatory role for NK cells within the 
CNS. Whether they are able to penetrate other parts of the human CNS, in particular 
white matter lesions, during RRMS remains to be seen. 
In summary, the data presented in this chapter does not support a role for NK cells 
within the CNS in either promoting or regulating demyelination in the Line 7 model. 
However, the absence of NK cell infiltration of the CNS in this particular model does 
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not exclude the possibility that they might regulate inflammation within the CNS of 
human RRMS patients. As a result of the studies initiated here and the problems of 
reconciling these with some of the published work on EAE, experiments were 
subsequently initiated in the lab to cross the Line 7 mice onto the E4BP4 
-/-
 strain 
lacking all NK cells, as reported from Hugh Brady’s lab (Gascoyne et al. 2009). 
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6. DISCUSSION 
In this study, I set out to identify subsets of NK cells with altered frequencies in MS 
patients that might be implicated in exacerbation or amelioration of disease, to 
characterise these subsets and determine whether they might have a role within the 
CNS itself. 
I identified subsets of NK cells with a decreased frequency as well as one subset with 
a higher frequency in untreated MS patients compared to healthy controls. I confirmed 
the previously reported expansion of CD56
bright
 NK cells in IFNβ-treated MS patients 
and showed that IFNβ also has pronounced effects on frequencies of CD56dim 
subpopulations. Three of the four CD56
bright
 subsets had a reduced frequency in MS 
patients compared to controls, and all were reduced in patients in relapse compared to 
remission, suggesting that CD56
bright
 subsets may share a protective 
immunoregulatory role in MS. However, these subsets were not all equally affected 
by IFNβ treatment. Three of them showed a slight, non-significant increase in IFNβ-
treated patients, but the average frequency of the CD8
-
 CD27
-
 subset of CD56
bright
 NK 
cells was doubled in IFNβ-treated patients and tripled in IFNβ-treated patients in 
remission. It is interesting that the only subset of CD56
dim
 NK cells that was increased 
in IFNβ-treated patients also lacked expression of CD8, CD27 and CD57 (the latter of 
which is absent from all CD56
bright
 NK cells). This suggests that CD56
dim
 and 
CD56
bright
 subsets lacking these markers share a common feature that increases their 
responsiveness to IFNβ treatment. They might for example have higher expression of 
signalling components associated with type I interferon signalling, allowing them to 
respond directly to IFNβ stimulation. However, there are many possible indirect 
mechanisms by which IFNβ might act on NK cells. These include modulation of IL-2 
signalling as discussed in chapter 3 and induction of other cytokines and growth 
factors by IFNβ, which might in turn affect NK cell function. NK cells also interact 
with other leukocytes including monocytes, macrophages and DCs (Ferlazzo et al. 
2002, Mocikat et al. 2003, Borg et al. 2004, Dalbeth et al. 2004, Ferlazzo et al. 2004, 
Gerosa et al. 2005, Mailliard et al. 2005, Nedvetzki et al. 2007). IFNβ has a number 
of effects on APCs and overall tends to inhibit their ability to induce Th1 polarisation 
(Genç et al. 1997, McRae et al. 1998, Karp et al. 2000, Ramgolam et al. 2009). Thus 
APCs exposed to IFNβ might also preferentially activate and induce proliferation of 
NK cells with a more immunoregulatory phenotype. It would also be interesting to 
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investigate whether the CD56
bright
 CD8
-
 CD27
-
 NK cell subset has any functional 
differences, besides responsiveness to IFNβ, to other CD56bright NK cell subsets and 
whether the functional overlap of CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells with 
CD56
bright
 CD8
-
 CD27
-
 NK cells is greater than that with the CD56
bright
 population as 
a whole.  
It is not clear from the data presented so far whether the changes in subset frequencies 
are the result of increased proliferation or survival rates of certain subsets, or if 
changes in the cytokine mileu and other factors are causing NK cells to alter their 
phenotype. Markers such as Ki67 could be employed to determine whether the 
proliferation of particular subsets is enhanced during disease or by treatments such as 
IFNβ. Cytokines such as IL-2, produced by activated T cells and IL-12, IL-15 and IL-
18 produced by DCs have previously been reported to induce changes in NK cell 
phenotype, in terms of both surface markers and functional attributes (Peritt et al. 
1998, Loza et al. 2004, Mailliard et al. 2005, Romagnani et al. 2007, Takahashi et al. 
2007, Lopez-Vergѐs et al. 2010, Béziat et al. 2011). Activation of other leukocytes 
and consequent release of proinflammatory cytokines during autoimmune disease 
could therefore induce changes in NK cell phenotype.  
Another interesting question is whether the frequency of NK cell subsets is influenced 
by genetic factors. Differences in KIR/HLA genotype might influence the process of 
NK cell maturation. MS-associated polymorphisms of IL-2Rα and IL-7R (Hafler et 
al. 2007, De Jager et al. 2009a) might affect the survival, proliferation and maturation 
of the more immature subsets, such as CD56
bright
 that typically express these receptors 
(Caligiuri et al. 1990, Nagler et al. 1990, Baume et al. 1992, Hanna et al. 2004b, 
Wendt et al. 2006, Nielsen et al. 2012). In addition, polymorphisms in the genes 
encoding T-bet and STAT3, of which I detected higher expression in the disease-
associated CD56
dim
 CD8
+
 CD57
+
 NK cell subset, were implicated in MS 
susceptibility by a recent GWAS study (Patsopoulos et al. 2011). NK cell-extrinsic 
genetic factors could also play a role in determining the way in which they develop.   
In order to gain insight into the function of the CD56
dim
 CD27
-
 CD8
+
 CD57
+
 subset 
and its CD8
-
 CD57
-
 counterpart, I sorted these two subsets by FACS and identified 
differences in their transcriptional profiles and cytotoxic function. If technicalities 
permitted, CD56
dim
 CD27
-
 NK cells which are single-positive for either CD8 or CD57 
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could be sorted and characterised in a similar manner, in order to dissect whether 
particular functional attributes are related to expression of one molecule or the other, 
or if they are defined solely by the combination of both markers. 
The CD56
dim
 CD8
+
 CD57
+
 subset expressed a higher level of mRNA encoding 
S1PR1, a surface molecule that is upregulated upon activation and which is involved 
in egression from lymph nodes (Matloubian et al. 2004, Pappu et al. 2007). It would 
be interesting to see if CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells, like CD56
bright
 NK cells, 
are enriched in lymph nodes and whether they express different levels of receptors 
associated with migration to lymph nodes, in particular CD62L, which has previously 
been identified as a marker of polyfunctional CD56
dim
 NK cells with similarity to the 
CD56
bright
 subset (Juelke et al. 2010). The phosphorylated form of fingolimod, a new 
therapy for MS, is an analog of  sphingosine-1-phosphate, which binds to S1PR1, 
causing its internalisation and therefore preventing egression of autoreactive T cells 
from lymph nodes (Mandala et al. 2002, Xie et al. 2003, Brinkmann et al. 2004, 
Matloubian et al. 2004, Brinkmann et al. 2009). Therefore this therapy may also have 
implications for migration of NK cells and if it preferentially blocks migration of the 
CD8
+
 CD57
+
 subset this might enhance suppression of autoimmunity by this therapy. 
CNS infiltration of leukocytes is thought to be reduced by fingolimod, primarily 
because T cells which have been primed in lymph nodes cannot access the CNS 
without first migrating out of lymph node into the blood. However, this receptor 
might also influence other aspects of cell migration and activate other functions. 
Therefore effects of this therapy on migration and function of NK cell subsets would 
be worth studying, since CD8
+
 CD57
+
 NK cells might be affected more strongly than 
CD8
-
 CD57
-
 CD56
dim
 NK cells. Another avenue for future investigation is comparing 
expression of chemokine receptors, including CX3CR1, which is crucial for migration 
of NK cells into the CNS during EAE (Huang et al. 2006, Hao et al. 2010). 
Differences in CX3CR1 expression between healthy controls and MS patients have 
been reported previously (Infante-Duarte et al. 2005) and it would be interesting to 
know whether the CX3CR1
+
 population corresponds to the CD56
dim 
CD8
+
 CD57
+
 
subset, since both have higher frequency in untreated MS patients. If so, this could 
indicate that this highly cytotoxic subset is likely to enter the human CNS and 
participate in killing of oligodendrocytes and neurons. 
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I did not detect CNS infiltration of NK cells in the humanised transgenic Line 7 
mouse model of MS. However, given the abundant presence of NK cells in the CNS 
in other disease models (Hammarberg et al. 2000, Huang et al. 2006, Hao et al. 2010, 
Leavenworth et al. 2010), it is still plausible that they enter the human CNS. 
Infiltration of NK cells has been demonstrated in CSF (Bielekova et al. 2011), 
however this does not prove that they are able to migrate into the parenchyma and 
contribute to demyelination in MS lesions. Very few NK cells were observed in white 
or grey matter lesions of post-mortem samples from progressive MS patients and their 
localisation tended to be perivascular rather than parenchymal (Durrenberger et al. 
2012). NK cells were only found in patients with pronounced focal demyelination and 
were more likely to be found in active lesions. Ideally, brain tissue samples would be 
obtained from a cohort of RRMS patients who have died prior to onset of progressive 
disease in order to determine if NK cells penetrate the parenchyma during the acute 
inflammatory stage of disease. However, even in RRMS patients, substantial NK cell 
infiltration may well only be observed during relapses and it is difficult to acquire 
such specific post-mortem samples. Given the limitations of studying tissue, it would 
be worth evaluating more precisely which subsets are present in the CSF of MS 
patients, both untreated and treated. If pathogenic NK cells are indeed entering the 
human CNS, then inhibition of NK cell migration might be another beneficial effect 
of treatments such as fingolimod and Tysabri. However, if such therapies prevented 
immunoregulatory subsets from entering the CNS this might prevent suppression of 
inflammation mediated by leukocytes that have already infiltrated the CNS prior to 
treatment.  
However, even if NK cells do not infiltrate and participate in or regulate inflammatory 
processes and damage within the CNS, they could still have important roles in 
regulating onset or exacerbation of disease by modulating activation of T cells and 
other leukocytes in blood or lymph nodes. In order for T cells to cross the BBB and 
initiate CNS inflammation, they must first become activated and upregulate molecules 
involved in cellular adhesion and migration (Hauser and Oksenberg 2006, Bauer et al. 
2009, Goverman et al. 2009, Holmann et al. 2011, Inoue et al. 2012). Interaction with 
other cells including NK cells could affect the activation status of T cells and 
therefore their ability to infiltrate the CNS, as well as their cytokine profile. In 
addition, NK cells have the ability to kill T cells that have been inappropriately 
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activated, or to kill Tregs and therefore prevent them from regulating effector cells 
(Rabinovich et al. 2003, Molinero et al. 2006, Cerboni et al. 2007, Roy et al. 2008, 
Lang et al. 2012, Nielsen et al. 2012). Therefore peripheral NK cells could be an 
important factor determining initiation of and relapses in MS, without ever entering 
the CNS. 
An important area for future investigation is the regulation of IFNγ production in the 
CD56
dim
 CD8
+
 CD57
+
 and CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cell subsets. IFNγ 
upregulates expression of MHC class II, CIITA and co-stimulatory molecules, 
enhancing the ability of APCs to activate antigen-specific T cells (Figueiredo et al. 
1989, Chang et al. 1995, Barrerra et al. 1997, Menèndez Iglesias et al. 1997, O’Keefe 
et al. 2001, Lee et al. 2006, Valledor et al. 2008). IFNγ produced by NK cells has a 
role in inducing Th1 polarisation, by upregulating T-bet in CD4
+
 T cells during 
priming and by enhancing DC production of IL-12 and IL-18, which preferentially 
induce IFNγ as opposed to Th2 cytokines (Afkarian et al .2002, Mocikat et al. 2003, 
Martín-Fontecha et al. 2004, Mailliard et al. 2005). Therefore production of IFNγ by 
NK cells could have important roles in regulating inflammation in the periphery and 
possibly the CNS. The CD56
dim
 CD8
+
 CD57
+
 subset expressed significantly higher 
levels of mRNA encoding IFNγ as well as T-bet and NFATC2 which promote IFNγ 
transcription (Szabo et al. 2002, Macian 2005). Therefore it seems likely that this 
subset might participate in the inflammatory process by producing IFNγ, leading to 
activation of T cells, DCs, macrophages and microglia. IFNγ produced by NK cells 
might also contribute to migration of both NK cells and other leukocytes across the 
BBB by upregulating ICAM-1 on vascular endothelial cells, thereby promoting 
attachment of leukocytes expressing LFA-1 (Kebir et al. 2009).  
However, in order to truly understand differences in IFNγ production, it will be 
important to compare the effects of different stimuli. IFNγ production is preferentially 
induced by cytokine stimulation in CD56
bright
 NK cells and by ligation of activating 
receptors in CD56
dim
 NK cells (Fauriat et al. 2010a). Antibody production in the CNS 
of many MS patients could trigger IFNγ production via CD16, therefore the response 
to ligation of this receptor in each subset should be tested in vitro. CD57
+
 NK cells 
have previously been reported to respond more strongly to stimulation via CD16 in 
terms of both IFNγ production and cytotoxic function (Lopez-Vergѐs et al. 2010). In 
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addition I found that the CD8
+
 CD57
+
 subset expressed higher levels of the CD3ζ 
adaptor protein that mediates signalling via CD16, NKp30 and NKp46 (Lanier et al. 
1989, Pessino et al. 1998, Vitale et al. 1998, Pende et al. 1999). Therefore this subset 
would be expected to produce more IFNγ in response to stimulation of activating 
receptors, especially given the higher levels of IFNγ transcript in this subset. 
However, IFNγ production in response to cytokines may not show the same trend. 
Since CD56
dim
 CD8
-
 CD27
-
 CD57
-
 NK cells share features with the CD56
bright
 subset, 
they might be expected to respond more effectively to stimulation with cytokines such 
as IL-12 and IL-18. IL-18R was not included in my PCR or flow cytometry analysis, 
but a previous study indicates that its expression is higher on CD57
-
 NK cells (Lopez-
Vergѐs et al. 2010). Given that NK cells might be exposed to IL-12 and IL-18 from 
activated APCs during MS, it would be worth investigating how each subset responds 
to stimulation with each of these cytokines both alone and in combination. 
Conversely, higher expression of STAT3, which is involved in the response to IFNγ, 
IL-6, IL-23 and other cytokines (Schindler and Plumlee 2008, Bluyssen et al. 2010), 
might enable the CD8
+
 CD57
+
 subset to be preferentially activated by certain MS-
associated cytokines. STAT3 promotes survival and proliferation (Takeda et al. 1998, 
Akira 2000, Narimatsu et al. 2001), which might explain the expansion of this subset 
by pro-inflammatory cytokines in the blood of MS patients.  
The ability to produce cytokines in response to direct interaction with other 
leukocytes may also be important in the context of MS. NK cell cytokines including 
IFNγ can be induced by interaction with APCs (Ferlazzo et al. 2002, Borg et al. 2004, 
Ferlazzo et al. 2004, Gerosa et al. 2005, Nedvetzki et al. 2007). NK cells which are 
activated in such a way form an immunological synapse with the other leukocyte and 
can direct secretion of cytokines and other factors towards the cell with which it is 
interacting, resulting in reciprocal activation (Borg et al. 2004, Ferlazzo et al. 2004, 
Semino et al. 2005). The ability to interact with DCs and to produce IFNγ in response 
to this interaction is likely to have a strong influence on the ability of each subset to 
promote T cell priming by APCs and Th1 polarisation. Therefore, it would be worth 
investigating the ability of each of these subsets to produce IFNγ and other cytokines 
such as TNFα and GM-CSF following in vitro incubation with APCs such as DCs, 
macrophages and microglia.  
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Another aspect of NK cell function that could be examined is responsiveness to viral 
and bacterial antigens via pattern recognition receptors such as TLRs. CD56
dim
 CD8
-
 
CD57
-
 NK cells exhibited higher expression of NF-κB, which is an important 
transcriptional mediator of TLR-induced signalling pathways (Kawai and Akira 
2007). There might also be differences in other components of the signalling pathway 
or in expression of the receptors themselves. Stimulation with ligands for TLR and 
NOD receptors or with whole bacteria could be used to determine the ability of each 
subset to directly recognise infectious agents. NF-κB is also associated with induction 
of antioxidants that protect against apoptosis in response to ROS produced by 
phagocytes (Mattson et al. 1997, Javelaud et al. 2001, Djavaheri-Mergny et al. 2004). 
The CD56
bright
 subset is reported to be more resistant to ROS (Harlin et al. 2007, 
Thorén et al. 2007) and it would be interesting to see if the higher level of NF-κB in 
the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset confers upon it a similar resistance to that 
seen in CD56
bright
 NK cells. 
One of the most crucial functions of NK cells, which could have roles in both 
pathogenesis and suppression of inflammation, is cytotoxicity. I observed higher 
expression of perforin and granzymes and higher cytotoxicity towards K562 cells in 
the CD56
dim
 CD8
+
 CD57
+
 subset. This more cytotoxic phenotype might indicate 
involvement of this subset in killing of oligodendrocytes and neurons, or of other 
leukocytes. However, NK cell subsets do not necessarily exhibit the same differences 
in cytotoxicity towards all types of target cell. For instance, the CD56
bright
 subset is 
fully capable of killing activated T cells, despite its lower cytotoxicity towards classic 
NK cell-susceptible target cell lines (Bielekova et al. 2006, Jiang et al. 2011, Nielsen 
et al. 2012). It would be interesting to see if the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset 
expresses granzyme K, a cytotoxic mediator associated primarily with the CD56
bright
 
subset, which is involved in killing of activated T cells (Hanna et al. 2004b, Wendt et 
al. 2006, Jiang et al. 2011). Comparing the ability of CD8
+
 CD57
+
 and CD8
-
 CD57
-
 
CD56
dim
 subsets to kill activated T cells would give more insight into their role in 
autoimmunity. In addition, there may be differences within the CD56
bright
 population; 
perhaps, for instance, the CD56
bright
 CD8
-
 CD27
-
 subset, which shows the greatest 
reduction in frequency in untreated MS patients compared to healthy controls and 
IFNβ-treated patients, is particularly important in mediating this function.  
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Human NK cells can also kill microglia in vitro (Lünemann et al. 2008) and killing of 
these CNS-resident APCs is thought to suppress disease in the EAE model (Hao et al. 
2010, Leavenworth et al. 2010). Murine microglia are reported to be more susceptible 
to NK cell-mediated killing than other leukocytes due to their low expression of the 
ligand for the inhibitory receptor NKG2A (Hao et al. 2010). Induction of this ligand 
in microglia protects them from killing by NK cells (Hao et al. 2010), suggesting that 
killing of microglia, at least in mice, is mediated primarily by NKG2A
+
 NK cells. 
This is not necessarily the case in humans, since mouse and human NK cells differ in 
their repertoire of inhibitory receptors. It would be interesting to test whether 
NKG2A
+
 or KIR
+
 human NK cells are more effective at killing autologous microglia. 
I observed a higher percentage of NKG2A
+
 cells in the CD8
-
 CD27
-
 CD57
-
 subset 
compared to the CD8
+
 CD57
+
 subset of CD56
dim
 NK cells. Therefore if NKG2A 
expression is important for activation of the cytotoxic response to microglia, the CD8
-
 
CD27
-
 CD57
-
 subset might kill this subset more effectively despite lower expression 
of the main cytotoxic mediators. 
The CD56
dim
 CD8
+
 CD57
+
 subset may have a role in exacerbation of disease by 
killing neurons and oligodendrocytes. During MS, antibodies are deposited at sites of 
active demyelination and these antibodies are thought to induce macrophage 
phagocytosis of myelin and oligodendrocytes by triggering their Fc receptors 
(Scolding and Compston 1991, Storch et al. 1998, Lucchinetti et al. 2000, Breij et al. 
2008). These antibodies might also trigger the Fc receptor CD16 on NK cells and if 
the myelin is coated with a sufficient density of immunoglobulin, this could trigger 
ADCC in the NK cell, leading to release of cytotoxic mediators that could kill the 
oligodendrocyte and possibly the underlying neuron. Human NK cells can also kill 
autologous oligodendrocytes by an NKG2D-dependent mechanism and 
oligodendrocytes in MS lesions express high levels of the NKG2D ligands MICA and 
MICB, meaning they are likely to be susceptible to NK cell lysis during MS if NK 
cells are present in the lesion (Morse et al. 2001, Saikali et al. 2007).  
NK cells can also kill immature DCs, thereby promoting interaction of T cells with 
mature DCs instead, resulting in their activation (Carbone et al. 1999, Wilson et al. 
1999, Spagiari et al. 2001, Ferlazzo et al. 2002, Della Chiesa et al. 2003, Vitale et al. 
2005). Cytotoxic NK cells could also exacerbate disease by killing of Tregs, thereby 
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impairing an important immunosuppressive mechanism. Therefore the CD56
dim
 CD8
+
 
CD57
+
 and CD8
-
 CD57
-
 subsets would ideally be compared in killing assays using a 
range of target cells with relevance to MS, including CD4
+
 and CD8
+
 T effector cells, 
Tregs, macrophages, microglia, oligodendrocytes and neurons. Due to the large 
quantities of cells and reagents required to perform such experiments, this was beyond 
the scope of this study.  
One of the more surprising results of the qRT-PCR array was the presence of CD3δ 
and CD3γ transcripts in CD56dim NK cells, particularly the CD8+ CD57+ subset. This 
observation could be investigated further by looking for protein expression. Clues as 
to the function of these receptor chains in NK cells might be gained by investigating 
their cellular localisation by fluorescence confocal microscopy and by searching for 
interactions with other proteins, including activating receptors and signalling 
molecules such as ZAP-70 and Syk.  
Another curious observation from the PCR assays was the higher level of IL-12Rβ1 
transcript in CD8
+
 CD57
+
 NK cells, whereas IL-12Rβ2 was expressed preferentially 
in the CD8
-
 CD57
-
 subset. Knockout of IL-12Rβ2 is reported to increase EAE 
severity, whereas IL-12Rβ1 deficiency ameliorates disease (Zhang et al. 2003a, 
Zhang et al. 2003b). This was presumed to indicate a more important role of Th17 
compared to Th1 cells, since IL-23 signalling, which promotes Th17 differentiation, is 
dependent on IL-12Rβ1 and not IL-12Rβ2 (Parham et al. 2002, Hoeve et al. 2006). 
However, since both Th17 and Th1 cells are able to mediate EAE (Kroenke et al. 
2008, Stromnes et al. 2008, Jager et al. 2009), it seems counterintuitive that 
preventing induction of T cell IFNγ production via IL-12Rβ2 would enhance EAE 
severity. Given the association of IL-12Rβ2 with immunoregulatory subsets of NK 
cells (Takahashi et al. 2001, Wendt et al. 2006, Perritt et al. 2008) and my 
observation that MS patients have a higher proportion of NK cell subsets that 
preferentially express IL-12Rβ1 rather than IL-12Rβ2, it is possible that some of the 
effects of IL-12Rβ2 and/or IL-12Rβ1 knockout are caused by loss of NK cell 
regulatory or effector function respectively. 
It would also be interesting to investigate whether the frequency of NK cell subsets 
could be used as a predictor of future disease progression or responsiveness to 
therapy. The higher frequency of CD56
bright
 NK cells in IFNβ-treated patients in 
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remission compared to those in relapse suggests that the frequency of this subset 
might correlate with disease activity. There is a pressing need for clinical application 
of biomarkers that will offer early indicators as to which patients will be responsive to 
IFN. The patients with the most striking expansion of CD56bright NKs were those 
with stable MS who had not had any relapses in the year prior to taking the sample. 
However, due to the relatively small number of samples, patients in remission with 
both stable and active disease were grouped together for analysis. Previous studies 
have reported that there is a relationship between expansion of CD56
bright
 cells and 
response to therapy with either daclizumab or IFNβ (Wynn et al. 2010, Martín-
Rodriguez et al. 2011). Extension of our study to compare stable and active patients 
could elucidate if there is a particular type of CD56
bright
 NK cell that is particularly 
important in determining responsiveness to therapy. The CD8
-
 CD27
-
 population was 
the only CD56
bright
 subset that was significantly expanded when the entire IFNβ-
treated group was compared to the untreated patients. However, the result may have 
been different if only patients who were responding well to IFNβ therapy were used 
for comparison, since all four CD56
bright
 subsets had higher frequencies in remission. 
Longitudinal studies could be performed in order to determine at what point 
expansion of CD8
-
 CD27
-
 CD57
-
 subsets and contraction of the CD56
dim
 CD8
+
 CD57
+
 
subset occurs during therapy. If it occurs early on in therapy, it could be used as a 
predictor of responsiveness in order to determine if IFNβ is an appropriate choice of 
therapy for each individual patient. CIS patients could also be followed up to 
determine if NK cell subset frequencies are a predictor of future disease course. CIS 
patients with more CD56
dim
 CD8
+
 CD57
+
 NK cells and fewer CD56
bright
 NK cells 
might be more likely to progress rapidly to MS or to have more active disease. If a 
convenient predictor of disease severity was available it might help to determine the 
choice of therapy. Patients with an NK cell profile predisposing to severe disease 
might then be started on therapy earlier, which could be more effective at suppressing 
accumulation of disability.  
Frequencies of these NK cell subsets could also be investigated in other autoimmune 
diseases such as arthritis, systemic lupus erythematosus (SLE) and type I diabetes, to 
see if there are similar changes to those observed in MS patients. However, evidence 
so far suggests that NK cell frequencies are altered in a different manner in different 
autoimmune diseases. CD16
+
 NK cell frequencies are reduced in the blood of SLE 
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patients but increased in arthritis patients (Li et al. 2010b). CD56
bright
 NK cells 
actually have a higher frequency in the circulation of patients with SLE, which is 
thought to be due to increased serum levels of IFNα (Schepis et al. 2009). It would be 
interesting to see if these patients exhibit the preferential expansion of CD8
-
 CD27
-
  
NK cells that I observed in IFNβ-treated MS patients. CD56bright NK cells are also 
found in the synovium of inflamed joints in arthritis patients and the phenotype of 
these cells could again be investigated further (Dalbeth and Callan 2002). Meanwhile, 
decreased numbers of circulating NK cells have been reported in psoriasis and 
Sjögren’s syndrome and my panel of antibodies could be used to investigate whether 
this is due to a selective deficiency in immunoregulatory NK cell subsets (Cameron et 
al. 2003, Izumi et al. 2006). 
6.1 Summary 
CD56
bright
 NK cells have a significantly lower frequency in untreated MS patients 
compared to healthy controls, both as a percentage of NK cells and of all 
lymphocytes. I discovered that this decrease is particularly prominent in the CD8
-
 
CD27
-
 subset of CD56
bright
 NK cells. CIS patients have a similar frequency of this 
subset to MS patients, indicating that this is a change that occurs early on in the 
disease process. I have also identified a subset of NK cells that has a significantly 
higher frequency in MS patients: the CD56
dim
 CD8
+
 CD57
+
 subset. This subset has an 
intermediate frequency in CIS patients, suggesting that its frequency is amplified by 
inflammatory disease processes. IFNβ has profound effects on the relative frequencies 
of different NK cell subsets. CD8
-
 CD27
-
 CD57
-
 NK cell subsets, both CD56
dim
 and 
CD56
bright, are significantly expanded in IFNβ-treated patients, whereas the CD56dim 
CD8
+
 CD57
+
 subset is substantially reduced in frequency. CD56
bright
 NK cells have 
previously been shown to kill activated T cells, therefore the decrease in CD56
bright
 
NK cells in MS patients is likely to have a role in promoting T cell-mediated 
inflammation. I have found that the CD56
dim
 CD8
-
 CD27
-
 CD57
-
 subset has some 
similarities with the CD56
bright
 subset, such as higher levels of IL-12Rβ2 transcript, 
and hypothesise that it might have a similar function. In contrast, I have demonstrated 
that the CD56
dim
 CD8
+
 CD57
+
 subset is highly cytotoxic and expresses higher levels 
of CD3ζ, which I hypothesise would make it more responsive to signals from 
activating receptors, enhancing its ability to release IFNγ and cytotoxic mediators 
upon encounter with target cells. It also expresses transcription factors associated with 
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induction of IFNγ and enhancement of survival and proliferation in response to IFNγ 
and other cytokines, which may allow this subset to be preferentially activated by 
elevated levels of pro-inflammatory cytokines in the blood of MS patients and to 
amplify inflammation by releasing further IFNγ that could promote Th1 polarisation 
and promote antigen presentation by upregulating components of the MHC class I and 
II pathways, APC co-stimulation molecules and the Th1 polarising cytokines IL-12 
and IL-18. Actual and hypothetical differences between the CD8
+
 CD57
+
 and CD8
-
 
CD57
-
 subsets of CD56
dim
 CD27
-
 NK cells are summarised in figure 6-i. 
In conclusion, I have succeeded in identifying NK cell subsets with altered 
frequencies in MS patients and I have elucidated transcriptional and functional 
characteristics of the disease-associated CD56
dim
 CD8
+
 CD57
+
 subset that could 
contribute to pathogenesis. Although the increased frequency of CD56
dim
 CD8
+
 
CD57
+
 and decreased frequency of CD56
bright
 CD8
-
 CD27
-
 NK cells in MS patients 
does not directly prove that they have a role in promoting and suppressing disease 
respectively, the data presented here, combined with previous studies demonstrating 
the immunoregulatory function of CD56
bright
 NK cells, are consistent with the 
hypothesis that the ratio of pro-inflammatory versus anti-inflammatory NK cell 
subsets is perturbed in MS patients. 
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Figure 6-i: Predicted signalling pathways and functions of CD8
+
 CD57
+
 and CD8
-
 CD57
-
 subsets of 
CD56
dim
 CD27
-
 NK cells. Signalling pathways likely to be associated with each subset were predicted 
based on differences observed in qRT-PCR comparisons. CD8
+
 CD57
+
 NK cells expressed higher levels of 
IFNγ and associated transcription factors (T-bet, NFATC2 and STAT3). During MS, IL-12 from APCs and 
IFNγ from T cells might induce IFNγ transcription via IL-12Rβ1 and type II IFN receptors respectively 
and IFNγ from NK cells could in turn activate APCs and T cells. CD8+ CD57+ NK cells express higher 
levels of CD3ζ which transduces signals from CD16 and the NCRs, NKp30 and NKp46, inducing IFNγ 
secretion and release of cytolytic granules containing granzyme A and B. CD8
-
 CD57
-
 NK cells express IL-
18, which might act in an autocrine manner together with IL-18 from DCs to induce surface expression of 
IL-12Rβ2, transcript of which is enriched in this subset. IL-18, TNF and TLR ligands could activate NF-
κB, which is also more abundant in this subset. NF-κB may be responsible for the upregulation of ICAM1 
observed in this subset and could confer resistance to ROS. Expression of granzyme K and killing of 
activated T cells is hypothetical, based on similarity to the CD56
bright
 subset. 
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